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The term ‘apoptosis’, derived from the Greek apo (- from), ptosis (- falling), refers, in the 
medical world, to the programmed death of unwanted cells in an organism (1). 
Apoptosis is essential for proper development and tissue integrity. Due to the tight 
regulation of this process, also called programmed cell death (PCD), cells are eliminated 
without harm to the surrounding tissues. (Epi)genetic alterations can disrupt a cell’s 
ability to enter apoptosis and thereby threaten homeostasis. The uncontrolled 
proliferation of these damaged cells can cause several diseases, including cancer. 
Apoptosis can be induced through two intertwined pathways known as the 
extrinsic and the intrinsic pathways, depending on the initiating event (2). Apoptotic 
cell death via the intrinsic (stress) pathway is initiated by cellular changes such as DNA 
damage (e.g., following radiation or treatment with chemotherapeutic drugs), which 
causes destabilization of the mitochondrial membrane via the proapoptotic Bcl-2 
homologs Bax and Bak. The extrinsic pathway is initiated by binding of extracellular 
death ligands to their cognate death receptors at the cell surface. This extrinsic pathway 
can also activate the intrinsic pathway of apoptosis via cleavage of the proapoptotic Bcl-
2 homology domain 3 (BH3)-only protein Bid. Both pathways strongly depend on 
sequential activation of a family of proteins called caspases, although the involvement of 
many non-caspase proteins is also critical.  
Chemotherapeutic agents can stimulate the mitochondrial pathway of apoptosis 
in cancer cells, but their effects are often hampered by the intrinsic resistance of these 
cells to apoptosis mediated by this pathway. Combining chemotherapeutic agents and 
stimulation of the extrinsic pathway has emerged as a rational strategy to bypass 
blockade of the intrinsic apoptotic pathway in cancer cells. In the clinic, tumor necrosis 
factor-related apoptosis-inducing ligand receptors 1 and 2 (TRAIL-R1 and TRAIL-R2), 
also named death receptors 4 and 5 (DR4 and DR5), are the most interesting targets for 
stimulation of the extrinsic pathway. Early clinical studies have indeed shown that 
TRAIL receptor ligands, such as recombinant human TRAIL (rh)TRAIL or agonistic 
anti-TRAIL receptor antibodies, are well-tolerated in patients (3).  
Colorectal cancer is one of the most frequent forms of malignancy. 150,000 new 
cases are diagnosed each year in the U.S. alone.  Colorectal cancer is also one of the most 
common causes of cancer-related death in the general population, second to lung cancer 
(4). The development of colorectal cancer has been associated with lack of exercise, 
obesity, smoking, alcohol consumption, a low-fibre, high-fat and high red-meat diet. 
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Although these factors contribute to the development of the disease, notably in its 
sporadic form, genetic predisposition also plays a major role in a subset of patients. Two 
main forms of inherited genetic disorders exist, namely familial adenomatous polyposis 
(FAP) and Lynch syndrome, formerly known as hereditary non-polyposis colorectal 
cancer (5,6). Although hereditary disorders account for less than 10% of colorectal 
cancers, their association with a high incidence of these cancers makes them a major 
concern. Tumor resection constitutes the standard treatment for localized colorectal 
cancer while adjuvant chemotherapy is used to  improve survival in a patients with 
metastases to the regional lymph nodes, i.e. stage III disease (7). The best curative option 
for those 20 % of patients who present with metastatic colorectal cancer at time of 
diagnosis remains surgical removal of both the primary tumor and the metastases, in 
particular of those in the liver (8). However, most patients will only benefit from 
palliative systemic treatment options (7). The five-year survival rates for patients with 
metastatic disease was only 10-30 % in 2005 (9). The recent addition of bevacizumab and 
cetuximab to standard chemotherapy for treating colorectal cancer has led to a raise of 
these survival rates over the last years (7). These encouraging results further support the 
introduction of novel targeted therapies. 
Intrinsic resistance against available therapeutics is frequently observed while 
acquired resistance can develop during treatment. In vitro studies suggest that, despite 
their resistance to chemotherapeutic drugs, a significant proportion of colon cancer cell 
lines exhibit sensitivity to extrinsic cell death as induced by rhTRAIL (10). Sensitivity to 
rhTRAIL and other TRAIL receptor agonists can be further improved by combining 
these agents with conventional cytotoxic chemotherapies, both in vitro in cancer cell 
lines and ex vivo in primary tumor material (11-13). Similar results have been found in 
vivo using human subcutaneous and orthotopic tumor xenograft mouse models (14,15). 
Early results from phase I and II studies have suggested that the optimal combinations 
incorporating TRAIL receptor-targeting agents remain to be defined.  The aim of this 
thesis is, therefore, to characterize new combinations that are favorable for inducing 
TRAIL death receptor-mediated apoptosis in colon cancer cells. We also aimed to define 
some of the key factors that influence TRAIL sensitivity in colorectal cancer cells, with 




Many studies have shown that by targeting the extrinsic apoptosis pathway, 
TRAIL can increase the effects of conventional anti-cancer treatments on the intrinsic 
pathway. In chapter 2, we present an extensive overview of the processes regulating the 
initial step of TRAIL death receptor-mediated apoptosis, the formation of the so-called 
death-inducing signalling complex (DISC). Reaching optimal DISC activity means fully 
exploiting mitochondria-independent apoptotic pathways while enhancing, via cleavage 
of the BH3-only protein Bid, apoptotic stress on the mitochondria as induced by 
conventional treatment modalities. 
Although colon cancer cells are more sensitive to TRAIL than their healthy 
counterpart, some cancer cells are either only moderately sensitive or completely 
resistant to TRAIL (10). Identifying the critical steps regulating TRAIL sensitivity will 
help to define possible targets for potentiating TRAIL-induced apoptosis. The potential 
for cancer cells to gradually acquire TRAIL resistance over time has been used 
previously to establish in vitro models of TRAIL resistance and to study the cellular 
changes associated with loss of TRAIL sensitivity. Previous studies have identified Bax 
as a key protein lost during drug resistance acquisition in colon cancer cells, including 
resistance to TRAIL (16,17). These findings were obtained in mismatch repair (MMR)-
deficient cells, which account for less than 20% of all colorectal cancers and are 
predisposed to mutations in genes with short tandem repeat sequences such as Bax 
(6,16). In chapter 3, we establish a model of TRAIL resistance in MMR-proficient colon 
cancer cells to identify the key protein(s), the expression of which may be preferentially 
altered during the acquisition of TRAIL resistance. Cellular differences between the 
TRAIL-sensitive SW948 cell line and its TRAIL-resistant daughter cell line SW948-TR are 
studied using a combination of survival assays, apoptosis quantification with acridine 
orange staining and Western blotting. The functional significance of the ratio between 
levels of caspase 8 and its competitive inhibitor FLIP for TRAIL sensitivity is evaluated 
using short interfering RNA. We also make use of several compounds which effectively 
re-establish a pro-apoptotic (high) caspase 8/FLIP ratio in SW948-TR cells. 
In addition to rhTRAIL, TRAIL-R1- and TRAIL-R2-specific antibodies can also be 
used to stimulate TRAIL death receptor-mediated apoptosis (3). Although these agents 
all stimulate the TRAIL apoptotic pathway, their efficacy might differ due to their ability 
to stimulate, respectively, TRAIL-R1/-R2, TRAIL-R1 or TRAIL-R2. In chapter 4, we 
compare the potency of these various ligands for inducing apoptosis in SW948 and 
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SW948-TR cells in vitro. Searching for optimal combinations, we also compare the 
efficacy of the cytokine interferon (IFN)-γ and of the proteasome inhibitor MG-132 in 
modulating sensitivity to the various TRAIL receptor ligands in our cell line model. In 
addition, the differential ability of TRAIL-R1 and TRAIL-R2 transduce apoptosis is 
investigated. 
Cetuximab, a humanized anti-epidermal growth factor receptor (EGFR) antibody, 
has recently been added to the arsenal of therapies used against colorectal cancer in the 
clinic (7). This reflects the current shift toward the development of specific anti-cancer 
therapies targeting key survival pathways. The insulin-like growth factor 1 receptor 
(IGF-1R), which is often over-activated in cancer, is now gaining much attention (18). 
We hypothesize that inhibition of IGF-1R in colon cancer cells might alter the balance 
between survival- and apoptosis-related factors, thereby increasing sensitivity to TRAIL.  
In chapter 5, we test the effects of the small molecule IGF-1R inhibitor NVP-AEW541 on 
cell survival in our TRAIL resistant colon cancer cell model. In view of the discrepancies 
seen between the effects of the various TRAIL receptor agonists in combination with 
IFN-γ and MG-132, we also compare the effects of rhTRAIL and the anti-TRAIL death 
receptor antibodies following IGF-1R inhibition. The contribution of the downstream 
IGF-1R substrate phosphatidylinositol 3-phosphate (PI3K) is also studied and 
experiments were expanded to another colon cancer cell line, namely Colo205.  
Although the precise mode of action is still debated, epidemiological studies have 
demonstrated that non-steroidal anti-inflammatory drugs (NSAIDs) have 
chemopreventive effects in vivo, notably in colorectal cells (19). Although NSAIDs can 
interfere with pathways that play an important role in cancer, the NSAID celecoxib 
failed to show anti-cancer properties in phase II studies (20,21). In vitro and human 
tumor xenograft mouse studies demonstrated that aspirin used in combination with 
rhTRAIL has anti-cancer activity (22,23). The obstacle constituted by the high 
concentrations of aspirin required could be potentially overcome through combinatorial 
approaches that would enhance the efficacy of aspirin and allow lowering the needed 
dose. Sorafenib is a broad spectrum kinase inhibitor targeting the RAF/MEK/ERK 
pathway and several tyrosine kinase receptors associated with angiogenesis and 
tumorigenesis (24). This drug has been approved for the treatment of advanced renal 
cell carcinoma and hepatocellular carcinoma, and its potential use against a number of 
other malignancies is under evaluation in over 380 clinical studies (Source: 
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ClinicalTrialsgov.com, March 2010). Because aspirin and sorafenib have similar cellular 
targets, such as the cell cycle protein cyclin D1 (25,26) and the anti-apoptotic protein 
Mcl-1 (27,28), we hypothesize that these two drugs might be able to interact with each 
other. In chapter 6, we combine sorafenib and aspirin in a panel of colon cancer cell lines 
and investigate the effects on cell survival. Furthermore, sorafenib and aspirin have 
independently demonstrated very attractive sensitizing properties for TRAIL receptor-
mediated apoptosis in vitro, albeit at doses bordering the clinically achievable range 
(19,29). We combine physiologically sustainable doses of both aspirin and sorafenib 
with TRAIL to investigate potential cross-amplification of their pro-apoptotic effects in 
vitro. The combination of aspirin and sorafenib led to downregulation of at least two 
anti-apoptotic proteins in several cell lines. The possible contribution of these proteins to 
TRAIL resistance is investigated. Finally, we assess the physiological relevance of the 
lesser-known of our two targets by evaluating its basic expression in normal colorectal 
epithelium, colorectal adenoma and colorectal carcinoma using immunohistochemical 
staining of patient tissue. Material from patients with the sporadic form of the disease 
and with Lynch syndrome has been included in this study. 
Finally, chapter 7 summarizes the results of this thesis and proposes future 
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Formation of the pro-apoptotic death-inducing signaling complex (DISC) can be 
initiated in cancer cells via binding of tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) to its two proapoptotic receptors, TRAIL receptor 1 (TRAIL-R1) and 
TRAIL-R2. Primary components of the DISC are trimerized TRAIL-R1/-R2, FADD, 
caspase 8 and caspase 10. The anti-apoptotic protein FLIP can also be recruited to the 
DISC to replace caspase 8 and form an inactive complex. Caspase 8/10 processing at the 
DISC triggers the caspase cascade, which eventually leads to apoptotic cell death. 
Besides TRAIL, TRAIL-R1- or TRAIL-R2- selective variants of TRAIL and agonistic 
antibodies have been designed. These ligands are of interest as anti-cancer agents since 
they selectively kill tumor cells. To increase tumor sensitivity to TRAIL death receptor-
mediated apoptosis and to overcome drug resistance, TRAIL receptor ligands have 
already been combined with various therapies in preclinical models. In this review, we 
discuss factors influencing the initial steps of TRAIL apoptosis signaling pathway, 
focusing on mechanisms modulating DISC assembly and caspase activation at the DISC. 
These insights will direct rational design of drug combinations with TRAIL receptor 
ligands to maximize DISC signaling. 






C. TRAIL-induced DISC formation and apoptotic signaling pathway 
D. Combination therapy enhances TRAIL-induced apoptosis  
E. TRAIL combination therapy enhances DISC formation 
F. Loss of TRAIL-R1 and TRAIL-R2 expression 
G. DISC component polymorphisms and functionality 
H. Death receptor-selective TRAIL variants 
I. TRAIL death receptor-specific antibodies 
J. Regulation of TRAIL death receptor-mediated apoptotic signaling at the cell 
membrane 
1. TRAIL-R1 and TRAIL-R2 aggregation promotes DISC formation 
2. Lipid raft localization stimulates TRAIL death receptor aggregation 
3. Receptor internalization hampers TRAIL death receptor-mediated apoptosis 
K. Post-translational modifications of the DISC components 
1. TRAIL death receptor O-glycosylation facilitates receptor aggregation 
2. TRAIL-R1 S-nitrosylation stimulates caspase 8 cleavage 
3. S-palmitoylation of TRAIL-R1 promotes its oligomerization 
4. Caspase 8 phosphorylation prevents its cleavage at the DISC 
5. FLIP phosphorylation lowers its affinity for the DISC 
6. DISC protein ubiquitination differentially regulates DISC composition 
L. Influence of survival pathways on DISC formation 
1. The pro- and anti-DISC effects of protein kinase C 
2. The ERK1/2 signaling pathway inhibits caspase 8 cleavage 
3. The anti-DISC effects of active CKIα and CKIIα 
M. DISC regulation by recruitment of additional proteins 
1. PED/PEA-15 blocks caspase 8 cleavage at the DISC 
2. Blockade of DISC formation by the DDX3/GSK3/cIAP-1 capping complex 
3. The pro- and anti-DISC properties of the various IG20 gene family isoforms 







Programmed apoptotic cell death (or apoptosis) is a process by which unwanted cells 
are eliminated from multicellular organisms in a non-harmful way (1-4). The list of such 
unwanted cells includes malignant cells, infected cells or certain lymphocytes. 
Interestingly, although cancer originates from uncontrolled cell proliferation, cancer 
cells tend to exhibit more apoptosis than normal cells (5-7). This property may 
contribute to the effectiveness of some of the cytotoxic and targeted agents used in the 
clinic (8). 
Apoptosis can be initiated via two canonical pathways: the intrinsic and the 
extrinsic pathway, which both ultimately activate the same effector caspases and 
apoptosis effector molecules. Extrinsic cell death is triggered by the binding of tumor 
necrosis factor (TNF) superfamily ligands to their cognate receptors, stimulating their 
respective apoptotic pathways. Although the CD95-mediated apoptotic pathway is by 
far the best understood of these pathways, the TRAIL death receptor-mediated 
apoptotic pathway is clinically more attractive while it still shares numerous key 
components with the CD95-mediated apoptotic pathway (9,10). The trimeric β-sheet 
endogenous protein TRAIL binds to its trimeric membrane TRAIL-R1 and TRAIL-R2, 
initiating the formation of death-inducing signaling complexes (DISCs) that stimulate 
the caspase cascade, eventually leading to apoptosis. Although CD95-mediated 
apoptosis has offered a very useful mechanistic model for the TRAIL apoptotic 
pathway, sensitivity to stimulation of these two pathways is not necessarily the same in 
identical cancer cells, suggesting critical regulatory differences (11,12). Importantly, the 
clinical development of TRAIL receptor ligands is markedly more advanced than that of 
CD95 ligands because of the minimal toxicity of the former and the high toxicity of the 
latter observed in preclinical studies (13,14). 
Two types of cancer cells have been identified based on their sensitivity to 
stimulation of the extrinsic pathway. Type I cells do not need the mitochondria to enter 
apoptosis, while type II cells require mitochondrial amplification of the extrinsic signal 
to achieve sufficient caspase cleavage for the initiation of apoptosis (15). Since most 
cancer cells express membrane TRAIL death receptors, there is a strong rational for 
modulating TRAIL-induced apoptosis directly at the DISC or at the level of the intrinsic 
pathway. Many of the drugs that have been combined with TRAIL receptor ligands thus 
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far have been chosen based on their primary ability to activate the mitochondrial 
pathway of apoptosis; the goal was thereby to stimulate both the intrinsic and extrinsic 
pathway. Substantial data show that TRAIL death receptor-mediated apoptosis can 
already be modulated at the cell membrane itself. This review will discuss the proteins 
and pathways that offer interesting or novel targets for combination with TRAIL 
receptor-targeted therapies, with a focus on approaches influencing caspase 8 activation 
at the DISC. We will emphasize on TRAIL receptor ligand-specific and drug-specific 
abilities to promote DISC formation, TRAIL death receptor signaling modulation in 





TRAIL was first identified independently by Wiley et al. and Pitti et al. (10,16). This 
naturally-occurring ligand is, in its recombinant human (rh) form rhTRAIL, a promising 
therapeutic agent. This is in part due to TRAIL’s ability to induce apoptosis in a wide 
variety of tumor cells while sparing normal cells. Endogenous TRAIL is expressed on 
natural killer (NK) cells, macrophages, T-cells, and dendritic cells and is thought to 
function as an immune defense mechanism by killing virus-infected and malignant cells 
(17). TRAIL knockout (-/-) mice were viable and did not display any hematological 
defects (18). An important role for TRAIL in tumor immune surveillance was 
demonstrated using TRAIL-/- mice. Compared to wild type (wt) mice, the TRAIL-/- 
mice showed increased susceptibility to experimental as well as spontaneous tumor 
metastases and showed increased tumor initiation following treatment with the 
chemical carcinogen 3-methylcholanthrene (MCA) (18). In addition, administration of a 
neutralizing monoclonal antibody against endogenous TRAIL increased MCA-induced 
tumor development in wt mice (19). In TRAIL receptor-deficient mice, the primary 
tumor as induced by the carcinogen 7,12-dimethyl-benz-anthracene (DMBA) and the 
tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) were unaffected by TRAIL 
neutralization (20). However, TRAIL receptor-deficient mice showed enhanced lymph 
node metastases, suggesting a more specific role for the TRAIL-TRAIL receptor 
interaction in the prevention of metastases. 
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Several TRAIL molecules have been generated to utilize TRAIL as an anti-cancer 
agent, namely histidine (his)-tagged TRAIL, leucine zipper (LZ)-TRAIL, isoleucine 
zipper (IZ)-TRAIL, flag-tagged TRAIL and recombinant human (rh)TRAIL. A central 
zinc atom bound to cysteine-230 of each rhTRAIL subunit is essential for stability and 
function of the trimer rhTRAIL molecule (21). LZ-TRAIL was formed by linkage of 
exogenous leucine zipper to the extracellular region of TRAIL, resulting in a stable 
trimeric molecule. His-tagged TRAIL and flag-tagged TRAIL induced apoptosis in 
cultured human hepatocytes and in human brain slices respectively, raising concerns 
about toxicity (22,23). In vitro and in vivo experiments with LZ-TRAIL and rhTRAIL 
demonstrated that these molecules, as stable trimers devoid of a his- or flag-tag, can be 
used safely without causing (liver) toxicity (24-26). 
The safety and pharmacokinetics of rhTRAIL as a single agent has been tested in 
a phase 1 clinical trial. RhTRAIL can be administered safely as drug-related toxicity was 
mild to moderate and the maximum tolerated dose was not reached. From the 51 
patients included in the trial, 1 had a partial response and 17 patients experienced a 
stable disease (27).  
 
C. TRAIL-induced DISC formation and apoptotic signaling pathway 
 
TRAIL can bind five receptors, including TRAIL-R1/death receptor 4 (DR4) and TRAIL-
R2/DR5, which contain a death domain (DD), and two decoy receptors (DcRs), TRAIL-
R3/DcR1 and TRAIL-R4/DcR2, without a functional DD. Osteoprotegerin (OPG) is a 
secreted soluble TRAIL receptor. Two isoforms of TRAIL-R2 have been described, 
designated TRAIL-R2(L)/DR5L for the longer form and TRAIL-R2(S)/DR5S for the 
shorter form (28). Both forms are expressed in normal and tumor tissues, but the ratio 
varied among the tissues and cell lines that were examined. Whether the two isoforms 
differ functionally is still unclear (28). A decoy function for TRAIL-R3 and TRAIL-R4 
has only been demonstrated in overexpression studies (29,30). It has been shown that 
TRAIL decoy receptors could prevent apoptosis signaling via complex formation with 
TRAIL-R1 and/or TRAIL-R2, resulting in an ineffective DISC (31,32). Upon binding of 
TRAIL to the TRAIL death receptors, receptor trimerization occurs, which leads to 
clustering of their DDs and formation of the DISC comprising of Fas-associated death 
domain (FADD), caspase 8 and 10 (33). The anti-apoptotic protein FLIP can also be 
Turning on TRAIL death-receptor mediated apoptosis in cancer 
23 
recruited to the DISC to replace caspase 8 and form an inactive complex (34). While 
caspase 8 is essential, caspase 10 is not required for apoptosis induction by TRAIL (35). 
DISC formation results in caspase 8 activation. In so-called type I cells, the extrinsic (or 
death receptor) pathway is induced whereby active caspase 8 directly activates the 
effector caspases 3, 6 and 7, eventually triggering apoptosis. In type II cells, the intrinsic 
(or mitochondrial) pathway is necessary to fully activate caspase 3 via caspase 8-
dependent cleavage of the Bcl-2 family member Bid into its active form tBid. 
Translocation of tBid to the mitochondria induces Bax and Bak to form pores in the 
outer mitochondrial membrane. This allows release of the pro-apoptotic intermembrane 
space of mitochondria proteins cytochrome c, apoptosis inducing factor (AIF) and 
Smac/DIABLO into the cytoplasm. In the presence of dATP, cytochrome c induces the 
interaction of apoptotic protease activating factor 1 (Apaf-1) with caspase 9 resulting in 
the formation of the so-called apoptosome in which caspase 9 is activated. This 
subsequently leads to the activation of effector caspases and apoptosis. In type I cells, 
this mitochondrial pathway can be activated as well, but is not essential for apoptosis 
induction.  
In addition to activation of apoptosis signaling pathways, TRAIL has been linked 
to non-apoptotic pathways as well, namely nuclear factor (NF)-kappaB, protein kinase B 
(PKB/Akt) and the mitogen-activated protein kinase (MAPK) signaling pathways, 
thereby promoting cell survival. This suggests that there is an important balance 
between cell death and survival signaling upon TRAIL binding, as extensively reviewed 
by Falschlehner et al. (36). 
 
D. Combination therapy enhances TRAIL-induced apoptosis 
 
TRAIL targets the extrinsic apoptosis pathway, while chemo- and radio-therapy mainly 
inhibit cell growth and/or activate the intrinsic apoptosis pathway. Combination of 
either chemo- or radio-therapy with TRAIL can activate both apoptosis pathways and 
increase their anti-tumor effect. Moreover, activation of both the extrinsic and the 
intrinsic pathway can initiate crosstalk between the two pathways. Such crosstalk can 
take place via caspase 8-induced tBid resulting in stronger activation of the 
mitochondrial apoptotic pathway, or via chemo- or radio-therapy induced enhanced 
expression levels of TRAIL death receptors. 
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Combinatorial treatments with TRAIL can therefore overcome tumor cell 
resistance to single agent therapies. In Table 1, examples are given of combination 
studies of TRAIL with various therapies such as proteasome inhibitors, DNA damaging 
agents, non-steroidal anti-inflammatory drugs, and ionizing radiation (37). Combined 
treatment with these therapies induced the expression of TRAIL-R1 and/or TRAIL-R2 
and promoted TRAIL-induced apoptosis. In many studies, the enhancement of TRAIL-
induced apoptosis has only been attributed to TRAIL death receptor upregulation. The 
overview presented in Table 1 demonstrates that there is a large variation in drug- or 
irradiation-induced TRAIL-R1 and/or TRAIL-R2 upregulation. Although TRAIL-R2 
was upregulated more frequently than TRAIL-R1, there is no drug that specifically 
upregulates either TRAIL-R1 or TRAIL-R2, or tumor-specific upregulation of a 
particular TRAIL death receptor. In addition, basal TRAIL death receptor membrane 
expression itself does not seem to correlate with TRAIL sensitivity, indicating the 
involvement of more downstream mechanisms (38). In this respect, drug-induced effects 
on other DISC components FADD, caspase 8 and 10, and FLIP have been considered 
(33). Transcription- and translation-dependent decreases in caspase 8 levels or increases 
in FLIP levels have both been frequently associated with TRAIL resistance. Numerous 
drugs have indeed been shown to restore TRAIL sensitivity primarily by increasing 
caspase 8 levels and/or decreasing FLIP levels (39-41).  
In the clinic, rhTRAIL has been combined with rituximab, a CD20-targeting 
antibody and chemotherapy. The combination of rhTRAIL with rituximab was well 
tolerated and the maximum tolerated dose was not reached. Twelve patients with 
relapsed low-grade non-Hodgkin’s lymphoma (NHL) were included and three complete 
tumor responses were observed as well as three partial responses (42). In another 
clinical trial, rhTRAIL was combined with carboplatin, paclitaxel and bevacizumab, an 
anti-VEGF antibody. The preliminary data reports of this ongoing study in non-small 
cell lung cancer (NSCLC) patients showed one complete response and nine partial 
responses out of twenty four patients (43). The clinical data obtained so far in phase 1 
trials demonstrate that rhTRAIL can be administered safely and shows potential as an 
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Table 1. Effects of anti-cancer treatments on TRAIL-R1 and/or TRAIL-R2 expression. 
Treatment 
TRAIL-R1 
mRNA   protein 
TRAIL-R2 
mRNA   protein 
Tumor type Reference 














































































































































































5-FU n.d.  n.d.  Hepatocellular (76) 
 
 
Legends: not determined (n.d.), not present (n.p.), upregulation (), downregulation (), no effect (=), Histone 
Deacetylase (HDAC), non-steroidal anti-inflammatory drugs (NSAIDs), 5-FU (5-fluorouracil). Bold references 




E. TRAIL combination therapy enhances DISC formation 
 
In order to dissect the underlying mechanisms that contribute to TRAIL sensitization, 
the efficiency of DISC formation needs to be addressed. Indeed, several studies have 
shown that the effect of pre-treatment with various therapies not only caused TRAIL-
R1/-R2 upregulation but also enhanced DISC formation as described by some examples 
below (bold references in Table 1). 
Irradiation of Jurkat cells overexpressing Bcl-2 slightly induced TRAIL-R2 
membrane expression but greatly modulated the TRAIL-DISC as shown by 
immunoprecipitation (IP) of this complex using flag-tagged TRAIL (64). FADD 
recruitment to the DISC was four- to five-fold increased. As a consequence, the TRAIL-
DISC contained more activated caspase 8 and 10 following irradiation while the level of 
the long FLIP isoform (FLIPL) was unchanged, resulting in an higher caspase 8 and 
10/FLIPL ratio (64). 
The effect of the proteasome inhibitor bortezomib on TRAIL-induced apoptosis 
has been examined in hepatocellular, colonic, and pancreatic cancer cell lines (48,77). 
Both TRAIL-R1 and TRAIL-R2 surface expression were enhanced following bortezomib 
treatment in all tumor types. TRAIL death receptor upregulation was, however, only 
partially responsible for TRAIL sensitization since pre-incubation with TRAIL followed 
by single treatment with bortezomib still sensitized cells. In addition to this, Kyritsis et 
al. showed that TRAIL sensitivity was generally unrelated to TRAIL-R2 expression 
levels in a panel of eight glioma cell lines but instead was due to FLIP downregulation 
and caspase dependent Akt inhibition (78). Bortezomib was also used in primary human 
glioma cells. A collection of TRAIL-resistant primary tumor cells were sensitized to 
TRAIL by co-treatment with bortezomib (77). Subsequent analysis of the TRAIL-DISC 
employing biotinylated IZ-TRAIL revealed that pre-treatment with bortezomib 
increased the caspase 8/FLIP ratio at the DISC (48). On the contrary, proteasome 
inhibition was found to inhibit TRAIL-induced apoptosis in cervical cancer cells by 
blocking FLIP and XIAP degradation, which decreased the caspase 8/FLIP ratio at the 
DISC (79). It was demonstrated that timing of treatment with proteasome inhibitors 
prior to TRAIL treatment was important; first the proteasome inhibitor plays an anti-
apoptotic role by stabilizing FLIP and XIAP but at a later stage it has a pro-apoptotic 
function by blocking degradation of caspases (79). The opposite effects of proteasome 
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inhibition depending on the timing of administration reveal the importance of the 
caspase 8/FLIP ratio at the DISC. 
TRAIL-resistant hepatocellular carcinoma cells co-treated with 5-fluorouracil (5-
FU) and TRAIL demonstrated synergistic effects on apoptosis induction (76).  TRAIL-R2 
membrane expression was induced in all cell lines tested, TRAIL-R1 surface expression 
only in one cell line. The authors showed that TRAIL-R1/-R2 upregulation by 5-FU was 
not required for TRAIL sensitization since pre-incubation with TRAIL followed by 
treatment with 5-FU alone still sensitized cells. DISC-IP with biotinylated TRAIL 
showed that although TRAIL-R1 and TRAIL-R2 levels at the DISC remained similar 
following 5-FU combination treatment, TRAIL recruited more FADD and caspase 8, and 
similar levels of FLIP to the DISC in the cells co-treated with 5-FU (76). Colon carcinoma 
cells were also sensitized to TRAIL by 5-FU and by the chemotherapeutic drugs cisplatin 
and doxorubicin (74). Again, DISC-IP with flag-tagged TRAIL showed that 
chemotherapy enhanced FADD and pro-caspase 8 recruitment to the DISC, while 
recruitment of FLIP was decreased (74). The results of both studies imply that treatment 
with various drugs can result in a higher caspase 8/FLIP ratio at the TRAIL-DISC. 
Histone deacetylase (HDAC) inhibitors have been shown to affect TRAIL-DISC 
formation. In both renal cell carcinoma and bladder tumor cells, TRAIL sensitization 
was accompanied by enhanced TRAIL-R2 but not TRAIL-R1 surface expression. 
Treatment of cells with TRAIL and HDAC inhibitors increased TRAIL-R2 levels and 
enhanced FADD recruitment to the DISC as demonstrated by DISC-IP with flag-tagged 
TRAIL (53,54). Both TRAIL-R1 and TRAIL-R2 protein and mRNA levels were 
upregulated by the HDAC inhibitor LAQ284 in acute myelocitic leukemia (AML) cells 
(55). Membrane expression of TRAIL-R2 and to a lesser extent of TRAIL-R1 was 
induced, suggesting that HDAC inhibitors are not TRAIL-R1 specific. DISC-IP with a 
TRAIL-R1 antibody showed that pre-treatment with LAQ284 increased caspase 8 and 
FADD levels at the DISC, while FLIP levels were unchanged (55). Similarly, other 
HDAC inhibitors had a synergistic effect when combined with TRAIL in chronic 
lymphocytic leukemia (CLL) cells (56). TRAIL-R2 surface expression levels were only 
slightly affected. DISC-IP with biotinylated TRAIL showed that TRAIL-R2, FADD and 
caspase 8 recruitment to the DISC was increased following pretreatment with HDAC 
inhibitors, resulting in a higher caspase 8/FLIP ratio at the DISC (56).  
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These studies clearly demonstrate that irradiation- or drug-induced TRAIL 
sensitization facilitate the formation of DISCs and is a main factor in combined 
treatment sensitization. It is noteworthy that in all these studies biotinylated or flag-
tagged TRAIL was used to immunoprecipitate the DISC and these tagged ligands are 
known to be both more potent than un-tagged TRAIL and toxic to normal cells (25). It 
remains to be elucidated whether these DISC-IP findings are representative for signaling 
induced by non-tagged TRAIL. In order to fully exploit the apoptotic effect of TRAIL or 
combination treatment with TRAIL, we should gain more insight into the mechanisms 
underlying TRAIL sensitivity and drug-induced TRAIL sensitization in relation to DISC 
formation. The studies mentioned above demonstrate that the caspase 8/FLIP ratio at 
the DISC is unequivocally important for effective TRAIL signaling. Apart from 
differences in caspase 8/FLIP ratios at the DISC, other factors have been described to 
influence DISC formation and these will be addressed in the next section.  
 
F. Loss of TRAIL-R1 and TRAIL-R2 expression 
 
The genes coding for the four membrane TRAIL receptors are located on the 8p21-22 
chromosome (80-82). This chromosome is a hot-spot for deletions and is frequently 
subject to allelic loss in various cancer types, including non-Hodgkin’s lymphoma and 
lung, colon, breast, prostate, hepatocellular, ovarian, and head and neck cancer (83-92). 
Epigenetic silencing of TRAIL-R1 and/or TRAIL-R2 has been reported in melanoma and 
ovarian cancer (93,94). Because of monoallelic deletion, frequent downregulation of 
these TRAIL death receptors has been found in primary B-cell non-Hodgkin’s 
lymphoma (B-NHL) (95). TRAIL resistance was correlated with 8p chromosome deletion 
and reduced TRAIL death receptor expression in most lymphoma cell lines tested. 
Enhancing TRAIL-R1 or TRAIL-R2 expression by less than two-fold re-sensitized these 
cells to TRAIL, which suggests a gene-dosage effect of these deletions. In the FaDu 
nasopharyngeal cancer cell line, homozygous loss of TRAIL-R1 has led to TRAIL 
resistance, while re-expression of TRAIL-R1 could again sensitize this cell line to TRAIL 
(96). Similar results were seen in the ovarian cancer line A2780, where reestablishing 
TRAIL-R1 expression with the demethylating agent 5-aza-2’-deoxycytidin or transient 
transfection with a full-length TRAIL-R1 construct restored sensitivity to TRAIL (94). It 
is noteworthy that TRAIL resistance in A2780 cells could also be overcome by specific 
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targeting of TRAIL-R2 with a TRAIL-R2-specific form of TRAIL or combination with 
cisplatin, both in vitro and in vivo (97). Additional data indicate that membrane TRAIL-
R1 levels correlate with TRAIL sensitivity in different cancer cell types (98-100). 
Conversely, studies showed that TRAIL death receptor expression generally tends to 
increase during carcinogenesis, and tumors often express at least one TRAIL death 
receptor (72,101,102). Thus, although complete loss of both TRAIL-R1 and TRAIL-R2 
might not be frequent, loss of one TRAIL death receptor only is sufficient to induce 
TRAIL resistance. In cells that have lost one of the TRAIL death receptor, combination 
therapies that either increase TRAIL-signaling via the remaining receptor or reestablish 
expression of the silenced receptor can restore TRAIL sensitivity. 
 Whereas mice lacking TRAIL are viable, both caspase 8 and FADD are crucial to 
embryonic development and normal lymphocyte proliferation (103). These findings 
make complete loss of expression of these proteins less likely than loss of TRAIL death 
receptors.  
MiRNAs are a family of small (18-25nt) non-coding RNAs that regulate protein 
expression at a post-transcriptional level via binding to specific mRNAs. Recently, 
several screens have been performed to identify miRs that are involved in TRAIL 
signaling and sensitivity in cancer (104,105). One of these screens identified miRs that 
regulate expression of DISC components (105). miR-145 and -216 were predicted to 
target TRAIL-R1 and TRAIL-R2, while FADD was a predicted target of MiR-182 and -96 
(105). Although these studies are preliminary, miRNAs affecting DISC components 
could constitute interesting markers for TRAIL death receptor-mediated sensitivity 
and/or drug targets in the future. 
 
G. DISC component polymorphisms and functionality 
 
Besides loss of TRAIL-R1 or TRAIL-R2 expression in tumor cells, alterations in the 
TRAIL death receptor gene sequences might play a role in TRAIL sensitivity (see Table 
2). 
 In hematological tumors, a variant of TRAIL-R1 with a single-nucleotide 
polymorphism within the extracellular cysteine-rich domain was associated with several 
types of cancer, including CLL and mantle cell lymphoma (MCL) (106). This is 
particularly interesting since TRAIL-induced apoptosis was shown to depend on 
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TRAIL-R1 in CLL cells (107). Several other polymorphisms leading to codon changes, 
often found in the DD or the cysteine-rich domain of TRAIL-R1 or TRAIL-R2, have also 
been associated with enhanced risk for MCL and B-cell lymphoid neoplasms (108). Since 
these cancers could, in part, develop due to inefficient TRAIL receptor-mediated 
signaling, they might also respond poorly to TRAIL death receptor-targeted therapies. 
In solid tumors, two missense polymorphisms potentially affecting TRAIL 
binding were found to co-segregate in the extracellular domain of TRAIL-R1 in primary 
NSCLC, gastric adenocarcinoma and in head and neck squamous cell cancer (HNSCC). 
These polymorphisms were also present in matched normal tissues and therefore do not 
constitute mutations per se. However, the frequency of being homozygous for these two 
polymorphisms was increased in the cancer samples compared to matched controls, 
suggesting a predisposition to cancer (109). Polymorphic alterations in TRAIL-R1, 
mostly in the extracellular cysteine-rich domain of the receptor, were increased in 
osteosarcoma, but also in prostate cancer metastases (110,111). TRAIL-R2 mutations 
were found in HNSCC, NSCLC, breast cancers, hepatocellular carcinomas and gastric 
cancers, often in the exon coding for the DD (exon 9) (112-116)(Table 2). 
In metastatic breast cancers, Shin et al. found at least four TRAIL-R2 mutations 
that interfere with apoptosis transduction in metastatic lesions, while three other 
mutations were both present in the primary tumors and in the metastatic lesions (116). 
Lack or truncation of the DD of TRAIL-R2 was reported in a sporadic colon cancer 
patient with liver metastasis and in the RT4 bladder cancer cell line, respectively 
(118,119). 
Several of the TRAIL-R1 and TRAIL-R2 mutations have been found in conserved 
hydrophobic residues and charged amino acids of the DD in cancer cells (113) where 
they hampered efficient DISC recruitment of FADD and caspase 8 (120). Bin et al. 
recently tested four additional point mutations frequently found in the DD of TRAIL-R2 
in cancer cells (121). Although his-tagged TRAIL could still bind to mutated TRAIL 
death receptors, efficient DISC formation was hindered, and TRAIL sensitivity was 
decreased. His-tagged TRAIL treatment did not induce formation of inactive wild type 
TRAIL-R1/mutant TRAIL-R2 heterotrimers. It is therefore unclear why excess 
concentrations of his-tagged TRAIL could not restore TRAIL sensitivity by activating 
the functional TRAIL-R1. Although this could be partially due to competition between 
the overexpressed mutant TRAIL-R2 and endogenous TRAIL-R1, it is interesting that 
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TRAIL signaling was less hampered by TRAIL-R2 loss than by TRAIL-R2 mutations. 
Only TRAIL-R1-selective agonists could overcome the effects of mutations in TRAIL-R2 
and induce apoptosis. Given the presence of TRAIL death receptor mutations in circa 
10% of human tumors, prior screening could therefore be critical for the choice of 
ligands. Furthermore, although the negative effects of TRAIL-R1 or TRAIL-R2 mutations 
on DISC formation have been described, the consequences on TRAIL receptor-mediated 
pro-survival signaling still need to be addressed. 
 
 














Mutations observed in 
TRAIL-R2 (location) 
Reference 
B-NHL 117 2 (DD) 117 6 (4 different 
mutations in the DD, 1 
truncating mutation 
before the DD) 
(117) 
HNSSC n.d. n.d. 60 2 (DD, incl. 1 germline 
truncating mutation) 
(114) 
NSCLC n.d. n.d. 104 11 (10 in the DD, 1 in 
intro 8) 
(113) 





n.d. n.d. 43 3 (115) 







Legends: not determined (n.d.), head and neck squamous cell cancer (HNSCC), non-small cell lung cancer 
(NSCLC), B-cell non-Hodgkin’s lymphoma (B-NHL), hepatocellular cancer (HCC). * Only the DD-coding 
region was analyzed. 
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It should also be noted that some rare polymorphisms and mutations have been 
reported in the genes coding for caspase 8 and FADD (122,123). In comparison, TRAIL-
R1 and TRAIL-R2 gene alterations have been found in a significant number of tumors. 
Without screening options to determine functionality of either TRAIL-R1 or TRAIL-R2, a 
combination of TRAIL-R1 and TRAIL-R2-specific ligands might be a strategy to increase 
the likelihood of activating the TRAIL death receptor(s) and prevent eventual 
decoupling effects due to the presence of a non-functional receptor. 
 
H. Death receptor-selective TRAIL variants 
 
As it has been shown that in CLL cells TRAIL specifically signals through TRAIL-R1 
(107), the generation of TRAIL variants with a higher affinity for TRAIL-R1 and/or 
TRAIL-R2 has raised interest in order to enhance DISC formation. Several TRAIL-R1- 
and TRAIL-R2-selective TRAIL variants were designed using computational design 
(124-126). Two TRAIL-R1-selective forms of TRAIL were generated with a single amino 
acid mutation at position 218 from asparagine to either histidine or tyrosine in the 
receptor binding domain. Binding assays revealed that both TRAIL-R1-selective forms 
had a decreased affinity for TRAIL-R2 and TRAIL decoy receptors as compared to 
normal TRAIL, while their affinity for TRAIL-R1 was unchanged. The TRAIL-R1-
selective TRAIL variants effectively induced apoptosis in cell lines that specifically 
signal via TRAIL-R1 whereas almost no apoptotic effect was induced in cells expressing 
exclusively TRAIL-R2. However, the TRAIL-R1- selective variants were less effective in 
TRAIL-R1-responsive cells when compared to TRAIL (124). Therefore, new TRAIL 
variants with increased affinity to both TRAIL-R1 and TRAIL-R2 were designed, by 
replacing glycine-131 by lysine or arginine (126).  The efficacy of these TRAIL variants 
was compared to the efficacy of  TRAIL in a panel of cell lines that signal TRAIL 
induced apoptosis via TRAIL-R1, TRAIL-R2 or both receptors, and demonstrated an 
increased apoptotic effect in all cell lines regardless of their TRAIL death receptor 
signaling status (126). Using the same computational design, van der Sloot et al. 
generated a TRAIL-R2-selective TRAIL variant with mutations D269H and E195R, 
resulting in largely reduced affinity for TRAIL-R1, less affinity to TRAIL decoy 
receptors, but higher affinity for TRAIL-R2. This TRAIL-R2-selective variant induced 
more apoptosis than TRAIL in colon carcinoma, ovarian carcinoma and chronic myeloid 
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leukemia (CML) cells, while TRAIL-R1-selective cells were only sensitive to TRAIL 
(125). Upon combination with cisplatin, the TRAIL-R2-selective TRAIL variant showed 
enhanced anti-tumor efficacy as compared to rhTRAIL both in vitro and in a 
bioluminescent ovarian cancer xenograft model (97). 
Kelley et al. generated TRAIL death receptor-selective TRAIL mutants using a 
phage display approach (127). The TRAIL-R1-binding TRAIL mutants carried an Y189A 
mutation and had increased affinity for TRAIL-R1, while binding to TRAIL-R2 was 
undetectable. Mutations Q193K and Q193R in TRAIL proved to be important for its 
affinity for TRAIL-R2. In apoptosis assays, the TRAIL-R1-selective mutants were less 
potent as compared to flag-tagged TRAIL in lung carcinoma cells, whereas the TRAIL-
R2-selective mutants retained their apoptosis-inducing ability. However, the potency of 
the TRAIL-R1-selective mutants was not verified in cell lines exclusively expressing 
TRAIL-R1. MacFarlane et al. (128) demonstrated that the TRAIL-R1-selective variants 
described be Kelly et al. (127) did not induce apoptosis in Ramos cells, which were 
previously shown to signal via TRAIL-R1 (107). This strengthens the possibility that the 
mutations in the TRAIL-R1-selective TRAIL variant caused a loss in apoptotic potency. 
Therefore, the authors synthesized several new TRAIL-R1-selective TRAIL mutants. 
One TRAIL variant with five mutations (Q193S, N199V, K201R, Y213W, and S215D) 
induced less apoptosis in TRAIL-R2-positive Jurkat cells as compared to TRAIL, while 
its TRAIL-R1-specific activity in Ramos cells was preserved. In addition, primary CLL 
and MCL cells were sensitive to treatment with the TRAIL-R1-selective variant. DISC-
IPs in cells treated with this variant demonstrated enhanced recruitment of FADD and 
caspase 8 to the DISC, as compared to DISC-IPs after TRAIL exposure. This suggests 
that specific activation of the dominantly signaling TRAIL death receptor by a selective 
TRAIL mutant results in enhanced DISC formation and apoptosis induction as 
compared to the use of TRAIL that binds both TRAIL death receptors. 
It is currently not possible to determine which TRAIL death receptor 
predominantly transduces the apoptosis signal in a given primary tumor. However, the 
development TRAIL-R1- and TRAIL-R2-selective TRAIL variants opens ways to 
circumvent the TRAIL decoy receptors and warranty activation of the dominant TRAIL 
death receptor when used in combination. 
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I. TRAIL death receptor-specific agonistic antibodies  
 
In addition to the receptor-selective TRAIL variants, TRAIL-R1- and TRAIL-R2-specific 
agonistic antibodies have been developed. One important difference between the 
agonistic antibodies and rhTRAIL is the extended serum half-life of the antibodies in 
men, which is around 2-2.5 weeks whereas it is 25 min for rhTRAIL (129,130).  
HGS-ETR1 (mapatumumab) is the only anti-TRAIL-R1 antibody currently in 
clinical development, while five anti-TRAIL-R2 antibodies are being tested, namely 
HGS-ETR2 (lexatumumab), Apomab (PRO95780), TRA-8 (CS-1008), AMG655 and 
LBY135. These agonistic antibodies effectively induced apoptosis in a broad panel of 
cancer cell lines, without toxicity to normal hepatocytes (131-139). Cross-linking of the 
anti-TRAIL-R2 antibodies was either required (TRA-8), or beneficial (HGS-ETR2 and 
Apomab) for their apoptotic effect in vitro (132,137,138). Apomab, TRA-8 and LBY135 
were shown to inhibit tumor cell growth in xenograft mice models (137-140). TRA-8 also 
induced cell death in ex vivo tissue slice models with primary human ovarian and 
cervical cancer tissue (141,142).  
Combination of chemotherapeutic drugs with the TRAIL death receptor-specific 
agonistic antibodies or TRAIL variants may show whether a drug specifically sensitizes 
cells via TRAIL-R1 or TRAIL-R2. Bortezomib was combined in vitro with both HGS-
ETR1 and HGS-ETR2 which resulted in additive or synergistic effects on (apoptotic) cell 
death in leukemic and lymphoma cells (133,136). Bortezomib treatment also sensitized a 
panel of NSCLC cells to both HGS-ETR1 and HGS-ETR2, while cells were resistant to 
treatment with the antibodies alone. Remarkably, bortezomib only induced expression 
of TRAIL-R2 while TRAIL-R1 levels remained the same. Sensitization to HGS-ETR1 can 
thus not be attributed to TRAIL-R1 upregulation (143). The effect of radiation on the 
sensitivity for different antibodies was also investigated. In colon carcinoma cell lines, 
increased sensitivity to HGS-ETR1 and HGS-ETR2 was seen following irradiation (134). 
In cervical cell lines, radiation was found to sensitize cells to TRAIL via TRAIL-R1, while 
radiation sensitized cells to both TRAIL-R1 and TRAIL-R2 antibodies (63). In addition, 
cervical and breast cancer cells were successfully sensitized to the anti-TRAIL-R2 
antibody TRA-8 in vitro as well as in vivo (144,145). Doxorubicin was shown to sensitize 
primary lymphoma cells to both HGS-ETR1 and HGS-ETR2 in vitro, and breast cancer 
cells to TRA-8 in vitro as well as in vivo (133,144). These examples of studies combining 
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different drugs or radiation with agonistic antibodies against TRAIL-R1 or TRAIL-R2 
further suggest that the observed sensitization is not TRAIL death receptor specific.  
TRAIL death receptor-specific antibodies are currently under investigation in 
several phase 1 and 2 clinical trials, as single agents or in combination with various 
chemotherapeutics (129,130,146-160). Tumor responses were observed in 3 out of 40 
extensively pretreated NHL patients (one complete and two partial responses) on anti-
TRAIL-R1 antibody (151). The antibodies are well-tolerated, also when combined with 
chemotherapy, and may be particularly interesting when used in combination with 
other anti-tumor agents. An overview of the anti-TRAIL-R1 and anti-TRAIL-R2 
agonistic antibodies under clinical investigation, and of particular interest in 
combination with other anti-tumor agents, was recently presented by Oldenhuis et al. 
(14). 
 
J. Regulation of TRAIL death receptor-mediated apoptotic signaling at the cell 
membrane 
 
The caspase cascade can be strongly influenced by membrane-proximal events, 
independent of TRAIL death receptor or caspase 8 expression levels. Several factors 
contributing to efficient DISC recruitment and apoptosis have been described. 
 
1. TRAIL-R1 and TRAIL-R2 aggregation promotes DISC formation 
TRAIL death receptors can trimerize independently of the presence of TRAIL (161), but 
stimulation by oligomers of at least 3 ligands is required for DISC activation (21). Unlike 
TRAIL, anti-TRAIL-R1 or anti-TRAIL-R2 agonistic antibodies bind only two receptor 
subunits and as a consequence these ligands possess different abilities to trigger TRAIL 
death receptor oligomerization. A study by Chuntharapai et al. established that mouse 
anti-human TRAIL-R1 antibodies require cross-linking to be effective in a variety of 
cancer cell lines in vitro (162). In vivo, these antibodies demonstrated efficacy in different 
human xenograft mouse models, even in absence of the exogenous cross-linking agents 
that are essential for their activity in vitro. These results support the existence of an 
endogenous oligomerization mechanism, which based on in vitro and in vivo 
experiments are independent of both the antibody-dependent cell-mediated cytotoxicity 
and the complement-dependent cytotoxicity (139,162). 
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Remarkable discrepancies have been found between TRAIL-R1 and TRAIL-R2 
requirement for ligand-induced aggregation. TRAIL-R2 only responded to membrane-
bound or cross-linked soluble flag-tagged TRAIL, whereas soluble flag-tagged TRAIL 
(sTRAIL) was sufficient to induce TRAIL-R1-mediated apoptosis (163,164). Not all 
TRAIL preparations require aggregation to activate TRAIL-R2 since rhTRAIL can 
stimulate this receptor without cross-linking (125,165). However, the results obtained 
with sTRAIL suggest that ligand aggregation is more important for TRAIL-R2 than for 
TRAIL-R1. It is noteworthy that the potency of sTRAIL, anti-TRAIL-R1 and anti-TRAIL-
R2 antibodies was enhanced upon ligand pre-aggregation, which indicates that 
aggregation can be beneficial to signaling via both TRAIL-R1 and TRAIL-R2 (163). The 
superior importance of ligand cross-linking for TRAIL-R2 compared to TRAIL-R1 was 
further demonstrated with anti-TRAIL death receptor agonistic antibodies.  Apoptotic 
signaling could only be initiated by cross-linked anti-TRAIL-R2 antibodies in CLL cells, 
whereas anti-TRAIL-R1 antibodies induced apoptosis in absence of cross-linking. 
Accordingly, TRAIL-induced apoptosis signaling was predominantly mediated by 
TRAIL-R1 in these cells (166). It is remarkable that HGS-TR2J, an anti-TRAIL-R2 
agonistic antibody, induced apoptosis in absence of cross-linking (direct agonist) and 
was more efficient than its cross-linking-dependent agonist counterpart HGS-ETR2 in a 
xenograft model. This indicates that binding to specific sites in the extracellular domain 
of TRAIL-R2 can induce sufficient aggregation (167). Unfortunately, no clinical trials 
have been reported for HGS-TR2J (http://clinicaltrials.gov/ct2/home).  Finally, the 
possibility that excessive aggregation might enhance toxicity in normal cells should be 
further evaluated in order to design optimal therapeutics. His-tagged and flag-tagged 
TRAIL, crosslinked or not with an antibody, tend to aggregate as opposed to non-tagged 
soluble trimeric forms such as LZ- or rh-TRAIL. The presence of aggregates that would 
induce excessive aggregation of TRAIL-R1 and TRAIL-R2 could explain the toxicity of 
these tagged forms of TRAIL toward normal cell types as opposed to stable TRAIL 
trimers (25,165,168).  
In addition to the epitopes recognized by the anti-TRAIL-R1 or anti-TRAIL-R2 
antibodies, studies have shown that the antibody isotypes should also be taken into 
account in vivo. Because of the strong aggregating properties of these isotypes, IgM and 
IgG3 antibodies raised against CD95 exhibited liver toxicity (13). Murine IgG2a isotype 
antibodies have been reported to be more potent than murine IgG1 isotype antibodies 
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for inducing complement-dependent death receptor oligomerization in vivo (169). 
Although both murine anti-TRAIL-R1 isotypes exhibit similar apoptosis induction in 
vitro, mouse IgG1 anti-human TRAIL-R1 antibodies are unexpectedly more effective in 
human xenograft mouse models than the IgG2 variants (162). Altogether, these findings 
highlight the need for further studies on the contribution of the immune response to the 
potency of the various isotypes targeting the same TRAIL death receptor in vivo. 
Although aggregation of the TRAIL death receptors can be induced via ligand 
binding, various drugs have also been shown to stimulate receptor aggregation. The bile 
acid glycochenodeoxycholic acid (GCDCA) increased TRAIL-R2 expression and 
aggregation in a punctuated pattern in a hepatocellular cancer cell line but this was not 
seen for TRAIL-R1. These changes were associated with an increase in TRAIL sensitivity 
(170). Similarly, LY303511, an inactive analogue of the phosphoinositide-3 kinase (PI3K) 
inhibitor LY294002, induced ligand-independent oligomerization of TRAIL-R2 in high 
molecular weight TRAIL-R2 complexes (200-400 kDa) and stimulated TRAIL-induced 
apoptosis. Imaging by confocal microscopy showed a more patchy distribution of 
TRAIL-R2 in LY303511-treated cells, which was coupled to higher FADD and caspase 8 
recruitment at the DISC (171). 
 
2. Lipid raft localization stimulates TRAIL death receptor aggregation 
The presence of TRAIL death receptors in lipid rafts on the cell membrane constitutes 
another essential mechanism for efficient TRAIL signaling. The term “lipid rafts” 
typically refers to insoluble detergent (often Triton X-100)-resistant membrane domains 
rich in sphingomyelin, sphingolipids and cholesterol (172-174). Proteins involved in 
various cellular signaling pathways, notably Src kinases, have been shown to 
distinctively associate with these lipid rafts, facilitating signal modulation (172,175). 
Numerous studies performed over the past 10 years have indicated that translocation of 
CD95 into lipid rafts is very important for its ligand sensitivity since it promotes 
receptor clustering and aggregation (176). Recent evidence now indicates that 
membrane rafts also play a crucial role in the regulation of TRAIL-induced cell death. 
TRAIL, alone or in combination with several chemotherapeutic agents, stimulates DISC 
formation by relocating DISC proteins into lipid rafts (Table 3). 
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Cell type Reference 
Edelfosine, 
perifosine 
MCD, filipin TRAIL-R1/-R2, 








Resveratrol nystatin TRAIL-R1/-R2, 




Depsipeptide nystatin TRAIL-R1/-R2 Lck Prostate 
cancer 
(180) 
rhTRAIL, cisplatin MβCD TRAIL-R1/-R2, 
FADD, caspase 8 




n.d. TRAIL-R2, caspase 8 Caveolin-1 Glioma (181) 
Quercetin nystatin TRAIL-R1/-R2, 

























Oxaliplatin nystatin TRAIL-R1/-R2 Ceramide Gastric 
cancer 
(185) 
Legends: not determined (n.d.), nystatin (cholesterol-sequestering agent), depsipeptide (FR901228, HDAC 
inhibitor), methyl-cyclodextrin (MCD, cholesterol-depleting agent), methyl-β-cyclodextrin (MβCD, 
cholesterol-depleting agent), filipin (cholesterol-sequestering agent), edelfosine and perifosine (synthetic 
alkyl-lysophospholipids), ganglioside (GM1), imipramine (acid sphingomyelinase inhibitor). 
 
Most studies have shown that lipid raft disruption leads to a loss of the 
sensitizing effects of these chemotherapeutic drugs, or to a general loss of TRAIL 
sensitivity. Work by Song et al. revealed that DISC formation could also take place in 
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non-raft fractions. However, the importance of the lipid rafts for effective TRAIL death 
receptor signaling was highlighted by the fact that their disruption with methyl-β-
cyclodextrin (MβCD) inhibited both caspase 8 cleavage and TRAIL-induced cell death in 
TRAIL-sensitive cells. Furthermore, in TRAIL-resistant NSCLC cells, TRAIL failed to 
recruit caspase 8 and FADD into lipid rafts, suggesting that lipid raft localization 
correlates with functional DISC formation (75).  
Although the molecular mechanisms behind TRAIL death receptor clustering into 
lipid rafts are not yet entirely clear, an intricate signaling cascade has already been 
established (see Figure 1). TRAIL stimulates accumulation of arachidonic acid by 
inducing release of reactive oxygen species (ROS) (186). This event induces translocation 
of acid sphingomyelinase (ASM) to the plasma membrane and activation of this 
enzyme, leading to ceramide production. Ceramide-rich caveolae are subsequently 
formed within the outer leaflet of the plasma membrane (183,186). These membrane 
domains promote TRAIL-R2 clustering and thereby enhance TRAIL sensitivity 
(183,186). Transient release of ceramide and clustering of TRAIL-R2 were seen in 
different types of ASM-positive cells, including cancer cells but not in ASM-negative 
splenocytes (186). The importance of this initial redox mechanism is supported by the 
fact that its inhibition by antioxidants such as N-acetylcysteine or Tiron blocks both 
ASM activation and TRAIL-induced apoptosis (186). Cyclooxygenase-2 (COX-2), which 
uses acid arachidonic as a substrate, prevents arachidonic acid accumulation, activation 
of ASM and TRAIL-induced apoptosis. Downregulation of COX-2 or addition of 
exogenous C16-ceramide can recapitulate these sensitizing effects, while inhibition of 
ASM with imipramine or lipid raft destruction with MβCD abolishes TRAIL-R2 
clustering in ceramide-rich domains (183). These findings underscore the importance of 
ASM-dependent lipid raft formation for TRAIL sensitivity. 
Martin et al. raised the possibility that type I and type II cells might have different 
lipid raft localization patterns. In type I cells, TRAIL-R2 and the DISC components were 
pre-existent within lipid rafts at the plasma membrane. In type II cells, pre-incubation 
with DuP697 was required for these proteins to colocalize. Interestingly, it was shown in 
glioma cell lines that TRAIL-induced translocation of TRAIL-R1 or TRAIL-R2 
concomitantly stimulates TNF-R1 and CD95 translocation into lipid rafts, suggesting a 










Figure 1: Model for TRAIL-R1/-R2 aggregation into lipid rafts. Upon binding of TRAIL to its TRAIL 
death receptors, little pro-apoptotic DISCs are formed. However, a rapid release of ROS causes 
arachidonic acid accumulation, which itself induces translocation of ASM to the plasma membrane and 
stimulates ASM activity. This leads to the production of sphingolipid ceramide in the outer leaflet of the 
cell membrane, initiating formation of ceramide-rich caveolae. These membrane structures, also called 
lipid rafts, promote aggregation of the TRAIL receptors. TRAIL death receptor aggregation within lipid 
rafts induces more efficient DISC formation, caspase cleavage and higher levels of apoptosis. 
Antioxidants such as N-acetylcysteine and Tiron can inhibit ROS production and lipid rafts formation. 
COX-2, by inhibiting the accumulation of arachidonic acid, inhibits acid sphingomyelinase activity as 
well as consequent TRAIL receptors aggregation in lipid rafts and apoptosis. TRAIL receptor aggregation 
and apoptosis can also be inhibited by imipramine, an ASM inhibitor. Lipid rafts can be disrupted by the 
cholesterol depleting agent β-MCD. Conversely, inhibition of COX-2 or addition of exogenous C16-
ceramide stimulates TRAIL-induced apoptosis. 
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Drug-induced lipid raft localization of TRAIL death receptors may not always 
contribute to the observed TRAIL sensitization. In breast cancer cells, the cyclin-
dependent kinase 2 inhibitor roscovitine increased the amounts of procaspase 8, FADD 
and TRAIL-R2 in the lipid raft fraction, DISC formation was enhanced, and cells were 
sensitized to TRAIL. However, lipid raft localization did not seem to contribute to the 
sensitizing effect of roscovitine as neither the cholesterol disrupting agent MβCD nor 
the ASM inhibitor imipramine were able to protect cells from the TRAIL-sensitizing 
effect of roscovitine (184). Importantly, predominant localization of TRAIL-R1 or 
TRAIL-R2 outside of lipid rafts can induce pro-survival signals, thereby adding even 
more complexity. In TRAIL-resistant NSCLC cell lines, TRAIL treatment only resulted 
in activation of the nuclear factor-kB and the extracellular signal-regulated kinase 1/2 
(ERK1/2) survival pathways. In these TRAIL-resistant cells, TRAIL-R1 and TRAIL-R2 
were primarily located outside of the raft fractions. Recruitment of Receptor-interacting 
protein (RIP) and FLIP at the DISC played a crucial role in both DISC assembly in the 
non-raft fraction and downstream stimulation of the survival pathways (75). 
Interestingly, although extensive data have been collected on the relation between 
lipid raft localization of TRAIL death receptors and apoptotic signal transduction, little 
is known about the recruitment of TRAIL decoy receptors to the lipid rafts, and its 
consequences for apoptosis. In various cell types, including cancer cells, TRAIL-R3 and 
TRAIL-R4 were mostly found in lipid rafts, where they competitively inhibited TRAIL 
binding to the TRAIL death receptors and consequently decreased TRAIL sensitivity 
(32). The influence of the lipid rafts on this decoupling effect of TRAIL decoy receptors 
has yet to be evaluated in a non-overexpression model. Future experiments are needed 
to determine whether TRAIL sensitizers directing TRAIL-R1 and TRAIL-R2 to 
membrane rafts also have stimulating effects on TRAIL-R3 and TRAIL-R4, which could 
at the same time dampen the pro-apoptotic effects of these drugs. If so, TRAIL-R1- or 
TRAIL-R2-specific agonists might potentially circumvent this problem. 
TRAIL death receptor localization seems to be regulated in a receptor-specific and 
cell-specific manner. Many studies have focused on TRAIL-R2, and have shown that 
signaling via this receptor depends on lipid raft localization. Type I cells, characterized 
by efficient DISC formation, tend to show more frequent TRAIL death receptor co-
localization within lipid rafts than type II cells. Many cytotoxic agents that enhance 
TRAIL sensitivity stimulate the recruitment of DISC proteins to membrane rafts. It is 
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noteworthy that within this new research field, the markers used to define membrane 
rafts often differ between studies. Results obtained following lipid raft isolation may 
depend largely on the type and concentrations of detergent used to extract the lipidic 
detergent-resistant fractions (187). Considering the exciting discoveries made during the 
last few years, further studies on the relationship between DISC formation, lipid rafts 
and the kinases found in these rafts are warranted. Upcoming studies should now 
greatly benefit from recent efforts to establish a consensus definition for these 
membrane rafts, for instance assessed by the Keystone symposium on lipid rafts and cell 
function (188). 
 
3. Receptor internalization hampers TRAIL death receptor-mediated apoptosis 
Receptor internalization plays a crucial role in TNF family member receptor signaling 
since this event is required for both TNF-R1- and CD95-mediated apoptotic signaling 
(189,190). Studies on the importance of TRAIL death receptor internalization have also 
been performed, with contrasting conclusions compared to TNF-R1 and CD95. TRAIL 
death receptor internalization, which was shown to be clathrin-dependent, does not 
seem to be necessary for TRAIL-induced apoptosis (191). In fact, caspase 8 cleavage was 
slightly enhanced when TRAIL death receptor internalization was blocked (191,192). 
TRAIL death receptor stimulation was found to disrupt the endocytosis machinery, 
possibly amplifying caspase cleavage at the DISC (191). In addition, it has been 
suggested that clathrin-independent mechanisms may also participate in TRAIL death 
receptor internalization (192). These substantial discrepancies between CD95 (or TNF-
R1) and TRAIL death receptor internalization are intriguing, and constitute one of the 
most striking differences between these pathways. In addition to TRAIL-induced 
internalization, TRAIL death receptors can also undergo constitutive endocytosis as part 
of a desensitizing mechanism, in leukemia as well as colon and breast cancer cells 
(98,100,193). This downregulation of the TRAIL death receptor was clathrin-dependent. 
Both TRAIL death receptor expression and TRAIL sensitivity could be restored by a 
general endocytosis inhibitor, phenylarsine oxide (PAO), by an inhibitor of clathrin-
mediated apoptosis, chlorpromazine, and by specific gene silencing of either adaptator 
protein 2 or clathrin (100). TRAIL-R1 was found to be internalized at a higher frequency 
than TRAIL-R2 despite similar mRNA and protein levels, which suggests an important 
role for TRAIL-R1 endocytosis in TRAIL resistance (98,100,193).  
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K. Post-translational modifications of the DISC components 
 
While the contribution of TRAIL death receptor upregulation to TRAIL sensitivity 
enhancement in response to chemotherapeutic drugs is still debated, it is clear that the 
caspase 8/FLIP ratio is one of the key factors influencing TRAIL sensitivity. Now, 
numerous post-translational modifications of the DISC proteins are also emerging as 
important mechanisms regulating TRAIL sensitivity in cancer cells (see Figure 2 and 3). 
 
1. TRAIL death receptor O-glycosylation facilitates receptor aggregation 
In connection with TRAIL death receptor aggregation, post-translational modifications 
of TRAIL-R1 and TRAIL-R2 such as receptor glycosylation have been shown to affect 
TRAIL signaling, thereby affecting TRAIL sensitivity (see Figure 2). O-linked 
glycosylation involves the binding of glycosyl groups to serine and threonine side 
chains that can improve ligand binding and membrane protein activation (194). Wagner 
et al. nicely demonstrated that specific O-glycosyltransferases were overexpressed in 
cancer tissue as compared to normal tissue and that their expression correlated with 
TRAIL sensitivity (38). Expression of the O-glycosylation initiating enzyme GALNT14 
was correlated with TRAIL sensitivity in pancreatic carcinoma, NSCLC cells and 
melanoma cells. In colon carcinoma, expression of GALNT3 and of the O-glycan-
processing enzymes FUT 3 and FUT 6 correlated with TRAIL sensitivity.  Inhibition of 
O-glycosylation enzymes by benzyl-a-GalNAc decreased TRAIL-induced apoptosis. 
SiRNA against GALNT14, GALNT3, FUT3, and FUT6 also reduced TRAIL sensitivity 
while overexpression of GALNT14 increased DISC formation and sensitized cells to 
TRAIL. Mass spectrometry of the extracellular domain of TRAIL-R2 indicated that 
TRAIL-R2 could be a direct target of GALNT14. It was suggested that O-glycosylation 
modulates TRAIL sensitivity by inducing TRAIL death receptor aggregation, thereby 
promoting DISC formation and caspase 8 activation (38). 
 
2. TRAIL-R1 S-nitrosylation stimulates caspase 8 cleavage 
S-nitrosylation refers to the covalent binding of a nitrogen monoxide group to a reactive 
thiol cysteine. This emerging post-translational protein modification regulates a wide 
range of signal transduction mechanisms, including apoptosis (195). TRAIL-R1 but not 
TRAIL-R2 was found to be S-nitrosylated following treatment with the nitric oxide- 
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Figure 2: The “good” DISC. Several events contribute to optimal caspase 8 cleavage at the DISC. In 
TRAIL-sensitive cells, TRAIL receptor-specific agonists bind to their cognate TRAIL receptor trimers, 
inducing their aggregation in lipid rafts. In this figure, TRAIL-R1 and TRAIL-R2 specifically designate 
homotrimers, while TRAIL-R1/-R2 refers to either type of trimer, including possible heterotrimers. 
Modified forms of the TRAIL death receptors such as O-glycosylated TRAIL death receptors, S-
nitrosylated TRAIL-R1 or S-palmitoylated TRAIL-R1 are more prone to aggregation and initiation of 
DISC formation. The SRP protein complex is involved in stabilizing TRAIL-R1 at the cell membrane, 
which increases its sensitivity to TRAIL-R1-specific agonists. Upon TRAIL death receptor stimulation, 
FADD is recruited to the TRAIL death receptor trimers, leading to caspase 8 recruitment and its cleavage 
into an active p18 cytoplasmic fragment. DISC formation and stability can be increased by IG20pa 
binding, PKCδ- or ROCK-dependent signals, thereby increasing caspase 8 processing. Caspase 8 cleavage 
is also enhanced by CUL3- and RBX-1-dependent polyubiquination of caspase 8, which allows p62 
binding, triggering both caspase 8 aggregation and auto-proteolytic cleavage of this protein. 




Figure 3: The “bad” DISC. Efficient DISC formation can be inhibited by numerous mechanisms in 
TRAIL-resistant cells. The soluble receptor to TRAIL (OPG) or the membrane TRAIL-R3/-R4 can prevent 
TRAIL binding to the TRAIL death receptors and/ or formation of pro-apoptotic membrane complexes 
(“Good” DISCs). TRAIL-R4 notably forms heterotrimers with TRAIL-R2. TRAIL-R2 can be directly 
ubiquitinated and targeted to the proteasome for degradation. Some mutations found in the TRAIL 
death receptors hamper efficient TRAIL binding or FADD recruitment.  DISC formation is less efficient 
in absence of TRAIL death receptor recruitment to the lipid rafts. If, however, DISC formation is to take 
place outside of the lipid rafts, non-functional complexes (“Bad” DISCs) are formed and stimulate pro-
survival pathways. FADD recruitment to the TRAIL death receptor can be inhibited by PKC-, ERK1/2- 
and CK-dependent signals. Several proteins and proteins complexes can be recruited to the DISC, 
preventing caspase 8 cleavage and/or stimulating pro-survival pathways. The list of such proteins and 
protein complexes includes FLIP, RIP, PED/PEA-15 and the TRAIL death receptor-capping 
DDX3/cIAP-1/GSK-3 complex. Recruitment to FADD of PED/PEA-15 is positively regulated by its 
double-phosphorylation, under the influence of Akt, CAMK2 and PKC signaling. MADD binds to the 
TRAIL death receptor and prevents auto-proteolytic cleavage of caspase 8. Phosphorylation of caspase 8 
by Src kinase also prevents its cleavage at the DISC. CARPs, namely CARP1 and CARP2, are ubiquitin-
ligase proteins that promote caspase 8/10 ubiquitination and block proteolytic processing of these 
caspases. Conversely, A20 binds caspase 8, thereby preventing its pro-apoptotic polyubiquitination by 




donor nitrosylcobalamin (NO-Cbl), a pro-drug based on vitamin B12 (see Figure 2). Site-
directed mutagenesis identified the amino-acid 336 as the S-nitrosylated cysteine 
residue in TRAIL-R1. Proliferation assays established that the TRAIL-R1 C336A mutant 
was less sensitive to NO-Cbl or TRAIL than other point mutants or vector-transfected 
cells, and showed reduced caspase 8 activation following NO-Cbl treatment. Since 
endogenous TRAIL-R1 S-nitrosylation was not detected in any of the three types of 
cancer cell lines tested, further experiments are needed to evaluate the extent of these 
findings in both normal and cancer cells (196). 
 
3. S-palmitoylation of TRAIL-R1 promotes its oligomerization 
The reversible attachment of a palmitate to a cysteine residue, a process also known as 
S-palmitoylation, can induce lipid raft localization of membrane receptors (197). Rossin 
et al. showed that TRAIL-R1 was partially palmitoylated within a cysteine triplet near its 
transmembrane domain (see Figure 2). Palmitoylation of TRAIL-R1 was required for its 
constitutive lipid raft localization and homo-oligomerization. In an overexpression 
system, only palmitoylated TRAIL-R1 could hetero-oligomerize with TRAIL-R2. TRAIL-
R2 itself lacks the cystein triplet and accordingly was not found to be palmitoylated. Pre-
treating cells with the palmitate analog 13-oxypalmitate or the cholesterol-depleting 
agent cholesterol oxydase hampered TRAIL-R1 constitutive lipid raft localization, 
decreased TRAIL-induced DISC formation and subsequently inhibited apoptotic cell 
death. Stimulation of the intrinsic apoptotic pathway with staurosporine in combination 
with cholesterol oxydase did not induce cell death. This suggests that cholesterol 
oxydase specifically affects the extrinsic pathway of apoptosis. Site-directed 
mutagenesis from cysteine to serine confirmed the C261-3S cysteine triplet to be critical 
to TRAIL-induced caspase 8 cleavage (198). 
 
4. Caspase 8 phosphorylation prevents its cleavage at the DISC 
Caspase 8 activity can be inhibited by phosphorylation of its tyrosine-380 by Src kinase 
(see Figure 3). TRAIL-resistant DLD1 cells transfected with a plasmid coding for a non-
phosphorylatable caspase 8 mutant were more sensitive to TRAIL than their 
counterparts transfected with the wt caspase 8 gene. In support of these findings, the Src 
inhibitor PP2 increased TRAIL-induced caspase 8 cleavage and apoptosis in several cell 
lines, independent of TRAIL death receptor upregulation (199). Importantly, the 
Turning on TRAIL death-receptor mediated apoptosis in cancer 
47 
combination of TRAIL and PP2 was not toxic toward primary hepatocytes (200). Src 
levels are high in lipid rafts and these rafts have been shown to influence TRAIL death 
receptor aggregation and DISC formation. It remains to be tested whether Src kinase-
dependent caspase 8 phosphorylation is increased in lipid rafts. 
 
5. FLIP phosphorylation lowers its affinity for the DISC 
In addition to caspase 8 phosphorylation, FLIP phosphorylation has also been described. 
The bile acid GCDCA did not affect protein expression of DISC components in 
hepatocellular cancer cells. However, pre-treatment with GCDCA increased caspase 8 
and 10 recruitment at the TRAIL-DISC by phosphorylating both FLIPL and the short 
isoform (FLIPs), thereby lowering their affinity for FADD (see Figure 3). These effects 
could be prevented by the PKC inhibitor chelerythrine, suggesting an involvement of 
this pathway in regulating phosphorylation of the FLIP isoforms and their translocation 
to the TRAIL-DISC (201). Surprisingly, the authors did not discuss whether the increase 
in DISC formation could also be attributed to the higher clustering of TRAIL-R2 seen 
upon GCDCA treatment as reported in one of their earlier publications (170,201). 
 
6. DISC protein ubiquitination differentially regulates DISC composition 
TRAIL-R2 can be ubiquitinated, and its stability increased, by the proteasome inhibitor 
bortezomib, leading to higher TRAIL sensitivity (202)(see Figure 2). Although both FLIP 
isoforms can be ubiquinated, FLIPs was shown to be more prone to ubiquitination than 
FLIPL and consequently exhibits a shorter half-life (203). Peroxisome-activated receptor 
γ (PPAR-γ) ligands and 2,5-dimethyl-celecoxib, a derivative of the COX-2 inhibitor 
celecoxib without COX-2 inhibitory activity, triggered ubiquitination of FLIP, induced 
degradation of both isoforms and sensitized various tumor cells to TRAIL (204,205). The 
effects of the PPAR-γ ligands seemed PPAR-γ-independent (205). In a yeast two-hybrid 
screen, two caspase 8- and 10-associated RING proteins (CARPs) with E3 ubiquitin 
ligase activity were identified by McDonald and El-Deiry (206). CARP1 and CARP2 
interact with caspase 8 and 10 prodomains via their RING domain, which promotes 
their ubiquitination and subsequent proteasomal degradation. Downregulation of 
CARP1 and CARP2 sensitized colon and lung cancer cells to TRAIL-induced apoptosis 
by increasing cleavage of caspase 8/10. It is noteworthy that CARP downregulation did 
not modulate the basal expression levels of caspase 8/10. CARP1 and CARP2 were 
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upregulated in various cancer cell lines, and in a number of primary tumors compared 
to normal tissue. In a recent publication, Jin et al. uncovered a novel mechanism of 
caspase 8 (but not caspase 10) polyubiquitination, with opposite consequences for 
apoptosis initiation (207). In TRAIL-sensitive cells of various origins, TRAIL death 
receptor stimulation leads to DISC formation and translocation into lipid rafts, where a 
cullin-based E3 ligase (CUL3) interacted with caspase 8 and induced a ring-box 1 
(RBX1)-dependent polyubiquination of caspase 8. The presence of polyubiquitin in the 
C-terminal region of caspase 8 triggered recruitment of the ubiquitin-binding protein 
p62, which targeted DISC caspase 8 to ubiquitin-rich foci. Aggregation of caspase 8 in 
these high molecular weight structures promoted auto-proteolytic cleavage and the 
release of active caspase 8 into the cytoplasm, leading to executioner caspases activation 
and ultimately apoptosis. Using tandem mass spectrometry on purified high molecular 
weight DISC fractions, the authors also identified a caspase 8-bound deubiquitinase 
named A20, overexpression of which could prevent CUL3-induced caspase 8 
ubiquitination and caspase 8 activity (see Figure 2). Caspase 8 ubiquitination thus 
appears to be a tightly regulated process involving several non-canonical DISC proteins. 
Downstream of the DISC in the TRAIL apoptotic pathway, Bcl-2 family proteins and 
executioner caspases are also regulated by ubiquitination (208,209). Altogether, changes 
in the balance between pro- and anti-apoptotic factors may account for the potent effects 
of proteasome inhibition on DISC formation and TRAIL sensitivity. 
 
L. Influence of survival pathways on DISC formation 
 
Beyond their role in cell cycle regulation, metabolism and cell differentiation, survival 
pathways can modulate TRAIL death receptor-mediated apoptosis. Studies show that 
numerous survival pathways are stimulated by the TRAIL apoptotic pathway, 
potentially initiating feedback loop mechanisms (36,210). It is now clear that survival 
pathways can also directly influence the apical events of DISC formation (Figure 2 and 
3). Since these signals are primarily mediated by kinases, the effects can occur without 
changing the cytoplasmic protein levels of DISC proteins (211-213). The frequent 
enrichment of kinases at the membrane, particularly within lipid rafts, supports the 
possibility that close proximity might facilitate modulation of TRAIL death receptor-
mediated signaling by these kinases. 
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1. The pro- and anti-DISC effects of protein kinase C 
Protein kinase C (PKC) describes a group of 12 lipid-dependent serine/threonine (S/T) 
kinases that regulate growth and differentiation. Stimulating this pathway with the PKC 
activator phorbo 12,13-dibutyrate (PDBu) inhibited caspase 8 cleavage in response to 
TRAIL treatment in Jurkat cells. This decrease in TRAIL sensitivity was partly due to 
PKC-induced activation of the MAPK pathway (214).  Meng et al. further demonstrated 
that caspase 8 cleavage was inhibited following treatment with the PKC activator 
phorbol 12-myistate 13-acetate (PMA) in type II cell lines from different tumor types. 
This was caused by disruption of FADD recruitment at the DISC (215). Similar results 
were obtained in the cervical cancer cell line Hela, where PKC stimulation using PMA 
could prevent FADD recruitment to the TRAIL death receptors (216)(see Figure 3). This 
strongly indicates that PKC can exert inhibitory effects on DISC formation in several cell 
types. The unique phosphorylation site of FADD (Serine-194) has been shown to 
regulate its non-apoptotic functions (217). It is therefore unlikely that the increase in 
FADD recruitment at the DISC seen upon PKC stimulation is caused by a PKC-
dependent phosphorylation of FADD itself. 
Studies specifically focusing on the δ isoform of PKC have led to opposite 
discoveries regarding the regulation of DISC assembly by PKC. Sandra et al. showed 
that the δ isoform of PKC could accelerate caspase 8 cleavage at the DISC following a 
positive feedback loop possibly involving the mitochondria. This feedback loop was 
initiated by a rapid production of diacylglycerol following TRAIL treatment, which 
induced activation of PKC δ and its relocation to the mitochondria, in a caspase-
independent manner (218). Although the precise mechanism between this activation of 
PKC δ and the increase in caspase 8 cleavage is unknown, a Rho kinase (ROCK)-
dependent contraction of myosin light chains has been shown to promote initiator 
caspases binding to FADD following PKC activation (219) (see Figure 2). A better 
knowledge of the properties of the different isoforms would facilitate the development 





2. The ERK1/2 signaling pathway inhibits caspase 8 cleavage 
The ERK1/2 or MAPK pathway is an important cell survival pathway involved in 
carcinogenesis. This pathway has also been shown to inhibit TRAIL sensitivity at the 
DISC (see Figure 3). Frankel et al. found that the cytoplasmic domain of TRAIL-R1 but 
not TRAIL-R2 was constitutively phosphorylated by p42MAPK/ERK2 in unstimulated 
peripheral blood lymphocytes (220). This suggests the possibility for a direct regulation 
of TRAIL-R1 activity by the ERK pathway. In activated T-cells, the MAPK/ERK 
signaling abrogated TRAIL-induced apoptosis upstream of caspase 8 and the 
mitochondrial amplification feedback loop (221). Similarly, MAPK kinase 1 (MEKK1) 
inhibition in Hela cells enhanced TRAIL-induced apoptosis while expression of a 
constitutively active (CA) MEKK1 could protect cells from TRAIL death receptor-
mediated apoptosis. TRAIL-induced caspase 8 processing was inhibited in cells 
expressing CA-MEKK1. Interestingly, TRAIL death receptor stimulation induced 
ERK1/2 activation, which appeared 5 min after treatment and lasted for about 1 h, 
thereby suggesting the involvement of this pathway in a negative feedback loop at the 
DISC (222).  
 
3. The anti-DISC effects of active CKIα and CK2α 
Casein kinase I α isoform (CKIα) and protein kinase CK2α, formerly known as casein 
kinase 2 (CK2α), are serine/threonine kinases which can modulate DISC formation (see 
Figure 2). In colon cancer and pediatric rhabdomyosarcoma cell lines, TRAIL sensitivity 
dramatically increased upon inhibition of CKI with CKI-7 or of CK2 with 5,6-
dichlorobenizimidazole (DRB). Formation and stability of the TRAIL-DISC were 
increased following CKI inhibition, while CK2 inhibition with DRB increased both 
TRAIL-induced caspase 8 recruitment at the DISC and TRAIL-induced apoptosis (223-
225). Caspase 8 cleavage can be enhanced following feedback activation from 
executioner caspases downstream of the mitochondria such as caspase 6 (226). Blockade 
of the mitochondrial amplification pathway using Bcl-2 or Bcl-xL overexpression did not 
hamper caspase 8 cleavage in presence of TRAIL together with CKI or CK2 inhibitors. 
This confirms that CKs can modulate caspase 8 cleavage at the DISC itself. Active casein 
kinases such as CKI might inhibit TRAIL-induced apoptosis by phosphorylating the 
TRAIL death receptor, thereby blocking FADD recruitment at the DISC (223-225). 
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M. DISC regulation by recruitment of additional proteins 
 
Beyond the DISC components discussed earlier in this review, several other non-
canonical proteins have been found to interact with the DISC at the membrane, where 
they either positively or negatively influence efficient DISC formation, caspase 8 
cleavage and consequent apoptosis. A schematic representation of the recruitment of 
these pro- and anti-apoptotic proteins to the DISC is given in Figure 2 and 3, 
respectively and the mechanisms are discussed more extensively below. 
 
1. PED/PEA-15 blocks caspase 8 cleavage at the DISC 
Phosphoprotein enriched in diabetes/ phosphoprotein enriched in astrocytoma-15 kDa 
(PED/ PEA-15) belongs to the category of non-canonical DISC proteins. Like FADD, 
FLIP and caspase 8, PED/PEA-15 possesses a death effector domain but no caspase-like 
domain. Hao et al. showed that PED/PEA-15 expression was about two times higher in 
TRAIL-resistant compared to TRAIL-sensitive glioma cell lines (227). PED/PEA-15 was 
not found in the TRAIL-DISC of three TRAIL-resistant primary gliomas (77). 
Overexpression of PED/PEA-15 in TRAIL-sensitive glioma cell lines blocked the TRAIL 
apoptotic pathway while a PED/PEA-15 anti-sense approach restored TRAIL sensitivity 
in TRAIL-resistant gliomas (227). PED/PEA-15 exists in three isoforms, namely an 
unphosphorylated, a singly-phosphorylated and a doubly-phosphorylated form. 
Calcium/calmodulin-dependent protein kinase II (CaMK2) or Akt phosphorylate 
PED/PEA-15 at serine-116 (228-230), thereby facilitating the second phosphorylation at 
serine-104 by PKC (231,232). Only the double phosphorylated form, present exclusively 
in TRAIL-resistant glioma cells, was found to be recruited to the TRAIL-DISC where it 
blocked caspase 8 activation (230)(see Figure 3). Inhibition of CaMK2 with the broad-
spectrum CaMK inhibitor KN-93 decreased PED/PEA-15 phosphorylation, thereby 
restoring caspase 8 cleavage and apoptosis in gliomas (230). Inhibition of Akt or PKC 
also hindered PED/PEA-15 phosphorylation, its recruitment at the DISC and restored 
TRAIL sensitivity in glioma cell lines (227,229). These results are consistent with the role 
of PED/PEA-15 as a common target for multiple survival pathways, allowing these 




2. Blockade of DISC formation by the DDX3/GSK3/cIAP-1 capping complex 
Li et al. described a novel protein specifically involved in acquired resistance to TRA-8, 
an agonistic anti-TRAIL-R2 antibody. DDX3, a member of the DEAD-box RNA helicase 
family, was endogenously associated with TRAIL-R2. Upon stimulation of the TRAIL-
sensitive breast cancer cell line MDA-MB-231 with TRA-8, DDX3 was cleaved and an 
active DISC was formed. In the TRA-8-resistant daughter cell line, the TRA-8 antibody 
failed to induce cleavage of DDX3. FADD and caspase 8 were not recruited to TRAIL-
R2, suggesting a role for DDX3 in inhibiting this process. Resistance to the anti-TRAIL-
R2 antibody could be reversed by several chemotherapeutic agents, including 
doxorubicin, which restored FADD recruitment and cleavage of both DDX3 and caspase 
8 (233). DDX3, together with GSK3 and cIAP-1, formed a capping complex at the DISC 
that counteracted TRAIL death receptor-mediated apoptosis (see Figure 3). 
Additionally, DDX3 and cIAP-1 were also recruited to the DISC in both sensitive and 
resistant cells following TRAIL death receptor stimulation but cleavage and inactivation 
of this capping complex was only induced in TRAIL-sensitive cells. In various cell lines, 
inhibition of GSK3 with compounds such as lithium was found to promote TRAIL death 
receptor-mediated apoptosis by increasing DISC formation (234). Altogether, these 
findings are particularly relevant in view of the numerous GSK3 inhibitors and IAP 
small molecule antagonists that are currently in clinical development (209,235). 
 
3. The pro- and anti-DISC properties of the various IG20 gene family isoforms 
The insulinoma-glucagonoma clone 20 (IG20) gene is frequently overexpressed in cancer 
and encodes several splice variants with various effects on cell proliferation and drug 
sensitivity (236). The IG20 pro-apoptotic (IG20pa) splice variant was shown to directly 
interact with both TRAIL-R1 and TRAIL-R2 (237) but not with FADD (238)(see Figure 
2). Cancer cells transfected with IG20pa displayed a higher recruitment of FADD and 
caspase 8 to TRAIL-R1 and TRAIL-R2 in response to TRAIL treatment, and were also 
more sensitive to this ligand (237,239). The precise mechanism behind this DISC-
enhancing effect is unknown, but IG20pa is most likely recruited to the TRAIL death 
receptors via its C-terminal 70 amino-acid death domain homology region (237). 
Unlike the IG20pa variant, the MAPK-activating death domain protein (MADD) 
splice variant of IG20 is a negative regulator of caspase 8 activation at the DISC (see 
Figure 3). Downregulation of endogenous MADD alone resulted in spontaneous 
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apoptosis via ligand-independent caspase 8 cleavage at the DISC, and also increased 
TRAIL sensitivity. MADD binds to the TRAIL death receptors but not to FADD or 
caspase 8 itself, and although it does not prevent DISC assembly, MADD inhibits 
caspase 8 cleavage at the DISC (240,241). In Kaposi’s sarcoma cells, MADD could be 
downregulated with the antineoplastic drug and TRAIL sensitizer actinomycin D 
(242,243). These results further confirm that versatile mechanisms regulate TRAIL 
sensitivity at the DISC itself. 
 
4. Regulation of cell membrane TRAIL-R1 levels by the signal recognition particle 
complex 
In search for proteins differentially regulating TRAIL-R1- and TRAIL-R2-mediated 
apoptosis in cancer cells, Ren et al. tested an arrayed library of siRNAs in combination 
with TRAIL-R1- or TRAIL-R2-specific antibodies, in HCT15 colon cancer cells (244). 
Several proteins were identified as pro- and anti-apoptotic for TRAIL-R1- and/or 
TRAIL-R2-mediated signaling. The authors found that expression of the signal 
recognition particle (SRP) complex was essential for TRAIL-R1-mediated sensitivity (see 
Figure 2). Downregulation of the 54-kDa or 72-kDa (SRP54 or SRP72) subunits of the 
SRP complex decreased cell sensitivity to TRAIL and to anti-TRAIL-R1 antibody, but not 
to anti-TRAIL-R2 antibody. Effects of SRP54 or SRP72 siRNAs on TRAIL sensitivity 
were also seen in cervical and pancreatic cell lines. The SRP complex is notably involved 
in the sorting process of nascent membrane proteins (245,246), which can be linked to 
the finding that cell membrane TRAIL-R1 levels decreased upon inhibition of SRP54 or 
SRP72 expression (244). In addition to the studies on TRAIL-R1 epigenetic silencing and 
endocytosis mentioned earlier in this review, these results support the hypothesis that 




So far, much focus has been placed on finding ways to modulate pro- and anti-apoptotic 
protein expression to enhance TRAIL-induced apoptosis. The efficacy of such 
combinations in vitro and in xenograft models is unquestionable, and preliminary 
clinical data are encouraging. However, to fully exploit the apoptotic effect of any such 
combination treatment, there should be more insight in the mechanisms regulating 
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TRAIL sensitization, DISC formation and caspase 8 activation. In view of the vast range 
of potential targets offered and rapidly accumulating data, the use of post-translational 
approaches to regulate the TRAIL-induced apoptotic cascade is also suggested. 
Furthermore, although TRAIL-R1 and TRAIL-R2 agonists both transduce apoptosis, 
extensive data suggests that TRAIL-R1- and TRAIL-R2-mediated signaling cascades are 
fine-tuned by different mechanisms. Even more so than TRAIL, receptor-selective 
agonists such as anti-TRAIL-R1 or anti-TRAIL-R2 antibodies or receptor-specific TRAIL 
variants are targeted therapies that necessitate screening for the presence of functional 
TRAIL death receptor in addition to screening for other DISC components. Elucidating 
potential TRAIL-R1- or TRAIL-R2-specific effects of novel and existing chemotherapies 
will be crucial to fully exploit the clinical potential of these TRAIL death receptor-
selective agonists. In the meantime, the best strategy may be to combine these 
chemotherapies with dual targeting of both TRAIL-R1 and TRAIL-R2, using either 
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Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers the apoptotic 
cascade in various colon cancer cell lines after binding to the membrane receptors DR4 
and DR5. However, not all cancer cell lines are sensitive to the therapeutic recombinant 
human TRAIL (rhTRAIL). To investigate the causes of TRAIL resistance in colon cancer 
cell lines, models have been developed, mostly in mismatch repair-deficient cells. These 
cells are prone to mutations in genes containing tandem repeat, including pro-apoptotic 
protein Bax. We therefore investigated the mechanism underlying TRAIL resistance 
acquisition in a mismatch repair-proficient colon carcinoma cell line. The TRAIL-
resistant cell line SW948-TR was established from the TRAIL-sensitive cell line SW948 
by continuous exposure to rhTRAIL, and exhibited 140 fold less sensitivity to rhTRAIL 
in a cell viability assay. Resistance was stable for over a year in the absence of rhTRAIL. 
Both cell lines had similar TRAIL receptor cell membrane expression levels. Treatment 
with the protein synthesis inhibitor cycloheximide sensitized SW948-TR to rhTRAIL-
induced apoptosis, indicating that the functionality of the TRAIL receptors was 
maintained. In SW948-TR, procaspase 8 protein levels but not mRNA levels were 
notably lower than in SW948. Downregulation of c-FLIP with short interfering RNA 
(siRNA) sensitized SW948-TR cells to rhTRAIL while caspase 8 siRNA decreased 
rhTRAIL sensitivity in SW948, indicating the importance of the caspase 8/c-FLIP ratio. 
Proteasome inhibition with MG132 did not restore basic procaspase 8 levels but 
stabilized cleaved caspase 8 in rhTRAIL-treated SW948-TR cells. Altogether, our results 
suggest that colon cancer cells can acquire rhTRAIL resistance by primarily reducing the 
basal procaspase 8/c-FLIP ratio and by increasing active caspase 8 degradation after 
rhTRAIL treatment. Proteasome inhibitors can effectively overcome acquired rhTRAIL 
resistance in mismatch repair-proficient colon cancer cells. 




TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) is a member of the 
TNF family with interesting anti-cancer activity (1,2). Binding of TRAIL to its two 
apoptosis-inducing receptors DR4 and DR5 induces formation of a complex called the 
death-inducing signaling complex (DISC), leading to caspase-dependent stimulation of 
the extrinsic pathway of apoptosis. The therapeutic agent recombinant human 
(rh)TRAIL has been shown to induce apoptosis in many types of human cancer cell lines 
in vitro, and also prevents tumor growth in preclinical models in vivo. By activating both 
the extrinsic and the intrinsic pathway of apoptosis, combination treatment of rhTRAIL 
and chemotherapy can also induce apoptosis in drug-resistant cell lines both in vitro and 
in vivo in human tumor xenograft mouse models. A phase I study has consequently been 
initiated with rhTRAIL and demonstrated safety of this agent (3-5). In a phase II study 
in heavily pre-treated colon cancer patients, the best response to an anti-DR4 antibody 
was stable disease in 32% cases (6). 
About 60% of cancer cell lines are moderately to completely resistant to rhTRAIL 
in vitro (7). Understanding the molecular basis of cancer cell resistance to TRAIL-
induced apoptosis may hold the key to optimal TRAIL receptor-targeted combination 
therapies and the development of novel treatment initiatives. Several key components 
for TRAIL sensitivity have been identified. This includes downstream pro- and anti-
apoptotic proteins of the Bcl-2 family such as Bax, Bak and Bcl-2, proteins inhibiting 
efficient DISC formation such as c-FLIP and finally caspase inhibitors such as X-linked 
inhibitor of apoptosis protein (XIAP)(8). In DNA mismatch repair (MMR)-deficient 
tumor colon cancer cell line, the acquisition of TRAIL resistance after extended exposure 
to the ligand was linked to the accumulation of Bax mutations resulting in Bax-/- 
phenotype, both in vitro and in vivo (9). MMR deficiency leads to micro-satellite 
instability (MSI). MSI-positive tumors have a high rate of frame-shift mutations in a 
number of genes containing tandem repeat sequences, including the pro-apoptotic gene 
Bax (10,11). Apart from hereditary non-polyposis colon cancer tumors, which accounts 
for approximately 2-5% of colorectal cancer cases, MSI as a result of MMR deficiency is 
present in around 15% of sporadic colon tumors (12).  Because the majority of the colon 
cancers are MMR-proficient, this group of tumors deserves attention as well. By 
retroviral transfection of a human cDNA library in the TRAIL-sensitive colon cancer 
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cells line SW480, others previously reported that FLIPs and Bcl-XL overexpression could 
induce TRAIL resistance (13). To further identify the components for rhTRAIL 
sensitivity in MMR-proficient colon carcinoma cells, we established a rhTRAIL resistant 
sub-line by prolonged exposure of the previously characterized TRAIL-sensitive SW948 
colon carcinoma cell line (14,15). The mechanisms of TRAIL resistance were analyzed in 
this distinct isogenic background. 
 
Materials and Methods 
 
Reagents 
RPMI 1640 medium was obtained from Life Technologies (Breda, the Netherlands) and 
fetal calf serum (FCS) from Bodinco BV (Alkmaar, the Netherlands). 3-(4,5-dimethyl-
thiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT)-solution, cycloheximide and 
actinomycin D were purchased from Sigma-Aldrich Chemie BV (Zwijndrecht, the 
Netherlands). RhTRAIL was produced non-commercially in cooperation with IQ-
Corporation (Groningen, the Netherlands) following a protocol described earlier (7). The 
TRAIL-receptor antibodies used for flow cytometry were obtained from Immunex 
(Seattle, WA). Caspase 9 inhibitor zLEHD-fmk, caspase 8 inhibitor zIETD-fmk, broad-
spectrum caspase inhibitor zVAD-fmk and proteasome inhibitor MG132 were obtained 
from Calbiochem (Breda, the Netherlands). Oligofectamine reagent was purchased from 
Invitrogen BV (Breda, the Netherlands). The NFB inhibitor SN-50 was obtained from 
Biomol (Tebu-bio, Heerhugowaard, the Netherlands). 
 
Cell lines 
The TRAIL-sensitive colon carcinoma SW948 cell line was cultured in Leibovitz L15-
RPMI 1640 (1:1) enriched with 10% FCS, 0.05 M pyruvate, 0.1 M glutamine and 0.025% 
-mercaptoethanol at 37C in a humidified atmosphere with 5% CO2. SW948 was 
harvested by treatment with protease XXIV for 5-10 min at 37 C. In order to obtain a 
TRAIL-resistant sub-line, SW948 was exposed continuously to 1.0 µg/ml rhTRAIL and 
incubated at 37C to allow resistant cells to grow. After 14 days these cells were cultured 
in the presence of 2.5 µg/ml rhTRAIL twice a week. After three months the stable 
TRAIL-resistant cell line SW948-TR was established and cultured similarly to its 
parental cell line. In the absence of rhTRAIL in the culture media SW948-TR remains 
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resistant to rhTRAIL for at least 75 passages. Based on cell viability assay, this cell line is 
at least 140 fold more resistant to rhTRAIL than the sensitive parental cell line. 
 
Sub-cloning of SW948-TR   
SW948-TR was harvested by treatment with protease XXIV for 5-10 min at 37C, washed 
once in Leibovitz L15-RPMI 1640 (1:1) without FCS. A single cell suspension was 
obtained by resuspending the cells repeatedly through an 18-gauge needle.  
Cells were diluted in two volumes HAM-DME (1:1) with 20% FCS and one 
volume conditioned Leibovitz L15-RPMI 1640 (1:1) medium with 10% FCS. The cell 
suspension was kept at 37C, then 1/10 volume of pre-warmed agarose (final 
concentration 0.3%) was added and carefully mixed. Two ml cell suspension was added 
to each Petri dish (200 or 20 cells) which was kept at 4C for 1 h. Then, Petri dishes were 
placed at 37C in a humidified atmosphere with 5% CO2. After 14 days individual 
visible clones were transferred to a 24-wells plate and cultured in Leibovitz L15-RPMI 
1640 (1:1) medium with 10% FCS. Growing clones were harvested by treatment with 
protease XXIV for 5-10 min at 37 C and cultured as described for SW948-TR.   
An alternative sub-cloning approach was minimal dilution of SW948-TR in two 
volumes Leibovitz L15-RPMI 1640 (1:1) medium with 10% FCS and one volume 
conditioned Leibovitz L15-RPMI 1640 (1:1) medium with 10% FCS. Cell suspension was 
diluted and thereafter 100 μl was added to each well of a 96-well plate. After 14 days, 
cells from wells with single colony were harvested with protease XXIV for 5-10 min at 
37C, transferred to a well of a 24-well plate, and incubated as described above. 
 
Cytotoxicity assay 
The microculture tetrazolium assay was used to determine cytotoxicity. SW948 and 
SW948-TR cells were incubated in a total volume of 200 l. Treatment consisted of 
continuous incubation with various rhTRAIL concentrations. After an incubation period 
of 96 h, 20 l of MTT-solution (5 mg/ml phosphate buffered saline (PBS): 6.4 mM 
Na2HPO4; 1.5 mM KH2PO4; 0.14 mM NaCl; 2.7 mM KCl; pH=7.2)) was added for 3.75 h. 
Subsequently, plates were centrifuged and the supernatant aspirated. After dissolving 
the formazan crystals by adding dimethyl sulfoxide (Merck, Amsterdam, the 
Netherlands), plates were read immediately at 520 nm using a microtiter well 
spectrometer (Bio-Rad microplate reader, Bio-Rad laboratories BV, Veenendaal, the 
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Netherlands). Controls consisted of media without cells. Cell survival was defined as 
the growth of treated cells compared to untreated cells. The IC50 was defined as the drug 
concentration inhibiting survival by 50%. Mean cytotoxicity was calculated from three 
independent experiments each performed in quadruplicate. 
 
SDS-polyacrylamide gel electrophoresis and Western blotting 
Preparation of protein lysates and Western blot analysis was performed as described 
previously (15). To detect poly-ADP-ribose-polymerase (PARP), FADD, X-linked 
inhibitor of apoptosis protein (XIAP), FLICE-like inhibitory protein (FLIP), caspase 3, 
caspase 9, caspase 8, caspase 10, DR4, DR5, Bid, Bax, Bak, Bcl-XL, Bcl-2, Bid and actin the 
following antibodies were used: rabbit anti-PARP from Roche applied science 
(Mannheim, Germany),  rabbit mouse-anti-FADD and mouse-anti-XIAP from 
Transduction Laboratories (Lexington, KY), rabbit-anti-caspase 3, rabbit-anti-Bid and 
rabbit-anti-caspase 9 from Pharmingen (Becton Dickinson, Erebodegem-Aalst, Belgium), 
goat-anti-DR4, mouse-anti-Bcl-2, rabbit-anti-BclXL, rabbit-anti-Bax (N20), goat-anti-Bak 
(N20) from Santa Cruz Biotechnology (Santa Cruz, CA) rabbit-anti-DR5 and rabbit-anti-
survivin from Oncogene Research Products (Calbiochem-Novabiochem, Germany). 
Mouse anti-caspase 8 was purchased from Cell Signaling Technology (Leusden, the 
Netherlands). Mouse-anti-caspase 10, rabbit-anti-cIAP-1 and rabbit-anti-cIAP-2 were 
obtained from R&D systems (Abingdon, UK). Mouse-anti-FLIP NF6 was kindly 
provided by Dr. M. Peter (Chicago, IL). Mouse-anti-actin was obtained from ICN 
Biomedicals (Zoetermeer, the Netherlands). The secondary antibodies were labeled with 
horseradish peroxidase (all from DAKO, Glostrup, Denmark) and chemiluminesence 
was detected using the ECL-chemiluminescence kit or with the Lumi-Light Plus 
Western blotting kit (Roche Diagnostics, Mannheim, Germany). Western blot analyses 
were performed at least three times. Protein concentrations were determined with the 
Bradford assay. In all experiments samples containing 15 or 20 g lysate were used, and 
membranes were stained with Ponceau S to check for equal protein loading.  
 
Flow cytometry 
Analysis of TRAIL-receptor membrane expression was performed with a flow cytometer 
(Epics Elite, Coulter-Electronics, Hialeah, FL) and cells were stained as described earlier 
(15). The following antibodies were used: for DR4, huTRAILR1-M271, for DR5, 
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huTRAILR2-M413, for DcR1, huTRAILR3-M430, and for DcR2, huTRAILR4-M444. 
Membrane receptor expression is shown as mean fluorescent intensity (MFI) of all 
analyzed cells. Membrane expression was observed as an increase in fluorescence 
intensity for the whole analyzed cell population. All experiments were performed at 
least three times. 
 
Apoptosis assay 
For each cell line 10,000 cells were seeded in 96-well plates. Apoptosis was identified by 
staining nuclear chromatin with acridine orange (AO), identifying morphological 
changes by fluorescence microscopy. Apoptosis was expressed as percentage apoptotic 
cells in a culture. Apoptosis experiments were performed at least three times. 
 
RNA interference 
Small interfering RNAs (siRNAs) specific for human c-FLIP were designed conforming 
to the sequence AA(N19)TT, where AA and TT are present in the c-FLIP open reading 
frame at a spacing of 19 nucleotides. Double-stranded RNA molecules specific for c-
FLIP (sense: 5’-GAGGUAAGCUGUCUGUCGGdTdT-3’, anti-sense: 5’-CCGACAGAC 
AGCUUACCUCdTdT-3’) or caspase 8 (sense: 5’-CUACCAGAAAGGUAUACCUdTdT-
3’, anti-sense: 5’-AGGUAUACCUUUCUGGUAGdTdT-3’) were synthesized by 
Eurogentec (Seraing, Belgium). Single stranded RNA molecules specific for the 
luciferase (Luc) gene were used as control (16). The sequences for Luc RNA molecules 
were 5’-CUUACGCUGAGUACUUCGAdTdT-3’ (sense) and 5’-UCGAAGUACUCA 
GCGUAA GdTdT-3’ (antisense). To form RNA duplexes, 20 M of both single-stranded 
RNAs were incubated in annealing buffer supplied by Eurogentec (50 mM Tris, pH 7.5-
8.0, 100 mM NaCl in RNase-free distilled water) for 1-5 min at 90C and cooled down to 
room temperature in approximately 1 h. Cells were harvested with protease and 
transfected in 6 wells plates (0.3 x 106 cells/well) with 2.5-10 μl of 20 μM siRNA 
duplexes using oligofectamine reagent according to the manufacturer’s instructions. The 
next day, cells were harvested and seeded in 96- or 6-well plates for apoptosis assay or 
protein isolation respectively. After 48 h siRNA transfected cells were incubated with 0.1 
μg/ml rhTRAIL for 5 h. After treatment, the percentage apoptosis was determined by 




Real Time PCR 
Total RNA was isolated by guanidine isothiocyanate-phenol-chloroform extraction 
using TRIzol (Invitrogen, Breda, the Netherlands) according to the manufacturer’s 
protocol. Total RNA was purified with the RNeasy mini kit (Qiagen, Leusden, the 
Netherlands) according to the manufacturer’s instructions. Trace amounts of DNA 
contamination were removed by on-column DNase I digestion following the 
manufacturer’s recommendations. 
Yield and quality of the total purified RNA was assessed by measuring A260/280 
nm and 260/230 nm ratio on a nanodrop ND-1000 spectrophotometer (Nanodrop, 
Isogen Life Science B.V., IJsselstein, the Netherlands) and by RNA gel electrophoresis 
visualization of 18S and 28S rRNA bands. cDNA was synthesized from 800 ng purified 
RNA as described by the manufacturer’s protocol (Life Technologies, Breda, the 
Netherlands) using oligo (dT)11 primers and MMLV transcriptase. Prior to the RT-PCR, 
purity and integrity of the synthesized cDNA was examined by qualitative RT-PCR for 
the housekeeping reference gene coding for the enzyme glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Real time RT-PCR was performed in 96-well plates using the 
SYBR Green method on a MyiQ real time detection system (all from BioRad) using 
GAPDH as an internal control. A gradient RT-PCR was performed to assess primer 
specificity and to optimize annealing temperature (Tann) for each set of gene specific 
primers. The sequences for the primers used in real time PCR of caspase 8 were 
GGAGCTGCTCTTCCGAATTA (forward) and GCAGGTTCATGTCATCATCC 
(reverse), for FLIP and, and those of GAPDH were CACCACCATGGAGAAGGCTGG 
(forward) and CCAAAGTTGTCATGGATGACC (reverse). Amplification of the samples 
was carried out in triplicate in a final reaction volume of 25 µl, containing 12.5 µl IQ 
SYBR Green Supermix (BioRad), 1 µl of each gene specific primer (5 µM) and 5 µl cDNA 
(1:50). The thermocycling program used for each real time RT-PCR consisted of an initial 
3 min denaturation at 95 °C, followed by 40 cycles of 15 s denaturation at 95 °C, 20 s 
primer annealing at the primer specific Tann and 30 s fragment elongation at 72 °C. 
Fluorescence data was acquired during the fragment elongation step at 72 °C. Presence 
of unique reaction products was determined from the melting curves obtained at the 
end of 40 cycles of amplification.  
To determine RT-PCR efficiency and initial starting quantity of the samples, a 
standard curve was generated using a 1:3 serial dilution from total starting cDNA 
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sample. Water controls were included to check for DNA contamination. Differences in 
the amount of starting cDNA between samples were corrected using GAPDH as a 
housekeeping reference gene. 
 
Statistics 
Statistic analysis was performed using the Student’s t-test. P values  0.05 were 




Characteristics of the rhTRAIL-resistant cell line 
The TRAIL-resistant sub-line (SW948-TR) was established from the parental colon 
carcinoma cell line SW948 following incubation with increasing concentrations of 
rhTRAIL for three months. The differences in rhTRAIL sensitivity within this isogenic 
cell model are shown in Figure 1A. SW948 is an extremely sensitive to rhTRAIL with an 
IC50 of 0.007 g/ml whereas SW948-TR is resistant to high concentrations of rhTRAIL, 
or 140 fold less sensitive than its parental cell line. SW948 cells were also more sensitive 
to rhTRAIL-induced apoptosis than SW948-TR cells as determined in an apoptosis assay 
(Figure 1B). The ~ 30% surviving fraction is consistent with previous model of TRAIL 
resistance in cancer cell lines treated with TRAIL for several months (17,18). 
TRAIL receptor membrane expression was evaluated in both cell lines to examine 
whether TRAIL receptors played a role in the acquisition of TRAIL resistance (Figure 
1C). The cell lines showed similar DR4 (p = 0.998) and DR5 (p = 0.109) membrane 
expression. DcR1 and DcR2 were not or hardly expressed on the cell surface of both cell 
lines. Western blotting was performed to determine whether the acquisition of TRAIL 
resistance in SW948-TR cells was caused by a change in basal protein expression levels 
of DISC components, Bcl-2 family members or members of the inhibitor of apoptosis 
protein (IAP) family (Figure 1D). Total DR4 and DR5 levels were similar between the 
two cell lines. No differences in FADD, Bid, Bax, Bak, Bcl-2, Bcl-XL, or caspase 9 were 
observed between SW948 and SW948-TR. Members of the IAP family, namely survivin, 
c-IAP1 and c-IAP2 were similarly expressed in both cell lines. Procaspase 8 levels were, 
however, lower and procaspase 10 levels slightly higher in SW948-TR than in SW948.
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Figure 1: The SW948-TR cell line is less sensitive to rhTRAIL than its parental SW948 cell line and 
expressed lower procaspase 8 protein levels. A: Survival (%) of SW948 (closed square) and SW948-TR 
(closed triangle), after continuous incubation with rhTRAIL as measured by cytotoxicity assays. Values 
are mean ± SD of at least three independent experiments. *: SW948 differs from SW948-TR at 0.01-1 g/ml 
rhTRAIL (p  0.05). B: Apoptosis (%) of SW948 (top) and SW948-TR (bottom), after incubation with 
various concentrations of rhTRAIL for 5 h, as assessed following AO staining. Values are mean ± SD of at 
least three independent experiments. C: Basic membrane expression of the TRAIL receptors DR4 (black 
bars), DR5 (dark gray bars), DcR1 (white bars), and DcR2 (light gray bars) in SW948 and SW948-TR. 
Receptor expression was detected as mean fluorescence intensity (MFI). Values are mean  SD of at least 
three independent experiments. D: Western blot analysis showing basic expression levels of several 
proteins involved in apoptosis for SW948 and SW948-TR. One representative of at least three different 
experiments is shown. Actin is shown as loading control. 
 
 
The protein synthesis inhibitor cycloheximide sensitizes SW948-TR cells to rhTRAIL in 
a caspase 8-dependent manner 
In SW948-TR, incubation with rhTRAIL induced apoptosis in approximately 30% of 
cells. The protein synthesis inhibitor cycloheximide strongly sensitized SW948-TR cells 
to rhTRAIL (Figure 2A). The levels of apoptosis reached in presence of cycloheximide 
were similar to the levels of apoptosis initially found in the parental cell line (compare 
with Figure 1B, top panel). These results demonstrate that the TRAIL receptor-mediated 
apoptotic pathway is still functional in SW948-TR cells. 
Caspase 8 activation is a crucial step in death receptor-mediated apoptosis. To 
study whether inhibition of TRAIL-induced apoptosis in SW948-TR originates 
upstream, downstream, or at the level of caspase 8, the cleavage of caspase 8 and Bid in 
response to rhTRAIL was studied by Western blotting. Caspase 8 activation was 
represented by either the intermediate caspase 8 product (p45/47) or the active caspase 
8 (p18) sub-units, and activation of Bid by disappearance of the full length protein. 
Exposure of SW948 to rhTRAIL for 5 h induced cleavage of procaspase 8 as well as Bid 
activation (Figure 2B, lane 2). In the presence of cycloheximide and rhTRAIL, caspase 8 
cleavage and Bid activation were also observed in SW948-TR (Figure 2B, lane 5). Since 
the TRAIL-sensitive fraction of approximately 30% in SW948-TR may have complicated 
our observations (see also Figure 2A), the apoptotic (A) and the surviving (S) fraction of 
SW948-TR were separated after exposure to rhTRAIL for 5 h. High levels of cleaved 
caspase 8 and complete Bid activation were detected in the apoptotic fraction (Figure 2B, 
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lane 7). In contrast, Bid was not cleaved in the surviving fraction where pro- and active 
caspase 8 were almost undetectable (lane 6 in Figure 2B). These results strongly suggest 
that resistance is initiated at the level of caspase 8 in SW948-TR, through 
downregulation of pro- and/or active caspase 8 levels. 
In presence of cycloheximide, both the caspase 8-specific inhibitor zIETD-fmk 
and the pan-caspase inhibitor zVAD-fmk inhibited TRAIL-induced apoptosis in the 
resistant cell line (Figure 2C), indicating the importance of caspases in TRAIL-induced 
apoptosis following cycloheximide treatment. In contrast, the caspase 9 inhibitor 
zLEHD-fmk could not inhibit TRAIL-induced apoptosis in SW948-TR (Figure 2D). Thus, 
in presence of cycloheximide, enough active caspases can be generated without the need 
for amplification via caspase 9 downstream of the mitochondria (19). 
 
Similar phenotypes in sub-clones of SW948-TR 
Since cell cycle distribution in the surviving fraction was similar to that of untreated 
cells, we excluded the possibility that the apoptotic fraction consisted of cells in a 
specific phase of the cell cycle (data not shown). To test whether SW948-TR consisted of 
a heterogeneous cell population causing differential expression of caspase 8 in 30% of 
the cells, 15 sub-clones were isolated using minimal dilution and soft agar sub-cloning 
methods. Effects of rhTRAIL incubation on cell survival in SW948, SW948-TR and four 
randomly-chosen clones are shown in Figure 3A. Screening for DISC protein expression, 
we found no difference in membrane TRAIL receptors, pro-caspase 8 and c-FLIP protein 
expression levels between the sub-lines (Figure 3 B-C). Remarkably, most sub-clones 
showed apoptosis in a range of 20-40% after incubation with rhTRAIL alone, and were 
completely sensitized to rhTRAIL by cycloheximide (CHX, Figure 3D). Clone 4 
exhibited slightly higher rhTRAIL sensitivity in survival and apoptosis assay (Figure 3A 
and D). This may be explained by the fact that clone 4 exhibited higher caspase 8 
expression and similar c-FLIP expression compared to other clones (for example, 
compare clone 1 and 4 in Figure 3B). The fact that we could not isolate individual stable 
TRAIL-sensitive and TRAIL-resistant clones suggest that the ~ 30% apoptosis seen in 
SW948-TR cells after rhTRAIL treatment is a general property of the cell population. The 
existence of an apoptotic fraction might partly be explained by small cell-to-cell 
variations in caspase 8 and FLIP levels in favor of apoptosis. 
 





Figure 2: The protein synthesis inhibitor cycloheximide (CHX) sensitizes SW948-TR cells to rhTRAIL-
induced apoptosis in a caspase 8-dependent fashion. A: Sensitization of SW948-TR cells to rhTRAIL-
induced apoptosis by CHX, as determined by AO staining. Cells were exposed to 0.1 or 1.0 g/ml 
rhTRAIL for 24 h with or without pre-incubation with 5 g/ml CHX for 1 h. Values are mean ± SD of at 
least three independent experiments. B: Western blot analysis of caspase 8 activation and Bid cleavage in 
SW948 and SW948-TR cells. Cells were treated with 5 g/ml CHX, 0.1 g/ml rhTRAIL alone or in 
combination. Total cell lysates were loaded (T) and for the SW948-TR the surviving sub-fraction (S) was 
separated from the apoptotic (A) cell fraction. Procaspase 8 (55 kD) is cleaved in an intermediate product 
(cleaved caspase 8, Cl. caspase 8) (47 kD) and an active p18 product (18 kD). Bid (24 kD) is cleaved in tBid 
(not detectable) by active caspase 8. Bands of interest are indicated with arrows. C: Caspase 8-dependent 
apoptosis in CHX-treated SW948-TR cells. Cells were pre-incubated for 1 h with 5 g/ml cycloheximide 
and/or 50 M zIETD-fmk or 50 M zVAD-fmk before treatment with 0.1 g/ml rhTRAIL for 4 h. D: 
SW948-TR cells were pre-incubated for 1 h with 5 g/ml CHX and/or 50 M zLEHD-fmk before 4 h-




(clones 1, 2, 3, 4). Expression was detected as mean fluorescence intensity (MFI) of the whole cell 
population. D: Apoptosis induced in SW948, SW948-TR and in the sub-clones of SW948-TR (clones 1, 2, 
3, 4). Cells were plated as control (black bars), exposed to 5 μg/ml CHX (white bars), 0.1 μg/ml 
rhTRAIL (light grey bars) or pretreated with 5 μg/ml cycloheximide for 1 h followed by 5 h incubation 
with 0.1 μg/ml rhTRAIL (dark grey bars). E: The NFB inhibitor SN-50 does not sensitize SW948-TR to 
rhTRAIL-induced apoptosis. Cells were pre-exposed to 25, 50 or 100 g/ml SN-50 alone or in 
combination with 0.1 g/ml rhTRAIL for 5 h.  
Figure 3: Sub-clones of SW948-TR have 
similar TRAIL sensitivity. A: Survival of 
SW948, SW948-TR and the SW948-TR 
sub-clones (1, 2, 3 and 4) after continuous 
incubation with rhTRAIL as measured 
with cytotoxicity assays. B: Western blot 
analysis of basic procaspase 8 and c-FLIP 
protein expression in SW948-TR (R) and 
in the SW948-TR sub-clones (1, 2, 3, 4). 
Bands of interest are indicated with 
arrows. C: Basic membrane expression of 
the TRAIL receptors DR4 (black bars), 
DR5 (white bars) in SW948, SW948-TR 
and in the sub-clones of SW948-TR 
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The NFB pathway has sometimes been attributed pro- and anti-apoptotic 
properties as regard to TRAIL-sensitivity (20,21). SW948-TR cells were treated with SN-
50, a cell permeable inhibitory peptide based on NFB p50, to investigate the role of 
NFB-activation in response to rhTRAIL (Figure 3E). Inhibition of NFB did not 
sensitize SW948-TR to rhTRAIL. Remarkably, SN-50 showed an apoptosis-inhibiting 
effect on the ~30% apoptotic cells detected after rhTRAIL exposure, suggesting potential 
pro-apoptotic effects of the NFB pathway in the rhTRAIL-sensitive fraction of the 
SW948-TR cell population. 
 
The caspase 8/ c-FLIP ratio plays a role in the differential rhTRAIL-sensitivity of 
SW948 and SW948-TR cells 
We previously reported that treating colon carcinoma cell lines with CHX strongly 
downregulated c-FLIP expression, notably in SW948 cells (15). CHX increased rhTRAIL-
sensitivity (Figure 2A) and downregulated c-FLIP in SW948-TR cells (Figure 4A). The 
increase in Bid activation (Figure 2B) suggests that CHX primarily modulate rhTRAIL-
induced apoptosis upstream of Bid by downregulating c-FLIP and thus facilitating 
caspase 8 cleavage. However, it cannot be ruled out that CHX inhibits expression of 
some additional anti-apoptotic proteins with a high turnover. To study the importance 
of c-FLIP downregulation by CHX in our TRAIL-resistant cell line, we downregulated c-
FLIP levels in SW948-TR cells using short interference RNA technology. c-FLIP siRNA 
specifically downregulated c-FLIP levels compared to luciferase siRNA (Figure 4A). 
This demonstrates the importance of CHX-induced c-FLIP downregulation for the 
increase in rhTRAIL-sensitivity in SW948-TR. Downregulating c-FLIP expression 
sensitized SW948-TR cells to rhTRAIL-induced apoptosis (Figure 4C). Since SW948-TR 
exhibited lower levels of procaspase 8 rather than having higher levels of its inhibitor c-
FLIP (Figure 1D), we tested the role played by caspase 8 levels in TRAIL sensitivity of 
the parental cell line. Caspase 8 levels were therefore downregulated using siRNA 
before TRAIL treatment in the parental cell line (Figure 4D). Cleavage of the executioner 
caspase substrate PARP was used to evaluate rhTRAIL-induced apoptosis in SW948 
cells following caspase 8 downregulation. As seen in Figure 4E, treatment with 0.01 
μg/ml rhTRAIL induced cleavage of ~50% of the available full-length PARP into its 
active form (89 kD), both in control and in luciferase-transfected cells. At the same 
rhTRAIL concentration, caspase 8 downregulation almost completely prevented PARP 
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Figure 4: Caspase 8- and FLIP-levels are important regulator of TRAIL sensitivity in the SW948/SW948-TR 
cell lines. A: Western blot analysis of c-FLIPL protein levels in SW948-TR cells after 24 h incubation with 5 
g/ml CHX. B: SW948-TR cells were transfected with siRNA duplexes directed against the luciferase gene 
(Luc) as control siRNA or the c-FLIP gene. Western blot analysis showed down-regulation of c-FLIP by c-
FLIP siRNAs. C: Apoptosis assay in siRNA transfected SW948-TR cells. Control cells and luciferase or c-
FLIP siRNA transfected cells were plated and 48 h after transfection cells were incubated with rhTRAIL. 
After 4-5 h rhTRAIL incubation the percentage of apoptosis was determined (p 0.05). D: Downregulation 
of caspase 8 by specific siRNAs in SW948-TR. Cells were transfected with 25-100 nM siRNA duplexes 
targeting luciferase (Luc) or the caspase 8 mRNA for 48 h before lysis and Western blot analysis. E: Effects 
of caspase 8 downregulation on PARP cleavage as determined by Western blot analysis. Cells were 
transfected with 66 nM siRNA for 48 h before treatment with rhTRAIL for 5 h before lysis. F: Relative 
caspase 8 and FLIP mRNA levels in SW948 and SW948-TR, as determined by real-time PCR. 
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cleavage in SW948. Thus, decreasing basal caspase 8 expression levels is sufficient to 
inhibit rhTRAIL-induced apoptosis in SW948 cells, despite the presence of caspase 10 
(see Figure 1D). We did not completely prevent rhTRAIL-induced PARP cleavage in 
SW948 by inhibiting caspase 8 expression, in particular at higher concentrations of 
rhTRAIL (Figure 4E). This could be due to incomplete downregulation of caspase 8 
(Figure 4D). Although procaspase 8 protein levels are lower in SW948-TR than in SW948 
(Figure 1D), we now show that mRNA levels of caspase 8 (and c-FLIP) are similar 
between the two cell lines (Figure 4F), indicating that the decrease in caspase 8 levels in 
SW948-TR is due to decreased translation and/or decreased stability of the protein. 
Altogether, these results indicate that the caspase 8/c-FLIP ratio plays an important role 
for rhTRAIL sensitivity in SW948 and SW948-TR cells. 
 
MG132 stabilized active caspase 8 protein levels and sensitized SW948-TR to rhTRAIL 
As an alternative to c-FLIP downregulation using CHX, restoring caspase 8 levels may 
also restore rhTRAIL sensitivity in SW948-TR cells. To elucidate whether rhTRAIL 
resistance could be caused by increased proteasomal degradation of procaspase 8 levels, 
SW948-TR cells were treated with the proteasome inhibitor MG132 (Figure 5A). MG132 
treatment did not increase procaspase 8 levels but induced a small increase in the 45/47 
kDa intermediate product of caspase 8. No effect on full length c-FLIP levels was found. 
To importance of caspase 8 expression levels was studied in the rhTRAIL-treated 
surviving fraction of SW948-TR (Figure 5B, lane 2) which expressed low caspase 8 levels. 
Following rhTRAIL incubation for 5 h, apoptotic cells were washed away and the 
surviving fraction was incubated with MG132 for an additional 2-4 h (Figure 5B, lane 6-
7). This induced high levels of both the intermediate product and the active form of 
caspase 8. The effect of MG132 treatment on c-FLIP levels was also assessed to provide 
an additional read-out for DISC activity (Figure 5B). In the surviving fraction, although 
some cleavage of c-FLIP was detected in presence of rhTRAIL, full-length c-FLIP was 
still available (Figure 5B, compare lane 2 to lane 3). While exposure to MG132 strongly 
increased intermediate and active caspase 8 levels in the surviving fraction, it only 
induced a slight augmentation in c-FLIP cleavage (Figure 5B, compare lanes 6-7 with 
lane 2). MG132 neither had effect on DR4 or DR5 protein levels nor on surface 
expression of these two receptors (data not shown). This indicates that the high levels of 
active caspase 8 found after MG132 treatment are not caused by an increase in death
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receptor or procaspase 8 levels. Altogether, these experiments support a role for MG132 




Previous research on long-term acquired TRAIL resistance mechanisms in colon 
carcinoma cell line reported the accumulation of Bax mutations in vitro and in vivo (9). 
Because most colorectal cancers are MMR-proficient, we analyzed the mechanisms of 
acquired rhTRAIL resistance in a MMR-proficient colon carcinoma cell line model. We 
now show that in these cells, resistance to rhTRAIL is caused by increased degradation 
of the pool of activated caspase 8. These results point toward preservation of the early 
TRAIL resistance mechanism and ressembles results obtained in MMR-deficient TRAIL-
resistant colon cancer cells obtained following four rounds of infection with TRAIL 
adenoviral vectors (22). In support of a generally critical involvement of active caspase 
destabilization mechanisms in TRAIL resistance, the stability of rhTRAIL-induced active 
caspase 3 (but not caspase 8) was found to be lower in a MMR-proficient ovarian cancer 
cell line exposed to rhTRAIL for 20 weeks. 
The TRAIL-resistant SW948-TR cell line was established from the extremely 
TRAIL-sensitive SW948 colon carcinoma cell line after three months of continuous 
incubation with rhTRAIL. TRAIL receptor membrane expression was similar between 
the two cell lines. CHX sensitized SW948-TR cells to rhTRAIL as indicated by increased 
activation of both caspase 8 and Bid. Although SW948 and SW948-TR cells had similar c-
FLIP protein levels, procaspase 8 levels were lower in SW948-TR, implying reduction of 
the caspase 8/c-FLIP ratio. We show that this ratio plays a crucial role in regulating 
TRAIL sensitivity in these cells. Downregulating c-FLIP protein levels with CHX 
increased rhTRAIL-sensitivity in SW948-TR cells. Treatment of SW948-TR with specific 
c-FLIP siRNA also sensitized SW948-TR cells to rhTRAIL, while downregulation of 
caspase 8 decreased rhTRAIL sensitivity in SW948. In rhTRAIL-treated SW948-TR cells, 
separation of the rhTRAIL-resistant surviving cell fraction from the apoptotic fraction 
showed that procaspase 8 levels were lower in the surviving fraction than in the 
apoptotic fraction or in the sensitive parental cell line. Additionally, only partial 
cleavage of full-length c-FLIP was found in the surviving cell fraction of SW948-TR, 
suggesting that the decrease in rhTRAIL-induced apoptosis was associated with lower 









DISC activity. Spencer et al. recently demonstrated that the so-called “fractional killing” 
of TRAIL was caused by cell-to-cell variability in protein expression due to noise in gene 
expression (23). The presence of a CD133 positive sub-population could also explain this 
Figure 5: MG132 stabilizes active caspase 8 protein levels and sensitizes SW948-TR to TRAIL in a 
caspase-dependent manner. A: Western blot analysis of caspase 8 and c-FLIP protein levels in SW948-TR 
cells incubated with MG132 for 0-7 h. B: Western blot analysis of caspase 8 activation (casp 8) and c-FLIP 
processing in SW948-TR. After 5 h rhTRAIL incubation (0.1 g/ml) the surviving cell fraction (S) was 
separated from the apoptotic cell fraction (A). U is untreated total cell population. Cells were then 
exposed to zVAD and or MG132 for 2 or 4 h.  
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differential killing of rhTRAIL (24,25). Altogether, our results support a key role for the 
caspase 8/c-FLIP ratio in initiating the acquired rhTRAIL resistance of SW948-TR cells. 
Accordingly, several studies have shown that a low caspase 8/c-FLIP ratio contribute to 
poor TRAIL sensitivity in cancer cell lines (26-31). Previously, we have reported that 
both c-FLIP and caspase 8 expressions are increased in colon cancer compared to normal 
epithelium (32). These changes were accompanied by large variations in caspase 8/FLIP 
ratio between colon tumors, which suggest the presence of subgroups of patients with 
pro- and anti-apoptotic caspase 8/c-FLIP ratios. 
We further investigated the decrease in caspase 8 in the TRAIL-resistant cell lines. 
Changes cell cycle distribution could not explain the differences in caspase 8 between 
SW948 and SW948-TR. Several studies observed downregulation of caspase 8 via 
hypermethylation of the caspase 8 promoter (33,34). Treatment of SW948-TR with the 
demethylating agent 5-aza-2 deoxycytidine had no effect on caspase 8 levels (results not 
shown). This finding is in line with the comparable mRNA levels present in SW948 and 
SW948-TR, indicating either decreased translation and/or decreased stability of caspase 
8 in SW948-TR. As previously observed by Zhang et al., proteasome inhibition could not 
restore procaspase 8 levels (22). SW948-TR cells could, however, be sensitized to 
rhTRAIL by MG132, in association with an increase in intermediate and active caspase 8 
levels. These results suggest that proteasome inhibition prevented the degradation of 
the cleaved forms of caspase 8.  
Little is known about the degradation mechanism(s) of procaspase 8 or active 
caspase 8. Bi-functional apoptosis regulator protein (BAR) was found to bind both forms 
of the protein. BAR possesses a RING domain with putative ubiquitin-protein 
isopeptide ligase-like activity. Stegh et al. speculated that active caspase 8 might be 
targeted for ubiquitination and proteasome-dependent degradation, although 
proteasome inhibitors failed to prevent caspase 8 degradation (35). Previously, a family 
of apoptotic inhibitors, the caspase 8 and 10 associated RING proteins (CARPs) has been 
identified (36). Binding of CARP1 and CARP2 negatively regulated death effector 
domain (DED) caspases by contributing to their ubiquitin-mediated proteolysis. 
Knockdown of CARPs did not result in an up-regulation of procaspase 8 but both 
TRAIL- and Fas-induced apoptosis were increased via enhanced caspase 8 processing. 
In Drosophila, MG132 treatment resulted in an accumulation of the processed form of the 
apical caspase DRONC but not of its full-length form (37). Recently, Jin et al. showed 
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that consecutively to TRAIL treatment, a cullin3 (CUL3)-based E3 ligase induces poly-
ubiquination of caspase 8 at the DISC, thereby causing caspase 8 aggregation and full 
activation of this protein (38). The authors also found that proteasome inhibition did not 
stabilize poly-ubiquitinated active caspase 8 in the moderately TRAIL-sensitive H460 
cell line. In Bid-depleted Hela cells treated with CHX, active caspase 8 activity persisted 
for several hours after TRAIL treatment (39). Altogether, these results suggest that 
proteasomal degradation might be specific for the activated forms of caspase 8, and 
more prevalent in rhTRAIL-resistant cells.  
A limited number of studies have looked at mechanisms of acquired TRAIL 
resistance by long-term culturing of cells in medium containing rhTRAIL. TRAIL 
resistance was associated with a change in TRAIL receptor membrane expression in 
osteosarcomas (40) and in melanomas (41). In another study TRAIL exposure selected 
for cells with Bax mutations in MMR-deficient colon carcinoma cell lines (9). The 
importance of caspase 8 in TRAIL sensitivity has been shown before in non-isogenic cell 
lines (23,26,27,42). Active caspase 8 degradation was involved in the TRAIL resistance of 
a MMR-deficient colon cancer sub-cell line obtained after four rounds of selection with 
adenoviral TRAIL vectors (22). We are, however, the first to show that increased 
degradation of active caspase 8 still plays a crucial role in rhTRAIL-resistant colon 
carcinoma cells obtained after long-term exposure to this agent. 
 In conclusion, acquired rhTRAIL-resistance in SW948-TR is caused by decreased 
basal procaspase 8/c-FLIP ratio and increased degradation of cleaved caspase 8 after 
rhTRAIL treatment. Modulating the procaspase 8/c-FLIP ratio using c-FLIP siRNA or 
by stabilizing active caspase 8 protein levels using proteasome inhibition can restore 
rhTRAIL sensitivity in MMR-proficient cells which have acquired rhTRAIL-resistance. 
These results may help overcoming TRAIL resistance using rational strategies with 
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RhTRAIL is a therapeutic agent, derived from the TRAIL cytokine, which induces 
apoptosis in cancer cells by activating the membrane receptors DR4 and DR5. Here, we 
investigated each receptor’s contribution to rhTRAIL-sensitivity and rhTRAIL-resistance 
and assessed whether anti-DR4 or anti-DR5 agonistic antibodies could circumvent 
rhTRAIL resistance. Our study was performed in an isogenic model comprised of the 
SW948 human colon carcinoma cell line and its rhTRAIL-resistant sub-line SW948-TR. 
SW948 cells were sensitive to all three of the DR-targeting agents tested, although the 
anti-DR5 antibody induced only weak caspase 8 cleavage and low apoptosis levels. 
Nonetheless, anti-DR4 and anti-DR5 antibodies induced equivalent DISC formation and 
caspase 8 cleavage at the level of their individual receptors, indicating that further 
caspase 8 processing is impaired upon stimulation of DR5. SW948-TR cells were 
resistant to all DR-targeting agents due to their lower caspase 8 expression levels. 
Caspase 8 levels were restored by MG-132 or IFN-γ pre-treatment, and sensitivity to 
rhTRAIL and the anti-DR4 antibody was increased. Surprisingly, MG-132 also enhanced 
DR5-mediated apoptosis. These results highlight a critical difference between DR4 and 
DR5 apoptotic signaling modulation, with possible implications for future combinatorial 
regimens. 




Tumor necrosis factor related apoptosis inducing ligand is a member of the tumor 
necrosis factor (TNF) superfamily. Recombinant human TRAIL (rhTRAIL) is currently 
drawing attention in the field of cancer therapy because of its specificity for inducing 
apoptosis in tumor cells. Five TRAIL-receptors have been identified. DR4 and DR5 can 
transduce the apoptotic signal, whereas decoy receptor (DcR1), decoy receptor 2 (DcR2) 
and osteoprotegerin (OPG) presumably serve as decoy receptors, inhibiting TRAIL-
mediated apoptosis (1,2). Administration of rhTRAIL in tumor-bearing animals induces 
significant tumor regression without systemic toxicity (3,4). Furthermore, rhTRAIL in 
combination with chemotherapy or radiotherapy greatly enhances anti-tumor efficacy 
both in vitro and in vivo (5-8).  
The TRAIL apoptosis pathway can also be initiated by death receptor (DR)-
specific agonistic antibodies. These anti-DR4 and anti-DR5 monoclonal antibodies, 
either used alone or in combination with chemotherapy (or irradiation), induce 
apoptosis in tumor cells in vitro and in vivo (9-12). Thus, both rhTRAIL and agonistic 
antibodies demonstrate interesting preclinical anti-tumor properties. A phase I clinical 
study with rhTRAIL has been initiated (13). Several phase I-II clinical studies with 
agonistic anti-DR4 antibody and a phase I study with agonistic anti-DR5 antibody have 
been performed (2,14,15). However, as rhTRAIL and DR-agonistic antibodies differently 
stimulate the apoptosis signaling cascade, drug-specific effects in the treatment of cancer 
patients are expected (16-18). rhTRAIL, which can bind to DR4 and DR5 but also to the 
decoy receptors, triggers cross-linking of these receptors into homo- and/or 
heterotrimers (19,20). In contrast, agonistic anti-DR4 or anti-DR5 antibodies have been 
suggested to trigger formation of multimeric complexes consisting of only one specific 
receptor, consequently bypassing the decoy receptors (21,22).  
Not all tumor cells are sensitive to rhTRAIL, since intrinsic or acquired resistance 
to this ligand can exist. Very little is known about potential DR agonist-specific 
properties on downstream signaling pathways activation (e.g. NFB) and on rhTRAIL-
resistance, but rhTRAIL and agonistic anti-DR5 antibodies exhibit different ability to 
induce the conformational changes of DR5 required to allow FADD recruitment (23).  
The cytokine IFN- and proteasome inhibitors modulate several components of 
the apoptotic signaling pathway involved in TRAIL resistance (24-26). Combinations of 
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these drugs with TRAIL or death receptor agonist antibody can enhance TRAIL-induced 
apoptosis and overcome TRAIL-resistance in tumor cells (27-32). However, potential 
receptor specific effects of rhTRAIL resistance acquisition have not been investigated 
before. This is of major interest, as it is not yet established whether anti-DR4 or anti-DR5 
antibodies or rhTRAIL have superior anti-tumor efficacy in the clinic. In addition, the 
biomarkers that should be used to select patients for the different anti-DR4 and anti-DR5 
therapies are still unknown.  
In the present study we used agonistic monoclonal antibodies to separately 
evaluate the roles of DR4 and DR5 in rhTRAIL-sensitivity and TRAIL-resistance. We 
compared rhTRAIL-induced apoptosis with agonistic DR4 and DR5 antibody-induced 
apoptosis in an rhTRAIL-sensitive human colon cancer cell line and its rhTRAIL-
resistant sub-line. Furthermore we analyzed whether modulation of agonistic anti-DR4 
and anti-DR5 induced apoptosis using IFN- or a proteasome inhibitor was comparable 
to modulation of rhTRAIL-induced apoptosis in these cell lines.  
 
Materials and Methods 
 
Reagents 
RPMI 1640 medium was obtained from Life Technologies (Breda, The Netherlands) and 
fetal calf serum (FCS) from Bodinco BV (Alkmaar, the Netherlands). 3-(4,5-dimethyl-
thiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT)-solution and CHX were purchased 
from Sigma-Aldrich Chemie BV (Zwijndrecht, the Netherlands). rhTRAIL was produced 
non-commercially in cooperation with IQ-Corporation (Groningen, the Netherlands) 
following a protocol described earlier (33). The agonistic anti-DR4 (HGS-ETR1) and anti-
DR5 (HGS-TR2J) antibodies were a gift from Human Genome Sciences (HGS, Rockville, 
MD, USA). The inhibiting anti-DR4 (HS 101) and anti-DR5 (HS 201) antibodies were 
purchased from Alexis (10 P’s BVBA, Breda, the Netherlands). The proteasome inhibitor 
MG-132 was obtained from Calbiochem (Breda, the Netherlands) and IFN- was 
purchased from Roche Diagnostics (Mannheim, Germany). The TRAIL receptor 
antibodies used for flow cytometry were obtained from Immunex Corporation (Seattle, 
WA, USA). 
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Cell lines 
The rhTRAIL-sensitive colon carcinoma SW948 cell line (34) was cultured as described 
previously (35). In order to develop a rhTRAIL-resistant sub-line, SW948 was first 
exposed to 1.0 µg/ml rhTRAIL and incubated at 37 C. After 14 days resistant cells were 
cultured twice a week in the presence of 2.5 µg/ml rhTRAIL. 3 months later the stable 
rhTRAIL-resistant cell line SW948-TR was obtained. In the absence of rhTRAIL in the 
culture medium SW948-TR remains resistant to rhTRAIL for at least 75 passages. This 
cell line is at least 140 fold more resistant to rhTRAIL than the sensitive parental cell 
line, as determined from the IC50 at 96 h, and is similarly cultured.  
 
Co-Immunoprecipitation of TRAIL-, DR4- or DR5-DISC 
DISC immunoprecipitation after TRAIL-receptor ligation was performed according to 
Bodmer et al. (36) with some modifications. Briefly, 50.106 cells per condition were 
grown, harvested and collected by centrifugation. The cell pellet was resuspended in 1 
ml pre-warmed medium and the tube was placed in a 37 C incubator. Recombinant 
human soluble flag-tagged TRAIL and anti-Flag monoclonal antibody M2 were 
premixed for 15-30 min on ice. Cells were stimulated in a final volume of 1 ml with 500 
ng/ml Flag-tagged TRAIL and 1.5 g/ml M2. In unstimulated cells the Flag-tagged 
TRAIL and M2 premix were added after lysis to immunoprecipitate non-stimulated 
TRAIL-receptors. Cell suspensions were incubated for 30 min at 37 C, and the reaction 
was stopped by the addition of 10 ml ice-cold phosphate buffered saline (6.4 mM 
Na2HPO4; 1.5 mM KH2PO4; 0.14 mM NaCl; 2.7 mM KCl; pH=7.2). The cells were 
immediately washed with ice-cold PBS and lysed in 1 ml lysis buffer (30 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 10% glycerol, 1 mM phenylmethylsulfonyl 
fluoride) with complete protease inhibitors (Roche Diagnostics, Almere, the 
Netherlands) for 15 min on ice. After centrifugation (2,500 x g) at 4 C for 10 min, the 
lysates were pre-cleared with 20 l Sepharose-6B (Pharmacia, Uppsala, Sweden) for 2 h 
at 4 C and immunoprecipitated with 30 l protein-A sepharose beads for 4 h-overnight 
at 4 C. Beads were washed three times with 1.5 ml lysis buffer, resuspended in 
standard Western blot sample buffer, and boiled for 5 min. Immunoprecipitated 
proteins were separated with SDS-PAGE. Western blot analysis for FADD, caspase 8, c-
FLIP, DR4, DR5 and TRAIL was performed as described in the SDS-polyacrylamide gel 
electrophoresis and Western blotting section. Goat HRP-conjugated secondary antibody 
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specific for mouse IgG1 and donkey-anti-goat-HRP were used for the detection of 
caspase 8, FADD, c-FLIP or DR4. 
DR4 and DR5-DISC co-immunoprecipitation with the HGS-ETR1 and HGS-TR2J 
antibodies were performed as described above, with some modifications. Briefly, 50.106 
cells per condition were grown in medium harvested and resuspended in fresh medium. 
Cells were stimulated with 5µg/ml HGS-ETR1 or HGS-TR2J in a final volume of 2 ml. 
The antibodies were added after cell lysis for the control treatment. Cell suspensions 
were incubated for 15 min at 37 C, and the reaction was stopped by the addition of 10 
ml ice-cold phosphate buffered saline (PBS). The cells were immediately washed with 
ice-cold PBS and lysed in 1 ml lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.2% 
Nonidet P-40, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride) with complete 
protease inhibitors (Roche Diagnostics, Almere, the Netherlands) for 30 min on ice. 
After centrifugation (12,000 x g) at 4 C for 10 min, the lysates were pre-cleared with 20 
l Sepharose-6B (Pharmacia, Uppsala, Sweden) for 2 h at 4 C and immunoprecipitated 
with 50 l protein-G agarose beads (Roche Diagnostics, Mannheim, Germany) for 3 at 4 
C. Beads were washed two times with 1 ml lysis buffer and one time with PBS before 
resuspension in standard Western blot sample buffer and boiling for 5 min. 
Immunoprecipitated proteins were separated with SDS-PAGE. Western blot analysis for 
FADD and c-FLIP was performed as described below. DR4 and DR5 were detected 
using rabbit anti-DR4 and rabbit anti-DR5 from ProSci Inc. (Poway, CA, USA). Caspase 
8 was detected with rabbit anti-caspase 8 (Abcam plc, Cambridge, UK). Goat anti-rabbit 
HRP-conjugated secondary antibody and rabbit-anti-mouse-HRP were used for the 
detection of DR4, DR5, FADD, caspase 8 or c-FLIP. 
 
SDS-polyacrylamide gel electrophoresis and Western blotting 




Apoptosis was assessed using acridine orange (AO) staining, using a method described 
earlier (35).  
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Cytotoxicity assay 
The microculture tetrazolium (MTT) assay was used to determine cytotoxicity. SW948 
and SW948-TR cells were incubated in a total volume of 200 l. After an incubation 
period of 96 h, 20 l of 5 mg/ml MTT solution diluted in PBS was added for 3.75 h. 
Subsequently, plates were centrifuged and the supernatant aspirated. After dissolving 
the formazan crystals by adding dimethyl sulfoxide (Merck, Amsterdam, the 
Netherlands), plates were read immediately at 520 nm using a microtiter well 
spectrometer (Bio-Rad microplate reader, Bio-Rad laboratories BV, Veenendaal, the 
Netherlands). Controls consisted of media without cells. Cell survival was defined as 
the growth of treated cells compared to untreated cells. IC50 was the concentration of 
drug inhibiting survival by 50%. Mean cytotoxicity was determined in three 
independent experiments where each condition was performed in quadruplicate.  
 
Flow cytometry 
Analysis of DR4 and DR5 membrane expression was performed as described earlier 
(35). For competition experiments with rhTRAIL, SW948 cells (2.106/condition) were 
harvested, resuspended in 2.5 ml ice cold PBS and incubated on ice with various 
amounts of rhTRAIL for 1 h. Cells were then washed twice with PBS before fluorescent 




TRAIL-resistance in SW948-TR can be partially explained by its inefficient TRAIL-
DISC formation 
Recently, we have developed a model for acquired rhTRAIL-resistance consisting of the 
rhTRAIL-sensitive human colon carcinoma cell line SW948 and its rhTRAIL-resistant 
sub-line SW948-TR. In the two cell lines, DR4 and DR5 were both expressed at the cell 
surface, while DR4 seemed more highly expressed (see Figure 1A).  
We next investigated whether differences in DR functionality may be involved in 
the rhTRAIL-resistance of SW948-TR. TRAIL-induced DISC formation was studied. 
Figure 1B demonstrates that SW948-TR exhibited weaker DISC recruitment of caspase 8 
compared to the TRAIL-sensitive cell line. In particular, lower amounts of the cleaved 
p43/41 form of caspase 8 were found. Other DISC proteins such as DR4 and DR5, 
Chapter 4 
108 
Figure 1. Inefficient DISC formation in SW948-TR cells. A: Membrane expression of the TRAIL receptors 
DR4 and DR5 in SW948 and SW948-TR cells as determined by flow cytometry. Values are expressed as 
the mean fluorescence intensity (MFI) and are mean  SE of at least three independent experiments. B: 
Analysis of the TRAIL-DISC in SW948 and SW948-TR. Cells were incubated for 30 min with Flag-tagged 
TRAIL and the assembled DISCs were immunoprecipitated and analyzed by Western blotting using 
antibodies to DR4, DR5, FADD, caspase 8 and c-FLIP. T = total cell lysates; C = control of 
immunoprecipitation, IP = immunoprecipitation (After a longer exposure DR5 bands were also detectable 
in the total cell lysates (T)). C: Western blot analysis comparing caspase 8 levels in SW948 and SW948-TR 
cells. One of at least three independent experiments is shown. 
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together with FADD and c-FLIP, were equally present in both cell lines. Looking for an 
explanation to the lower caspase 8 recruitment in the DISC of SW948-TR cells as 
compared to SW948 cells, we compared caspase 8 levels in whole cell lysates of both cell 
lines. As seen in Figure 1C, SW948 expressed lower amount of procaspase 8. 
 
Specific blocking of the individual death receptors indicates that DR4 is more 
important than DR5 for rhTRAIL-induced apoptosis 
To evaluate the contribution to apoptosis of either DR4 or DR5 in the sensitive and 
resistant cell line, antagonistic TRAIL receptor antibodies were used. In SW948, 
rhTRAIL-induced apoptosis was reduced by 60% using a blocking anti-DR4 antibody, 
while blocking DR5 only had a slight effect on rhTRAIL-induced apoptosis (Figure 2A). 
A competition experiment was performed in SW948 to look for possible mutations in the 
extracellular domain of DR4 or DR5 that would affect rhTRAIL-binding to DR4 or DR5. 
SW948 cells were pretreated with rhTRAIL and kept on ice to prevent receptor 
internalization, before detection of DR4 and DR5 using flow cytometry (Figure 2B). A 
similar decrease in detectable amounts of both death receptors for increasing 
concentrations of rhTRAIL was observed. Thus, we conclude that the binding of 
rhTRAIL is comparable for each DR in SW948 cells. 
Following initial sensitization with the protein synthesis inhibitor CHX, SW948-
TR cells were also exposed to rhTRAIL (Figure 2C). Apoptosis was decreased by 60% 
upon inhibition of rhTRAIL binding to DR4 with an anti-DR4 antibody. Inhibition with 
anti-DR5 antibody had almost no effect on rhTRAIL-induced apoptosis. Thus, blocking 
of DR4 and DR5 with antagonist antibodies revealed that DR4 was more important than 
DR5 for rhTRAIL-induced apoptosis in SW948 and SW948-TR. Surprisingly, in SW948 
and SW948-TR the combination of both DR-antagonistic antibodies inhibited rhTRAIL-
induced apoptosis even further, with 15.7% and 31.9% more, respectively, than anti-DR4 
antibody alone. This suggests that although rhTRAIL mostly signals via DR4, both DR4 































rhTRAIL sensitivity of each DR corresponds with sensitivity to agonistic anti-DR4 and 
anti-DR5 monoclonal antibodies 
To gain more insight into the functionality of DR4 and DR5 in apoptosis signaling, the 
effects of agonistic monoclonal DR4 and DR5 antibodies on DR-mediated apoptosis 
were determined by survival assay. As shown in Figure 3A (left), the rhTRAIL-sensitive 
cell line SW948 was sensitive to both the HGS-ETR1 and HGS-TR2J antibody. The 
Figure 2. Important contribution of DR4 to 
rhTRAIL-induced apoptosis. A: Apoptosis 
assay in SW948. Cells were pre-incubated 
with 10 g/ml antagonistic anti-DR4 (αDR4), 
anti-DR5 (αDR5) antibodies or IgG1 control 
for 1 h before 4-5 h rhTRAIL treatment (0.1 
g/ml). Values are mean  SD of at least 
three independent experiments. B: rhTRAIL 
binding to DR4 and DR5 in SW948 cells. Cells 
were incubated with increasing 
concentrations of rhTRAIL before detection 
of accessible cell surface DR4 and DR5. 
Values are expressed as the mean 
fluorescence intensity (MFI) and are mean  
SE of at least three independent experiments. 
C: Apoptosis assay in SW948-TR. CHX (5 
g/ml) was combined or not with the 
blocking antibodies 1h before TRAIL 
treatment as described in (A). 
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agonistic anti-DR4 antibody was more effective than the agonistic anti-DR5 antibody, in 
particular at higher concentrations. SW948-TR cells were resistant to both HGS-ETR1 
and HGS-TR2J (Figure 3A, right). These findings were confirmed by apoptosis 
measurements using AO staining (Figure 3B).  Thus, the sensitivity to agonistic anti-DR4 
or anti-DR5 antibodies of SW948 and SW948-TR cells seems to partially reflect the 
individual sensitivity to rhTRAIL of each receptor. Interestingly, the low sensitivity to 
the agonistic DR5 antibody in comparison to the agonistic DR4 antibody could be 
enhanced by CHX in SW948 (Figure 3B, left). CHX could also strongly sensitize SW948-
TR cells to HGS-ETR1 and to a lesser extend to HGS-TR2J (Figure 3B, right). 
Figure 3. Sensitivity of SW948 and SW948-TR to HGS-ETR1 and HGS-TR2J antibodies. A: Survival (%) of 
SW948 and SW948-TR after continuous incubation with HGS-ETR1 () and HGS-TR2J (▲) as measured 
by cytotoxicity assays. B: Apoptosis assay in SW948 and SW948-TR. Cells were pre-incubated with 5 
g/ml CHX for 1 h before incubation with various concentrations of HGS-ETR1 or HGS-TR2J for 24 h. 
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Upon stimulation with agonistic antibodies, comparable DISC formation occurs at the 
level of DR4 and DR5 in SW948 
We showed that DR4 was more competent at initiating apoptosis when compared to 
DR5 in SW948 cells. This was demonstrated by stimulating each receptor with rhTRAIL 
in combination with blocking antibodies, but also by stimulating each receptor with 
agonistic antibodies only. To investigate possible differences in DR4-DISC versus DR5-
DISC formation, we stimulated SW948 cells with either HGS-ETR1 or HGS-TR2J, and 
individually co-immunoprecipitated DR4- and DR5-DISC (Figure 4A). Surprisingly, 
DISC formation was comparable for both stimuli. HGS-ETR1 could recruit DR4, FADD, 
caspase 8 and c-FLIP. Using an antibody directed against the N-terminal fragment of 
caspase 8, three forms of this protein were detected in the DR4-DISC: the full form, the 
intermediate p43/41 cleaved form and the p26/24 cleavage product. The latter indicates 
full cleavage of caspase 8 and thereby release of active caspase 8 from the complex (for 
comprehensive review see (37)). c-FLIP was mostly present in its intermediate form. 
HGS-TR2J recruited DR5 and similar amounts of FADD, c-FLIP and caspase 8 as 
compared to HGS-ETR1. Later time points displayed similar DISC content (data not 
shown). Caspase 8 cleavage was also investigated in whole cell lysates of SW948 cells 
treated with either DR-agonistic antibody (Figure 4B). Within 3 hours, HGS-ETR1 
induced full cleavage of the available procaspase 8 into its intermediate and active form. 
Caspase 8 cleavage in cells stimulated with HGS-TR2J was only partial, as active caspase 
8 could not be detected, while unprocessed procaspase 8 molecules were still present 
after 3 hours.  
 
Resistance to rhTRAIL, HGS-ETR1 and HGS-TR2J can be overcome by the proteasome 
inhibitor MG-132 
Several studies have demonstrated that proteasome inhibition can overcome rhTRAIL-
resistance (24,38,39). Previously, we have observed that SW948-TR could be sensitized to 
rhTRAIL using the proteasome inhibitor MG-132 (unpublished observations). To 
investigate whether MG-132 sensitized cells in receptor-specific manner, SW948-TR cells 
were pre-incubated with this compound before treatment with rhTRAIL or agonistic 
anti-DR4 and -DR5 antibodies. HGS-ETR1- and HGS-TR2J-induced apoptosis was 
enhanced by approximately 50-60% following MG-132 treatment, which was similar to 
the observed enhancement of rhTRAIL-induced apoptosis (Figure 5A). As seen in Figure
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Figure 4: Equivalent DISC protein recruitment but not caspase 8 activation following HGS-ETR1 and 
HGS-TR2J treatment. A: Analysis of the DR4 and DR5-DISC in SW948. A: Cells were incubated for 15 min 
with HGS-ETR1 or HGS-TR2J before co-immunoprecipitation of the associated DISCs using protein G-
agarose beads, and subsequent analysis by Western blotting using antibodies directed against DR4, DR5, 
FADD, caspase 8 and c-FLIP. Post = antibodies added after cell lysis; Stim = cells stimulated with the 
indicated antibody for 15 min. One representative of at least two independent experiments is shown. B: 
Time-dependent cleavage of pro-caspase 8 in SW948 cells treated with 50 nM HGS-ETR1 or HGS-TR2J. 
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Figure 5: Sensitization of SW948-TR to rhTRAIL, HGS-ETR1 and HGS-TR2J by MG-132. A: Apoptosis 
assay in SW948-TR after 17 h of incubation with MG-132 in combination with rhTRAIL, HGS-ETR1 or 
HGS-TR2J. B: The effect of MG-132 on DR4 (left figure) and DR5 (right figure) membrane expression as 
determined by flow cytometry. Receptor expression was detected as the average antigenic density of the 
whole cell population and resulted in a peak shift to the right. (1 = control; 2 = basal DR4 or DR5 
membrane expression level; 3 = DR4 or DR5 expression after exposure to 10 M MG-132 for 17 h). C: 
Western blot analysis of caspase 8 activation in SW948-TR after 17 h incubation with 1 μM MG-132 in 
combination with rhTRAIL (0.1 μg/ml), HGS-ETR1 or HGS-TR2J (50 nM).  
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5B, the effects were not the result of cell membrane DR4 (left figure) or DR5 (right 
figure) up-regulation by MG-132. Western blot analysis demonstrated that MG-132 
increased the intermediate p43/41 cleavage product of caspase 8 (Figure 5C). The 
combination of MG-132 with either rhTRAIL, HGS-ETR1 or HGS-TR2J led to an almost 
identical processing of caspase 8 into its active caspase 8 subunit (p18). 
 
IFN- sensitizes SW948-TR to rhTRAIL and HGS-ETR1 but not to HGS-TR2J 
Our experiments with MG-132 suggested that TRAIL-sensitivity might be increased due 
to the enhancement of caspase 8 expression. Upregulation of caspase 8 by IFN- has 
been described as a mechanism of sensitization to rhTRAIL (40). Since reduced caspase 8 
expression levels were detected in SW948-TR as compared to SW948 (Figure 1C), we 
hypothesized that IFN- might overcome rhTRAIL resistance in SW948-TR. Upon 
treatment with IFN-, caspase 8 protein expression was enhanced in a concentration-
dependent manner, in both cell lines (Figure 6A). We excluded an effect of IFN- on cell 
surface DR expression levels in these cells, as no change in either DR4 or DR5 surface 
expression was observed following IFN- treatment (Figure 6B left and right, 
respectively). In a previous study we did not observe any additional effect of IFN- on 
rhTRAIL sensitivity in SW948, a cell line that is already extremely sensitive to rhTRAIL 
(35). Survival assays now showed that IFN- could sensitize SW948-TR to both rhTRAIL 
and HGS-ETR1 but not to HGS-TR2J (Figure 7A). Similar results were also seen in an 
apoptosis assay using AO staining (Figure 7B). Cell survival assays in SW948 indicated 
that IFN- enhanced the sensitivity to HGS-ETR1 but not to HGS-TR2J (results not 
shown). TRAIL receptor blocking antibodies were used to determine the relative 
contribution of each individual DR to IFN- induced sensitization to rhTRAIL in SW948-
TR. The observed sensitization to rhTRAIL was DR4-specific, since the anti-DR4 
blocking antibody reduced rhTRAIL-induced apoptosis by 50%, whereas the anti-DR5 
blocking antibody only had a minor effect on apoptosis in SW948-TR cells pre-sensitized 
with IFN- (Figure 7C). Western blot analysis of caspase 8 cleavage was performed to 
gain further insights into the possible mechanism underlying IFN--induced 
sensitization of DR-mediated apoptosis in SW948-TR cells (Figure 7D and E). IFN- 
elevated procaspase 8 levels and induced cleavage of procaspase 8 into the intermediate 
p43/41 product. The combination of IFN- with rhTRAIL or HGS-ETR1 induced 
cleavage of caspase 8 to its p18 active form. When cells were treated with IFN- and 
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HGS-TR2J, only the intermediate form of caspase 8 (p43/41) could be detected. These 
results contrasted with the most effective combination of HGS-TR2J with MG-132 (see 
Figure 5C). This suggests that only DR4-mediated apoptosis benefits from the increase 
in caspase 8 levels in IFN- pretreated cells. 
  
 
Figure 6: Increase in caspase 8 levels following treatment of SW948-TR with IFN-. A: Effects of 48 h 
incubation with increasing concentrations of IFN- on caspase 8 levels in SW948 and SW948-TR. B: Effects 
of IFN- on DR4 (left figure) and DR5 (right figure) membrane expression as determined by flow 
cytometry. Receptor expression was detected as the average antigenic density of the whole cell population 
and resulted in a peak shift to the right. (1 = control; 2 = basal DR4 or DR5 membrane expression level; 3 = 
DR4 or DR5 expression after exposure to 1000 units (U) /ml IFN- for 48 h). 
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Figure 7: Stimulation of rhTRAIL and HGS-ETR1-induced but not HGS-TR2J-induced apoptosis by IFN-
. A: Survival (%) of SW948-TR cells after continuous incubation with rhTRAIL, HGS-ETR1 or HGS-TR2J 
in combination with 0 (), 10(○), 1000 (▼) U/ml IFN-. B: Apoptosis assay of SW948-TR after 48 h 
incubation with rhTRAIL, HGS-ETR1 or HGS-TR2J in combination with various concentrations of IFN-. 
C: Apoptosis assay in SW948-TR after 48 h incubation with 1000 U/ml IFN-. Cells were then incubated 
with 10 g/ml antagonistic anti-DR4 (αDR4), anti-DR5 (αDR5) antibodies, both (αDR4/5) or IgG1 control 
for 1 h before 4-5 h rhTRAIL treatment (0.1 g/ml). D: Western blot analysis of caspase 8 activation in 
control cells (C), cells treated with IFN- or rhTRAIL (T), or the combination of both drugs. Cells were 
analyzed after 48 h of incubation with or without 1000 U/ml IFN-  before 4-5 h treatment with rhTRAIL 
(0.1 μg/ml). E: Western blot analysis of caspase 8 activation in control cells (C), cells treated for 4-5h with 





DISC formation is the first step toward apoptosis after engagement of DR4 and DR5 by 
their ligands. Not surprisingly, resistance to TRAIL-mediated apoptosis is often initiated 
at the DISC level (41). We found that upon stimulation with TRAIL, all canonical DISC 
proteins were recruited to DR4 and DR5 in SW948 and SW948-TR cells. In relation with 
the other DISC proteins, smaller amounts of cleaved caspase 8 were found in the TRAIL-
DISC of SW948-TR cells as compared to SW948 cells. These results were in agreement 
with the lower basal caspase 8 protein levels found in SW948-TR. Altogether, these 
findings point toward less active recruitment and processing of caspase 8 in these cells. 
We also describe a DR5-specific mechanism of apoptosis resistance in our cell line model 
since DR4 stimulation achieves superior caspase 8 processing than DR5 despite 
equivalent initial DISC formation at the level of each receptor. 
Antagonistic anti-DR4 or anti-DR5 antibodies were used to specifically block the 
function of their respective receptors during rhTRAIL-induced apoptotic signaling. 
These experiments proved that DR4 was more critical to rhTRAIL-induced apoptosis 
signaling than DR5, in both cell lines. It was previously reported that apoptosis 
induction in keratinocytes with leucine zipper TRAIL was also mainly mediated by DR4 
(42). In contrast, Kelley et al. generated receptor selective mutants of TRAIL, with three 
to six ligand amino acid substitutions (17), and found DR5 to be more important for 
apoptotic signaling than DR4 in cancer cells expressing both  receptor (including colon 
cancer cells). Van der Sloot et al. demonstrated that DR5-selective TRAIL variants did 
not induce apoptosis in cell lines mostly responsive to DR4 stimuli but greatly 
stimulated apoptosis in DR5-responsive cancer cell lines (43). Little is known about the 
origins of these discrepancies. Blocking of both DR4 and DR5 prevented apoptosis more 
efficiently than single blocking of DR4, suggesting that DR5 also contributes to 
rhTRAIL-induced apoptosis. While DR4 was more potent in transducing apoptosis, DR5 
might, at least in our model, increase the overall apoptotic stimulus compared to DR4 
stimulation alone. 
We found that in SW948 and SW948-TR cells, sensitivity to HGS-ETR1 and HGS-
TR2J antibodies mostly reflected the sensitivity to rhTRAIL of each receptor. Although 
the agonistic anti-DR4 antibody was more potent than its anti-DR5 counterpart, HGS-
TR2J could induce apoptosis at some extent in SW948 cells, and also in SW948-TR 
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following pre-sensitization with CHX. This strongly suggests that DR5 is potentially 
functional in both cell lines. Georgakis et al. found that in primary non-Hodgkin’s 
lymphoma samples, an anti-DR4 agonistic antibody was also more effective than an 
agonistic anti-DR5 antibody (16).  
We investigated the ability of each receptor to initiate DISC formation and 
caspase 8 cleavage in SW948 by co-immunoprecipitating DR4- and DR5-DISC. To our 
surprise, similar DISC formation and caspase 8 cleavage were triggered at the level of 
both receptors, although caspase 8 processing was much higher in whole cell lysates of 
cells stimulated with HGS-ETR1 compared to HGS-TR2J. Resistance to DR5–mediated 
apoptosis begins after the initial caspase 8 cleavage, and could be due to a lower turn-
over of procaspase 8 at the DISC. Data on such DISC protein turn-over following TRAIL 
receptor stimulation are limited, although studies by McDonald et al. and Jin et al. put 
forward the influence of caspase 8 ubiquitination on the cleavage of the available 
caspase 8 cellular pool (44,45). Because brief pre-incubation with CHX could also restore 
DR5-mediated caspase 8 cleavage and sensitivity, a short-lived protein might be involve 
in this process.  
IFN- is known to increase caspase 8 expression and consequently sensitizes 
cancer cells, including colon cancer cells, to rhTRAIL (24,40,46-48). Our results slightly 
contrast with these findings, as upregulation of caspase 8 by IFN- did not enhance 
apoptosis induction in SW948 cells. Caspase 8 levels might not be a limiting factor in 
these cells since procaspase 8 recruitment to the DISC is first determined by the amount 
of FADD molecules available at the DISC (49).  IFN- did, however, increase apoptosis 
induction by rhTRAIL and HGS-ETR1 in SW948-TR cells, which express lower caspase 8 
levels than their parental cell line. In SW948-TR, IFN- induced a marked increase in 
both pro- and intermediate forms of caspase 8, which were cleaved to the active form 
upon DR4 stimulation. In contrast, DR5 stimulation failed to induce the appearance of 
active caspase 8. This was shown using DR-agonistic antibodies, but also rhTRAIL in 
combination with receptor-blocking antibodies. 
Unlike IFN-γ, MG-132 markedly increased both DR4 and DR5-mediated 
sensitivities in SW948-TR cells. Another proteasome inhibitor, bortezomib, was 
previously reported to enhance the effect of agonistic anti-DR4 and agonistic anti-DR5 
antibody in Hodgkin’s disease cell lines (18,50). MG-132 could increase TRAIL-induced 
apoptosis in both Bax-deficient and proficient colon cancer cells, suggestive of a 
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sensitization mechanism independent of the mitochondrial pathway of apoptosis (24). 
DR4 and DR5 upregulation by proteasome inhibitors is thought a major factor 
contributing to TRAIL-induced apoptosis sensitization, although this hypothesis has 
been subject to an extensive debate (51). We found that upon MG-132 treatment, DR4-
mediated sensitivity increased in absence of DR4 upregulation. The intermediate form 
of caspase 8 was upregulated by MG-132, an event we found sufficient to restore HGS-
ETR1 or rhTRAIL sensitivity following IFN-γ treatment. Importantly, MG-132 also 
increased caspase 8 cleavage and enhanced DR5-mediated apoptosis. MG-132 has 
previously been shown to modulate DR5 expression (24,52). Our flow cytometry 
analysis only showed negligible DR5 upregulation by MG-132, which again points 
towards a mechanism of sensitization independent of this effect. MG-132 upregulated 
caspase 8 in SW948-TR, but we demonstrated using IFN-γ that restoring caspase 8 levels 
was not sufficient to increase DR5-mediated caspase 8 cleavage and apoptosis. Taken 
together, these results support the existence of additional sensitizing mechanisms of 
MG-132 at the level of DR5-DISC, beyond DR5 and caspase 8 upregulation. Many of the 
proteins involved in the DR-mediated apoptotic pathways are regulated by 
ubiquitination (53), and some of these proteins could play a crucial role in specific 
regulation of DR5 signaling. Binding of the DEAD-box RNA helicase DDX3 to a non-
death domain region of DR5 was found to specifically mediate resistance to a DR5-
targeting antibody (TRA-8) in the TRA-8-resistant MDA-MB-231R breast cancer cell line 
(54). Understanding how MG-132 in particular can overcome DR5-resistance may be of 
crucial importance since Johnsen et al. previously reported that IFN- failed to increase 
TRAIL-induced apoptosis in 3 out of 8 neuroblastoma cancer cell lines, despite caspase 8 
upregulation and presence of all the proteins known to be necessary for DISC formation 
(40). It would be interesting to verify whether DR4 signalling is functional in the non-
responding cells. Furthermore, in view of the large number of agents in clinical 
development targeting DR5 as opposed to DR4, a deeper knowledge on DR5-mediated 
signaling regulation is critical for a more rational design of therapies aiming specifically 
at DR5-mediated apoptosis. 
In summary, we have demonstrated that cell sensitivity to rhTRAIL signaling via 
DR4 and DR5 mostly coincided with sensitivity to agonistic anti-DR4 and anti-DR5 
antibodies, respectively. Apoptosis induced by DR4 stimuli in SW948-TR cells seemed 
limited by the lesser amounts of caspase 8 available as compared to the parent cell line. 
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Resistance to DR5-mediated apoptosis in SW948-TR cells most likely stemmed from a 
combination of at least two mechanisms; (1) low caspase 8 levels and (2) sub-optimal 
capacity to process the existing caspase 8 at the level of this receptor, which was also 
seen in the parent cell line. Only MG-132 was able to restore generation of active caspase 
8 in SW948-TR upon DR5-stimulation. These results underscore the DR-specificity of 
drug combination and the presence of different resistance mechanisms at the level of 
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Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) initiates 
apoptosis in tumor cells upon binding to its cognate agonistic receptors, death receptors 
4 and 5 (DR4 and DR5). The activity of the insulin-like growth factor 1 (IGF-1) survival 
pathway is often increased in cancer, influencing both cell proliferation and apoptosis. 
We hypothesized that inhibiting the IGF-1 receptor (IGF-1R) using NVP-AEW541, a 
small molecular weight tyrosine kinase inhibitor of the IGF-1R, could increase death 
receptor (DR)-mediated apoptosis in colon cancer cells. Methods: The analyses were 
performed by caspase assay, flow cytometry, Western blotting, immunoprecipitation 
and fluorescent microscopy. Results: Preincubation with NVP-AEW541 surprisingly 
decreased apoptosis induced by recombinant human TRAIL (rhTRAIL) or an anti-DR4 
antibody while sensitivity to an anti-DR5 antibody was increased. NVP-AEW541 could 
inhibit IGF-1-induced activation of the phosphatidylinositol 3-kinase (PI3K) pathway. 
The effects of the PI3K inhibitor LY294002 on TRAIL-induced apoptosis were similar to 
those of NVP-AEW541, further supporting a role for IGF-1R-mediated activation of 
PI3K. We show that PI3K inhibition enhances DR5-mediated caspase 8 processing but 
also lowers DR4 membrane expression and DR4-mediated caspase 8 processing. 
Inhibition of PI3K reduced rhTRAIL sensitivity independently of the cell line preference 
for either DR4 or DR5-mediated apoptosis signaling. Conclusions: Our study indicates 
that individual effects on DR4 and DR5 apoptosis signaling should be taken into 
consideration when combining DR-ligands with PI3K inhibition. 




Colorectal cancer is the second leading cause of cancer-related deaths in western 
countries.  Despite improvements in the area of prevention and treatment, mortality 
remains high because of the frequent presence of distant metastases at the time of 
diagnosis. At that stage, treatment results in a five year survival of only 10% to 30% (1). 
New therapies are greatly needed, and novel agents like those targeting the TRAIL 
apoptotic pathway are currently under investigation (2).  
The TRAIL apoptotic pathway is initiated by tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL), a type II transmembrane protein of the tumor 
necrosis factor superfamily. TRAIL binds to cell surface homo- and/or heterotrimers of 
death receptors 4 and 5 (DR4 and DR5), thus triggering the “caspase cascade” (3). The 
extracellular domain of TRAIL can be processed proteolytically, leading to the release of 
a soluble trimeric form of TRAIL with similar proapoptotic properties (4,5). The 
potential of the TRAIL apoptotic pathway as a target to treat cancer was first established 
when soluble recombinant human TRAIL (rhTRAIL) was found to selectively induce 
apoptosis in tumor cells without serious toxicity to normal tissues (6,7). Several other 
agents that target the two death receptors have been engineered since the discovery of 
the TRAIL apoptotic pathway. So far, this pathway can be activated by rhTRAIL, by 
mutant forms of TRAIL which bind preferentially to either DR4 or DR5 homotrimers (8-
10), and by agonistic monoclonal antibodies also designed to bind specifically DR4 or 
DR5 (11-14). The potential of the TRAIL receptors as therapeutic targets is underscored 
by the fact that their expression and sensitivity have both been shown to increase during 
colorectal tumor progression (15,16). Although the sensitivity of tumor cells to TRAIL-
induced apoptosis is heterogeneous as a result of intrinsic or acquired resistance, 
combination therapies to overcome this phenomenon are already under investigation 
(for review see (17,18)).  
Numerous growth factor receptor pathways are altered in colorectal cancer, 
influencing gene expression, cell proliferation and apoptosis (19). Some of these 
pathways constitute interesting targets for drugs that could be combined with rhTRAIL 
(20-22). The insulin-like growth factor (IGF) signaling pathway is involved in the growth 
and development of many tissues, and plays a crucial role in the normal functioning of 
the organism (23). IGF signaling cascades begin at the cell surface with IGF ligands (IGF-
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1 and -2) binding to several transmembrane receptors, namely IGF-1R, IGF-2R and the 
insulin receptor (IR). Downstream from these receptors, mitogen-activated protein 
kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt pathways are stimulated 
(23). Diverse cellular responses such as gene expression, cell proliferation and apoptosis 
suppression are induced, thus promoting cell survival. Importantly, the IGF system is 
frequently deregulated in colorectal cancers (23,24), more than 90% of which express 
IGF-1R while normal colonic mucosa does not show substantial expression levels (25). 
The downstream PI3K/Akt receives signals not only from the IGF-1R but also 
from human epidermal growth factor receptor (HER) family receptors such as HER-2 
and epidermal growth factor receptor (EGF-R) (26,27), which can also promote 
carcinogenesis when deregulated. Furthermore, alterations in the PI3K/Akt signaling 
itself have been found in many forms of cancer and can originate at multiple levels of 
the cascade (28,29). For these reasons, the PI3K/Akt pathway holds promise as a target 
for cancer treatment. Clinical trials are being carried out with IGF-1R blocking 
antibodies and inhibitors targeting PI3K are currently being developed (30,31). In this 
context, we investigated whether inhibiting the IGF-1R survival pathway, and more 
specifically its downstream PI3K/Akt pathway, could functionally increase rhTRAIL-
induced apoptosis. 
We tested the effects of the IGF-1R inhibitor NVP-AEW541 (32) on TRAIL-
sensitivity in SW948, a colon cancer cell line and in SW948-TR, the TRAIL-resistant sub-
line. Furthermore, we investigated whether sensitivity to DR4- or DR5-specific 
monoclonal antibodies was differentially affected by NVP-AEW541. We analyzed the 
effects of LY294002, an inhibitor of the downstream PI3K/Akt pathway, on the 
sensitivity to these various activators of TRAIL-mediated cell death. Finally, we 
validated these findings in another colon carcinoma cell line, Colo205. 
 
Materials and methods 
 
Reagents 
rhTRAIL was produced non-commercially following a protocol described previously 
(6). The agonistic anti-DR4 (HGS-ETR1) and anti-DR5 (HGS-TR2J) antibodies were a gift 
from Human Genome Science (HGS, Rockville, MD, USA).  The TRAIL-receptor 
antibodies used for flow cytometry experiments were obtained from Immunex 
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corporation (Seattle, WA, USA). NVP-AEW541 was kindly provided by Novartis 
Pharma AG, Basel, Switzerland. LY294002 was purchased from Cell Signaling 
Technology, Leiden, the Netherlands. The ZB ActiveFluor Caspase 3/7 kits were 
obtained from Zebra Bioscience, Enschede, the Netherlands. 3-(4,5-dimethyl-thiazol-2-
yl) 2,5-diphenyltetrazolium bromide (MTT)-solution was purchased from Sigma-
Aldrich Chemie BV (Zwijndrecht, the Netherlands) 
 
Cell lines 
The TRAIL-sensitive colon carcinoma cell line SW948 was purchased from the American 
Type Culture Collection (ATCC, Manassas, VA, USA) and cultured as described 
previously (33). For a detailed description of the generation of the TRAIL-resistant sub 
cell line SW948-TR, see supplementary materials and methods. 
Colo205 colon carcinoma and MCF7 breast carcinoma cell lines were purchased from 
the ATCC and grown in RPMI containing 10% FCS at 37 °C in a humidified atmosphere 
with 5% CO2.  
 
Cytotoxicity assay 
A microculture tetrazolium (MTT) assay was used to determine cytotoxicity. SW948 and 
SW948-TR cells were incubated in a total volume of 200 l. Treatment consisted of 
continuous incubation with various concentrations of NVP-AEW541 for 96h. Assays 
were performed as described before (33). 
 
Flow cytometry 
Cells were stained for TRAIL-receptor membrane expression as described previously 
(33) and analyzed with a Epics Elite flow cytometer (Coulter Electronics, Hialeah, FL, 
USA). Membrane expression was measured as the increase in mean fluorescence 
intensity of the whole analyzed cell population. 
To determine surface expression of IGF-1R, a similar protocol was used.  Cells were 
stained for 45 min on ice with phycoerythrin(PE)-conjugated anti-human IGF-1Rα or 
PE-conjugated mouse IgG1 as an isotype control (BD Pharmingen, Alphen aan den Rijn, 




Caspase 3/7 activity assay 
Caspase 3/7 activity was assayed using the caspase-specific fluorescence peptide 
substrates DEVD-MCA according to the manufacturer’s instructions (Zebra Bioscience 
BV, Groningen, the Netherlands). A Bradford assay was used to normalize protein 
concentrations between samples. Fluorescence from free 7-amino-4-trifuluoromethyl 
coumarin was monitored in a FL600 Fluorimeter Bio-tek plate reader (Beun de Ronde, 
Abcoude, the Netherlands) using 340 nm excitation and 460 nm emission filters.  
 
SDS-polyacrylamide gel electrophoresis and Western blotting 
Sample preparation and Western blot analysis were performed as described previously 
(33). Proteins were detected with the following antibodies: mouse-anti-FADD from 
Transduction Laboratories (Lexington, KY, USA), mouse anti-caspase 8 from Cell 
Signaling Technology (Leusden, the Netherlands) and mouse anti-actin from ICN 
Biomedicals (Zoetermeer, the Netherlands). Mouse-anti-FLIP NF6 was kindly provided 
by Dr. M. Peter (University of Chicago, IL, USA). The secondary antibodies were labeled 
with horseradish peroxidase (HRP) (DAKO, Glostrup, Denmark), and 
chemiluminescence was detected using the BM-chemiluminescence kit or with the 
Lumi-Light Plus Western blotting kit (Roche Diagnostics, Mannheim, Germany). A 
slightly modified lysis protocol was used to investigate Akt, MAPK44/42, phospho-




Briefly, 50.106 cells per condition were grown in medium harvested and resuspended in 
fresh medium. Cells were stimulated with 5µg/ml HGS-TR2J in a final volume of 2 ml. 
The antibodies were added after cell lysis for the control treatment. Cell suspensions 
were incubated for 15 min at 37 C, and the reaction was stopped by the addition of 10 
ml ice-cold phosphate buffered saline (PBS). The cells were immediately washed with 
ice-cold PBS and lysed in 1 ml lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.2% 
Nonidet P-40, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride) with complete 
protease inhibitors (Roche Diagnostics, Almere, the Netherlands) for 30 min on ice. 
After centrifugation (12,000 x g) at 4 C for 10 min, the lysates were pre-cleared with 20 
l Sepharose-6B (Pharmacia, Uppsala, Sweden) for 2 h at 4 C and immunoprecipitated 
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with 50 l protein-G agarose beads (Roche Diagnostics, Mannheim, Germany) for 3 at 4 
C. Beads were washed two times with 1 ml lysis buffer and one time with PBS before 
re-suspension in standard Western blot sample buffer and boiling for 5 min. 
Immunoprecipitated proteins were separated with SDS-PAGE. Western blot analysis for 
FADD and c-FLIP was performed as described above. DR5 was detected using rabbit 
anti-DR5 from ProSci Inc. (Poway, CA, USA). Caspase 8 was detected with rabbit anti-
caspase 8 (Abcam plc, Cambridge, UK). Anti-rabbit and anti-mouse HRP-conjugated 
secondary antibodies were used for signal detection (DAKO, Glostrup, Denmark). 
 
Propidium iodide staining 
Staining was performed according to Nicoletti’s protocol (34). Sub-G1 DNA content was 
analyzed using a FACSCalibur flow cytometer (BD Biosciences, Brussels, Belgium). 
 
Fluorescent microscopy 
SW948 cells were seeded in 6-well plate on poly-L-lysine coated glass cover slides 
(Sigma-Aldrich Chemie BV, Zwijndrecht, the Netherlands). Cells pretreated or not with 
LY294002 for 16 hours were incubated for 45 min on ice with anti-DR5 antibody 
(eBiosciences, via ITK diagnostics BV, Uithoorn, the Netherlands), diluted 1:100 in ice-
cold PBS. After two washing steps with ice-cold PBS, the cells were incubated with the 
secondary antibody Alexa Fluor 488-goat anti-mouse IgG1 (Invitrogen, Molecular 
probes, Breda, the Netherlands), diluted 1:200 in ice-cold PBS for 1 hour on ice. Next, 
cells were either left on ice or stimulated with 200 nM HGS-TR2J diluted in medium for 
30 min at 37 ˚C. Cells were then fixated with ice-cold methanol-acetone (1:1) for 10 min 
at -20˚C. After three washing steps with ice-cold PBS, the cells were stained with 
Hoechst 33258 (Invitrogen, Molecular Probes, Leiden, the Netherlands) for 5 min on ice, 
diluted 1:10 000 in ice-cold PBS to visualize the nuclei. After mounting the slides in 
Vectashield Mounting medium H-1000 (Vector, via Brunschwig Chemie, Amsterdam, 









Data are represented as the mean ± SE. In all cases, statistical analyses were done using 
2-tailed student’s t test. P-values < 0.05 were considered significant and are indicated 




IGF-1R inhibition using NVP-AEW541 modulates sensitivity to rhTRAIL and DR-
agonistic antibodies  
We evaluated the role of IGF-1R expression and its inhibition on TRAIL sensitivity using 
the isogenic SW948/SW948-TR model. Membrane expression of IGF-1R was similar in 
the SW948 cell line and its TRAIL resistant sub-line SW948-TR (Fig. 1A-B). The surface 
levels were not as elevated as those seen in the MCF7 cells, known to express high levels 
of IGF-1R (Fig. 1B). We then incubated the cells with various concentrations of the IGF-
1R inhibitor NVP-AEW541. Both cell lines showed nanomolar sensitivity to the 
compound, with a mean GI40 (concentration inhibiting cell growth by 40%) below 1 μM 
in a survival assay (Fig. 1C).  
NVP-AEW541 was combined at a concentration corresponding to the GI60 with 
rhTRAIL or the DR-agonistic antibodies to stimulate apoptosis. Cleavage of poly-ADP 
ribose phosphate (PARP) was used to assess apoptosis in SW948 (Fig. 1D). The 
untreated cells and the cells incubated with NVP-AEW541 alone only exhibited the full 
form of PARP, indicating that NVP-AEW541 does not induce apoptosis at the 
concentration used. Upon treatment with rhTRAIL PARP was fully cleaved into its 89 
kDa fragment, reflecting high levels of apoptosis. To study DR4 and DR5-mediated 
Figure 1: SW948 and SW948-TR cells express surface IGF-1R, and inhibition of this receptor modifies 
sensitivity to death receptor agonists. A: Representative example of IGF-1R expression in SW948. Positive 
receptor expression was detected as an increased fluorescence intensity of the whole cell population and 
resulted in a peak-shift to the right (a: control; b: IgG1 and c: IGF-1R). B: Surface expression of IGF-1R in 
SW948, SW948-TR and MCF7 cells (positive control for IGF-1R expression), as determined by flow 
cytometry. IGF-1R expression is given as Mean Fluorescent Intensity (MFI), normalized to 100. Values are 
mean  SE of at least 3 independent experiments. C: Survival (%) of SW948 and SW948-TR cells after 
continuous incubation with NVP-AEW541 for 96 h, as measured by cytotoxicity assays. Values are mean  
SD of at least three independent experiments. D: Western blot analysis of PARP cleavage in SW948. The 
cells were pre-incubated for 15-18 hours with 5 μM NVP-AEW541, then either left untreated or exposed 
for 3 additional hours with rhTRAIL (0.1 μg/ml), HGS-ETR1 (50 nM) or HGS-TR2J (50 nM) before 
harvest. 




apoptosis individually, cells were stimulated with agonistic DR4 (HGS-ETR1) or DR5 
antibody (HGS-TR2J).  Similarly to rhTRAIL, HGS-ETR1 was a very effective inducer of 
PARP cleavage. HGS-TR2J also induced PARP cleavage, but only partially, indicating 
that DR5 was less potent than DR4 in transducing the apoptotic signal. When NVP-
AEW541 was combined with rhTRAIL or HGS-ETR1, the cleavage of PARP was 
unexpectedly lower compared to rhTRAIL or HGS-ETR1 alone, which suggested that 
NVP-AEW541 decreased the sensitivity to these ligands. In contrast, the amount of 
cleaved PARP was higher when HGS-TR2J was combined with NVP-AEW541 in 
comparison to HGS-TR2J alone, signifying an increase in DR5-mediated apoptosis. Next, 
we performed caspase 3/7 enzyme activity assay as an additional method to assess 
apoptosis in SW948, and also in the TRAIL-resistant SW948-TR cells. Incubation with 
NVP-AEW541 alone had no effect on caspase 3/7 activation in either cell line (Fig. 2A-
B). Upon inhibition of IGF-1R using NVP-AEW541, the sensitivity to rhTRAIL decreased 
by 46.2% ± 11.5 (mean ± SE) in SW948. Similar findings were done in SW948-TR cells, 
which became even more resistant to rhTRAIL (42.6% ± 2 decrease in caspase 3/7 
activity after rhTRAIL treatment). IGF-1R inhibition effectively decreased DR4-mediated 
caspase 3/7 activity by 39.8% ± 10.8 in SW948 cells, while SW948-TR cells followed 
asimilar trend (19.3% decrease ± 15.2). In contrast, both cell lines exhibited an increase in 
DR5-mediated caspase 3/7 activity (an increase of 78.2% ± 5.9 in SW948 and of 92.7% ± 
26.7 in SW948-TR). 
 Although we do not show a formal concentration-dependent analysis here, the 
effects of NVP-AEW541 on DR-mediated apoptosis proved to be concentration 
dependent. Concentrations below the GI60 showed similar, although less pronounced 
Figure 2: IGF-1R inhibition modulates DR-mediated apoptosis and downregulates surface DR4 
expression. Modulation of rhTRAIL or agonistic antibody induced apoptosis by NVP-AEW541 in SW948 
(A) and SW948-TR (B), as assessed by caspase 3/7 activity assay. Cells were pre-incubated for 15-18 hours 
with 5 μM NVP-AEW541, then either left untreated or exposed to rhTRAIL (0.1 μg/ml), HGS-ETR1 (50 
nM) or HGS-TR2J (50 nM) for 3 additional hours before harvest. Caspase 3/7 activity is expressed in 
arbitrary units (a.u.), as the ratio of caspase 3/7 activity in treated cells to untreated cells. Values are mean  
  SE of at least 3 independent experiments. C: Western-blot analysis of the expression levels of several 
proteins located downstream from the TRAIL receptors, after IGF-1R inhibition and treatment with 
rhTRAIL or agonistic DR antibody, in SW948. The cells were pre-incubated for 15-18 hours with 5 μM 
NVP-AEW541, then either left untreated or exposed for 3 additional hours with rhTRAIL (0.1 μg/ml), 
HGS-ETR1 (50 nM) or HGS-TR2J (50 nM) before harvest. D: Surface expression of TRAIL receptors in 
SW948 and SW948-TR, in control cells and after 15-18 hours exposure to 5 μM NVP-AEW541. 
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Figure 3: PI3K mediates the effects of IGF-1R inhibition on DR-mediated apoptosis. A: Western-blot 
analysis showing inhibition of IGF-1 induced Akt phosphorylation by NVP-AEW541 in SW948 and 
SW948-TR. Cells were pretreated for 1 hour with 5 μM NVP-AEW541 before treatment with increasing 
concentrations of rhIGF-1 and subsequent harvesting. B: Western-blot analysis showing inhibition of Akt 
phosphorylation by LY294002 in SW948 and SW948-TR. Cells grown in medium with FCS were treated or 
not for 1 hour with increasing concentrations of LY294002 before harvest. C: Modulation of rhTRAIL or 
agonistic antibody induced apoptosis by PI3K inhibition in SW948, as assessed by caspase 3/7 activity 
assay in SW948. Cells were pre-incubated for 15-18 hours with 20 μM LY294002, then either left untreated 
or exposed to rhTRAIL (0.1 μg/ml), HGS-ETR1 (50 nM) or HGS-TR2J (50 nM) for 3 additional hours 
before harvest. C: Caspase 3/7 activity assay in SW948 cells. Cells were pre-incubated for 15-18 hours 
with 20 μM LY294002, then either left untreated or exposed to rhTRAIL (0.1 μg/ml), HGS-ETR1 (50 nM) 
or HGS-TR2J (50 nM) for 3 additional hours before harvest. D: Western blot analysis of PARP cleavage in 
SW948. The cells were pre-incubated for 15-18 hours with 20 μM LY294002, then either left untreated or 
exposed for 3 additional hours with rhTRAIL (0.1 μg/ml), HGS-ETR1 (50 nM) or HGS-TR2J (50 nM) 
before harvest. E: Caspase 3/7 activity assay in SW948-TR. Cells were treated as described in (C). 
 
 
effects, and higher concentrations of NVP-AEW541 (up to 10 µM) had even more 
dramatic effects on DR-mediated apoptosis, in absence of additional cell death as a 
single agent (data not shown). 
 
IGF-1R inhibition can modulate processing and expression of DISC components 
The effects of NVP-AEW541 on the protein levels of the components of the death-
inducing signaling complex (DISC) were analyzed by Western blotting. NVP-AEW541 
did not decrease the basal expression of procaspase 8, nor did it affect the expression of 
fas-associated death domain (FADD) or cellular Flice inhibitory protein (c-FLIP), in 
SW948 (Fig. 2C). Following treatment with rhTRAIL, procaspase 8 was cleaved into its 
intermediate (p43/41) and ultimately active forms (p18). However, after pretreatment 
with NVP-AEW541, rhTRAIL failed to cause a complete cleavage of procaspase 8. As 
expected, c-FLIP was cleaved after treatment with rhTRAIL. NVP-AEW541 
pretreatment did not induce any noticeable change in the processing of c-FLIP induced 
by rhTRAIL. After pretreatment with NVP-AEW541, HGS-ETR1 induced the same 
pattern of caspase 8 and c-FLIP content exhibited after the combination of rhTRAIL with 
NVP-AEW541. In contrast, DR5 targeting using HGS-TR2J alone failed to fully cleave 
procaspase 8 and c-FLIP. NVP-AEW541 pretreatment enhanced the responsiveness to 
HGS-TR2J, triggering almost full cleavage of both proteins. Such changes in the 
apoptotic response could be due to modulation of the surface expression of DR4 and 
DR5. We assessed the effects of NVP-AEW541 on cell membrane DR4 and DR5 
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expression in both SW948 and SW948-TR (Fig. 2D). Incubating the cells with NVP-
AEW541 indeed resulted in a downregulation of membrane DR4. On the other hand, no 
changes were observed in DR5 membrane level. 
 
IGF-1R exerts its effects on TRAIL sensitivity via the PI3K pathway 
Because we expected NVP-AEW541 to influence DR-mediated apoptosis by inhibiting 
pathways downstream of IGF-1R, we tested whether IGF-1 could induce Akt 
phosphorylation, and whether NVP-AEW541 was able to inhibit this phosphorylation. 
Akt is one of the key proteins phosphorylated by PI3K downstream of IGF-1R (23). Cells 
were serum-starved for 24 hours, pretreated or not with NVP-AEW541 for one hour at a 
concentration neighboring the GI20 of both cell lines, and finally either left untreated or 
treated for 15 minutes with recombinant human (rh)IGF-1. Concentrations of rhIGF-1 
(10-50 ng/mL) within the physiological range induced phosphorylation of Akt in both 
cell lines (Fig. 3A). Pretreatment with NVP-AEW541 dramatically reduced IGF-1 
induced phosphorylation of Akt in both cell lines. Total Akt levels were similar in the 
two cell lines and were not affected by NVP-AEW541 or rhIGF-1. Phospho-MAPK44/42 
(pMAPK44/42) levels were studied as this protein can also be activated by 
phosphorylation in response to IGF-1. The levels of MAPK44/42 and pMAPK44/42 were 
similar with and without NVP-AEW541 treatment, suggesting that the activity of this 
pathway might be independent of IGF-1 in these cells (data not shown). We then 
decided to investigate whether a specific PI3K inhibitor could also inhibit Akt 
phosphorylation in SW948 and SW948-TR cells. As seen in Fig. 3B, upon treatment with 
10-20 μM LY294002 for 1 hour, Akt phosphorylation in both cell lines was inhibited in a 
concentration-dependent manner. LY294002 had no effects on total Akt expression 
levels.  
Next, LY294002 was combined with rhTRAIL or death receptor-specific 
antibodies. Treatment of SW948 cells with LY294002 alone did not affect apoptosis, as 
measured by caspase 3/7 activity (Fig. 3C). HGS-ETR1-induced caspase 3/7 activity was 
reduced by 27.6% ± 8.2. Although there was only a statistical trend, rhTRAIL-induced 
caspase 3/7 activity decreased when the cells were pretreated with LY294002 (by 14.7% 
± 9.8).  In contrast, sensitivity through DR5 was clearly increased by 107.8 % ± 38.5. 
Analysis of PARP cleavage confirmed the changes in susceptibility to these agents in 
SW948 (Fig. 3D).  
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In SW948-TR (Fig. 3E), LY294002 similarly decreased sensitivity to rhTRAIL (by 
38.3 % ± 0.6), as assessed by caspase 3/7 activity measurement. Although these 
differences were not statistically significant, pretreatment with LY294002 lowered 
sensitivity to HGS-ETR1 (by 32.3 % ± 10.3) but increased HGS-TR2J sensitivity (41.2% ± 
14.7 increase). 
 
PI3K inhibition modulates caspase 8 and c-FLIP cleavage 
We examined whether LY294002 induced similar effects to NVP-AEW541 at the level of 
the DISC proteins. The results for caspase 8 were similar to those previously seen using 
NVP-AEW541, albeit the inhibition of procaspase 8 processing to the intermediate and 
active forms upon rhTRAIL and HGS-ETR1 seemed less strong (Fig. 4A). Basal c-FLIP 
and FADD levels were not affected by LY294002. The changes in c-FLIP cleavage after 
LY294002 exposure followed the pattern seen after NVP-AEW541 treatment, although 
the loss of c-FLIP through cleavage upon HGS-ETR1 or HGS-TR2J treatment after 
LY294002 was slightly higher. 
Next, we looked whether inhibiting PI3K would modulate death receptor 
expression at the cell surface, as seen with NVP-AEW541.  As expected, LY294002 
downregulated DR4 to the level of DR5 in SW948 and SW948-TR, providing an 
explanation for the reduction in rhTRAIL sensitivity (Fig. 4B). 
 Localization of the death receptors is known to be modulated by certain drugs 
which cause them to aggregate and thereby increase their sensitivity to death inducing 
ligands (35). This prompted us to examine whether the distribution of DR5 at the cell 
surface was affected by PI3K inhibition. Fluorescent microscopy imaging of membrane 
DR5 in SW948 cells did not show any change in DR5 distribution at the cell surface 
following treatment with 20 µM LY294002 (Fig. 4C). Because differences in DR5 
aggregation following LY294002 treatment might only occur after stimulation of the 
receptor, we stimulated DR5 for 30 minutes using HGS-TR2J. As seen in Fig. 4C, DR5 
aggregated following stimulation with HGS-TR2J, but the staining pattern was similar 
between LY294002-treated and untreated cells. 
Since PI3K inhibition increased caspase 8 activation, suggesting modifications in 
DR5-DISC formation, we performed a co-immunoprecipitation of this complex using 
HGS-TR2J, with or without pre-incubation with LY294002. To our surprise, DISC 
formation was comparable for both stimuli (Fig. 4D). HGS-TR2J could recruit DR5, 
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FADD, caspase 8 and c-FLIP. In control cells, 3 caspase 8 forms were detected in the 
DR5-DISC: the full form, the intermediate p43/41 cleaved form and the p26/24 cleavage 
product. The latter indicates full cleavage of caspase 8 and therefore release of active 
caspase 8 from the complex. c-FLIP was mostly present in its intermediate form. In cells 
pretreated with LY294002, the ratio of each DISC component was similar. No DR4 was 
found in the DR5-DISC complex, in both LY294002-treated and -untreated cells (data not 
shown). Later time points (up to 1 hour, when active caspase 8 becomes detectable in 
whole cell lysates from LY294002-pretreated cells) displayed similar DISC content (data 
not shown). Thus, the relative proportion of each DISC protein in the DR5-DISC is 
similar with and without LY294002. 
 
The opposite effects on DR4- and DR5-sensitivity induced by PI3K signaling pathway 
inhibition are not specific to the SW948/SW948-TR isogenic model 
To expand our results to a non-isogenic model, we also assessed the effects of PI3K-
specific inhibition with LY294002 on TRAIL receptor-mediated apoptosis in Colo205. 
These cells were initially highly sensitive to rhTRAIL and to the DR5-targeting antibody 
and less to the DR4-targeting antibody, indicating that here DR5 was the most potent of 
the two agonist death receptors. We therefore used concentrations of 50 nM for HGS-
ETR1 and 5 nM for HGS-TR2J to induce equivalent amounts of apoptosis via each death 
receptor. Our results show that LY294002 treatment decreased sensitivity to rhTRAIL 
Figure 4: PI3K inhibition modulates DISC proteins cleavage and surface DR4 levels, but not cell 
membrane localization of DR5 or initial DR5-DISC formation. A: Expression levels of several proteins 
located downstream of the TRAIL receptors were determined by western-blotting in SW948. The cells 
were pre-incubated for 15-18 hours with 20 μM LY294002, then either left untreated or exposed for 3 
additional hours with rhTRAIL (0.1 μg/ml), HGS-ETR1 (50 nM) or HGS-TR2J (50 nM) before harvest. B: 
Surface expression of TRAIL receptors in SW948 and SW948-TR, in control cells and after 15-18 hours 
exposure to 20 μM LY294002. Receptor expression was detected as the average antigenic density of the 
whole cell population (Black line histograms: fluorescence of the untreated cells, grey shaded histograms: 
fluorescence of the cells treated with 20 μM LY294002 for 15-18 hours). C: Fluorescent microscopy 
imaging of DR5 in SW948 cells in untreated cells and cells exposed with 20 μM LY294002 for 17 hours, 
stimulated or not with HGS-TR2J for 15 min. Cells were first pretreated with LY294002 and stained for cell 
membrane DR5. Next, cells were either kept on ice or treated with HGS-TR2J for 15 min at 37○C before 
fixation. One representative of at least 3 independent experiments is shown. D: DR5-DISC 
immunoprecipitation in SW948 cells, using the HGS-TR2J antibody. Cells were pretreated or not for 17 
hours with 20 μM LY294002 before stimulation for 15 min using HGS-TR2J and immunoprecipitation with 
protein G agarose (C: antibody added after cell lysis, T: cells treated with HGS-TR2J). DR5-DISC analysis 















and HGS-ETR1 (Fig. 5A). Importantly, DR5-mediated sensitivity increased following 
LY294002 treatment, as seen in SW948 and SW948-TR. Moreover, Colo205 cells also 
exhibited a reduction in surface membrane DR4 after PI3K inhibition, as seen in SW948 




Prosurvival signals originating from growth factor receptors, including IGF-1R, prevent 
cell death induced by radiation, cytotoxic drugs and members of the tumor necrosis 
factor family (21,36-38). In the present study, we demonstrated that inhibition of 
prosurvival signaling using the IGF-1R inhibitor NVP-AEW541 exclusively increased 
sensitivity to DR5-mediated apoptosis in SW948 and SW948-TR colon carcinoma cells. 
SW948 cells in particular were initially very sensitive via DR4, and therefore contained 
all the proteins necessary to form a DISC, but they exhibited significant resistance to 
apoptosis mediated via DR5. The IGF-1R inhibitor exclusively released the blockade of 
caspase 8 cleavage at the level of DR5. The TRAIL-resistant cell line SW948-TR became 
more sensitive to the anti-DR5 agonistic antibody, suggesting that the effects of IGF-1R 
inhibition are not restricted to rhTRAIL-sensitive cells. Surprisingly, we found that IGF-
1R inhibition decreased sensitivity to rhTRAIL or an anti-DR4 agonistic antibody. The 
decrease in sensitivity to rhTRAIL and to the anti-DR4 antibody could be explained in 
part by the ~50% downregulation of membrane DR4 following IGF-1R inhibition seen in 
all 3 cell lines. We correlated this DR4 downregulation with a decrease in caspase 8 
cleavage following rhTRAIL or anti-DR4 treatment. This surprising decrease in 
sensitivity to some DR-ligand is supported by prior demonstrations that inhibition of 
Figure 5: The effects of PI3K inhibition on DR-mediated apoptosis can also be seen in cells that are already 
more sensitive to HGS-TR2J than to HGS-ETR1 initially. A: Sub-G1 content analysis in Colo205. Cells were 
pre-incubated for 15-18 hours with 20 μM LY294002, then either left untreated or exposed to rhTRAIL (0.1 
μg/ml), HGS-ETR1 (50 nM) or HGS-TR2J (50 nM) for 3 additional hours before harvest. Nuclear DNA 
was then stained with propidium iodide and the cells analyzed by flow cytometry. The value in percent 
indicates the amount of apoptosis as measured by the count of sub-G1 events. One representative of at 
least 3 independent experiments is shown. B: Surface expression of TRAIL receptors in Colo205, in 
untreated cells and after 15-18 hours exposure to 20 μM LY294002. Receptor expression is measured as 
Mean Fluorescent Intensity (MFI) normalized to 100. 
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oncogenic pathways such as HER-2 and Ras also reduces the expression of TRAIL 
receptors, as well as their sensitivity (39,40). Mahalingam et al. recently found that 
inhibition of the c-Jun N-terminal kinase (JNK) stress pathway antagonized TRAIL-
induced apoptosis but stimulated anti-DR antibody-induced apoptosis in several colon 
cancer cells (41). Likewise, a proapoptotic effect of  IGF-1 on rhTRAIL sensitivity in 6 out 
of 9 colon cancer cell lines was described (42). We identified PI3K as the mediator of 
both DR4 decrease and DR5 increase in sensitivity to their respective agonist antibodies.  
In our combination study, we used a concentration of NVP-AEW541 above the 
submicromolar amounts strictly needed to inhibit IGF-1 induced Akt phosphorylation. 
Although using higher concentrations of NVP-AEW541 might lower its selectivity and 
inhibit additional receptor tyrosine kinases, inhibiting these additional targets 
apparently leads to stronger inhibition of the PI3K/Akt pathway. Furthermore, our 
work using the widely-accepted LY294002 compound clearly indicates a role for PI3K in 
modulating DR-mediated apoptosis. Thus, our experiments provide a link between the 
involvement of IGF-1 in PI3K/Akt activity in colon cancer cells and the role of this 
pathway in death receptor-mediated apoptosis regulation.  
We investigated several hypotheses for the increase in DR5-mediated sensitivity 
following PI3K inhibition. No change in membrane DR5 expression was seen. It has 
been reported that active PI3K can directly act on the DISC and interfere with caspase 8 
cleavage by up-regulating c-FLIP (43). We found that neither basal levels of c-FLIP nor 
DR5-DISC c-FLIP levels were altered by the PI3K inhibitor in SW948 cells. This indicates 
that the effects of PI3K on the DR5-DISC are independent of c-FLIP in our model. 
Similar observations were made regarding the basal levels of other proteins recruited to 
the DISC. Furthermore, we also excluded that sensitivity to the anti-DR5 antibody 
following PI3K inhibition increases was caused by receptor aggregation. A number of 
proteins identified as downstream substrates of PI3K/Akt can modulate the 
mitochondrial apoptotic pathway of apoptosis, for instance caspase 9 and Bad (44-46). 
Inhibition of caspase 9 activity using zLEHD-fmk did not protect SW948 cells from 
apoptosis induced by either TR2J or the combination of TR2J with LY294002, pointing 
toward a mitochondria-independent mechanism (data not shown). Following LY294002 
treatment, both caspase 8 and c-FLIP cleavage was enhanced upon stimulation of DR5 
with its agonistic antibody, which strongly supports the existence of a sensitizing 
mechanism at the DR5-DISC itself. We suggest that PI3K inhibition leads to a higher 
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turn-over of c-FLIP and caspase 8 at the DR5-DISC, thus gradually increasing the 
amount of their cleaved cytoplasmic forms. 
In Colo205, which is a DR5-driven cell line with regard to the relative potency of 
each DR to transduce apoptosis (10), sensitivity to the DR5 antibody was remarkably 
enhanced by LY294002. Conversely, DR4-mediated sensitivity was almost completely 
lost and sensitivity to rhTRAIL decreased by ~ 50%. Although the downregulation of 
DR4 could explain part of these effects, the benefits of PI3K inhibition on DR5 signaling 
seemed restricted to the DR5 antibody but not to rhTRAIL. Thomas et al. established (47) 
that the cytoplasmic tail of DR4 and DR5 had an important role in facilitating FADD 
binding and DISC formation upon stimulation with DR ligands. Depending on this 
cytoplasmic tail, the ability of the various DR-ligands to trigger apoptosis differed. 
Unlike TRAIL, the anti-DR5 agonistic antibody HGS-ETR2 could induce apoptosis 
independently of the last c-terminal amino-acids of DR5. In view of these findings, we 
suggest that PI3K inhibition might induce intracellular conformational changes at the 
level of DR5 that only benefits to HGS-TR2J. 
Since PI3K is an essential component in the transduction of survival signals 
originating from the growth factor receptors, we consider a better understanding of its 
influence on the TRAIL pathway necessary. Interestingly, while chemotherapy requires 
the p53 gene to upregulate DR5 and thereby increase death ligand sensitivity in colonic 
carcinoma (48) PI3K inhibition improved DR5-mediated sensitivity without requiring a 
functional p53 (the 3 cell lines used in our experiments express mutant p53). Elucidating 
the mechanism of action of PI3K on DR5 could therefore be decisive for future DR 
agonist-based therapies, since the vast majority of colorectal cancers carry mutations in 
p53. Conversely, inhibition of PI3K combined with chemotherapy might further 
improve sensitivity to DR5 agonists. 
DR4 and DR5 can be targeted individually (using antibodies or death-receptor 
specific forms of TRAIL) or simultaneously (using rhTRAIL), and these ligands will 
have to be combined with other therapies to overcome resistance mechanisms. We 
conclude that DR5-targeting agents, such as agonistic antibodies, might be optimal to 
elicit maximum cell death induction from DR agonist-based regimens combined with 
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The multikinase inhibitor sorafenib is highly effective against certain types of cancer in 
the clinic and prevents colon cancer cell proliferation in vitro. Non-steroidal anti-
inflammatory drugs such as acetylsalicylic acid (aspirin) have shown activity against 
colon cancer cells. The aims of this study were to determine whether the combination of 
aspirin with sorafenib has enhanced anti-proliferative effects and increases recombinant 
human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL)-induced 
apoptosis in the human SW948, Lovo, Colo205, Colo320, Caco-2, and HCT116 colon 
cancer cell lines. In four cell lines, aspirin strongly stimulated the anti-proliferative 
effects of sorafenib (~ four-fold enhancement) by inducing cell cycle arrest. Furthermore, 
combining low doses of aspirin (≤ 2.5 mM) and sorafenib (≤ 2.5 μM) greatly sensitized 
TRAIL-sensitive and TRAIL-resistant colon cancer cells to rhTRAIL. The increase in 
rhTRAIL sensitivity was caused by a reduction in basal levels of the anti-apoptotic 
proteins FLIP and Mcl-1 following aspirin and sorafenib cotreatment, as confirmed with 
small interfering RNA. Next, the clinical relevance of targeting FLIP and Mcl-1 in colon 
cancer was examined. Using immunohistochemistry, we found that Mcl-1 expression 
was significantly increased in colon adenoma and carcinoma patient material compared 
to healthy colonic epithelium, similar to the enhanced FLIP expression we recently 
observed in colon cancer. These results underscore the potential of combining low doses 
of aspirin with sorafenib to inhibit proliferation and target the anti-apoptotic proteins 
FLIP and Mcl-1. Our findings also support further pre(clinical) investigation of  this 
combination  with TRAIL receptor-targeting agents in colon cancer. 




Colon cancer is a leading cause of cancer-related death in the Western world, accounting 
for nearly 52,000 death every year in the U.S. only (1). Mortality remains high despite 
improvements in the area of prevention and treatment. Patients with advanced disease 
stage might benefit from novel chemotherapeutic options. By inhibiting cyclooxygenase 
2 (COX-2) enzymes, non-steroidal anti-inflammatory drugs (NSAIDs) exert anti-
inflammatory and anti-pyretic properties. Interestingly, these drugs also exhibit COX-
dependent and -independent anti-cancer cell properties (2,3). Although until now 
clinical trials have failed to show benefits from combining the NSAID celecoxib with 
chemotherapy in colorectal cancer (4,5), combinations with other NSAIDs and novel 
chemotherapeutic agents are of potential interest (6). 
Sorafenib is a broad spectrum kinase inhibitor targeting the RAF/MEK/ERK 
pathway and several tyrosine kinase receptors in tumor cells but also the vascular 
endothelium growth factor (VEGF) receptor 2 and 3 in endothelial cells (7). It is 
currently applied in the clinic to treat renal cell cancer and hepatocellular cancer. Its use 
against additional forms of malignancies, including colon cancer, is also being 
investigated in over 380 studies (source: ClinicalTrials.gov, 2010). Interestingly, some of 
the indirect targets of sorafenib in cancer cells such as cyclin D1 (8) and Mcl-1 (9) are 
also targets of aspirin (10,11), suggesting that these drugs could interact with each other 
in cancer cells through overlapping and/or complementary effects. 
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a trimeric 
protein of the tumor necrosis factor superfamily that has the ability to specifically 
induce apoptosis in cancer cells (12). By binding to trimers comprised of TRAIL receptor 
1 (TRAIL-R1) and/or TRAIL-R2 at the cell membrane, TRAIL triggers formation of the 
so-called death-inducing signaling complex (DISC) which activates the caspase cascade. 
Therapeutically, the TRAIL receptors are of particular interest for colon cancer since 
both TRAIL receptor expression and sensitivity to TRAIL increase during colorectal 
tumor progression (13-15). Phase I clinical studies have demonstrated that TRAIL is 
well-tolerated in its recombinant human (rh) form, and combination therapies to 
improve rhTRAIL effectivity are under investigation (16,17).  
To increase sensitivity to rhTRAIL in cancer cells, much focus has been placed on 
combining rhTRAIL with single-drug therapies. Although many agents can sensitize 
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cells to rhTRAIL in vitro, the relevance of such findings is limited due to the high 
concentrations, often far above the clinically achievable range, needed to induce a pro-
apoptotic modulating effect. We therefore chose a different approach and used a 
combination of two drugs, namely aspirin and sorafenib. Each of these two drugs has 
already been shown to have potential in combination with rhTRAIL in colon cancer 
cells. We first studied possible interactions between these two drugs at the molecular 
level, in colon cancer cell lines. Next, we tested whether combining low doses of aspirin 
and sorafenib with rhTRAIL would successfully stimulate rhTRAIL-induced apoptosis 
and determined the intracellular targets involved. Finally, we assessed the clinical 
relevance of these targets in colon cancer patient material using immunohistochemistry.  
  
Materials and Methods 
 
Reagents 
Recombinant human (rh)TRAIL was produced non-commercially following a protocol 
described earlier (18). The TRAIL-receptor antibodies used for flow cytometry 
experiments were obtained from Immunex Corporation. 3-(4,5-dimethyl-thiazol-2-yl) 




The rhTRAIL-sensitive colon carcinoma cell line SW948 was purchased from the 
American Type Culture Collection and cultured in Leibovitz L15-Myeloma medium 
(1:1) enriched with 10 % fetal calf serum (FCS), 0.05 M pyruvate, 0.1 M glutamine and 
0.025 % -mercaptoethanol at 37 C in a humidified atmosphere with 5 % CO2.  Colo205, 
Colo320 and Lovo colon carcinoma cell lines were purchased from the ATCC and grown 
in RPMI containing 10 % FCS at 37 °C in a humidified atmosphere with 5 % CO2.  The 
Caco-2 colon carcinoma cell line was purchased from the ATCC and grown in RPMI 
containing 13 % FCS at 37 °C, in a humidified atmosphere with 5 % CO2.  HCT116 cells 
were kindly provided by Dr. Bert Vogelstein (John Hopkins University, Baltimore, MD) 
and cultured in McCoy’s 5A medium supplemented with 10 % FCS in a humidified 
atmosphere at 37 °C with 5 % CO2. 
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Cytotoxicity assay 
A microculture tetrazolium (MTT) assay was used to determine cytotoxicity. Cells were 
incubated in a total volume of 200 L. After an incubation period of 96 h, 20 L of 5 
mg/ml MTT solution diluted in PBS (6.4 mM Na2HPO4; 1.5 mM KH2PO4; 0.14 mM 
NaCl; 2.7 mM KCl; pH=7.2) was added for 3.75 h. Subsequently, plates were centrifuged 
and the supernatant aspirated. After dissolving the formazan crystals by adding 
dimethyl sulfoxide (Merck, Amsterdam, The Netherlands), plates were read 
immediately at 520 nm using a microtiter well spectrometer (Bio-Rad microplate 
reader). Controls consisted of media without cells. Cell survival was defined as the 
growth of treated cells compared to untreated cells. Mean cytotoxicity was determined 




Analysis of TRAIL-receptor membrane expression was performed with a flow cytometer 
(Epics Elite, Coulter Electronics), and cells were stained as described previously (18). 
The following antibodies were used: huTRAILR1-M271 for DR4, huTRAILR2-M413 for 
DR5 (both were a gift from Amgen). Membrane expression was measured as the 
increase in mean fluorescence intensity (MFI) of the whole analyzed cell population. 
 
Apoptosis assay 
For each cell line 5 X 103 cells were seeded in 96-well plates and after attachment cells 
were treated with appropriate reagents for the desired courses. Apoptosis was assessed 
by staining nuclear chromatin with acridine orange and identification of the 
morphological changes by fluorescence microscopy. Apoptosis was determined by 
counting the number of apoptotic cells in a total of 300 cells and expressed as percentage 
apoptotic cells. All apoptosis assays were performed in triplicate and at least three 
independent assays were performed. 
 
SDS-polyacrylamide gel electrophoresis and Western blotting 
Preparation of protein lysates and Western blot analysis were performed as described 
previously (18). The following antibodies were used: mouse anti-FADD from 
Transduction Laboratories, rabbit anti-phosphorylated pRB (Ser780), mouse anti-
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caspase 8, rabbit anti-caspase 9, anti-caspase 3,  anti-cleaved caspase 3 and anti-Bak from 
Cell Signaling Technology, mouse anti-actin from ICN Biomedicals, mouse-anti-FLIP 
NF6 from Alexis, mouse anti-c-myc, rabbit anti-cyclin D1 from Santa Cruz. Mouse anti-
Mcl-1 was purchased from Calbiochem. Rabbit anti-poly ADP ribose phosphate was 
from Roche. The horseradish peroxidase-labeled secondary antibodies were from 
DAKO, and chemiluminescence was detected using the BM-chemiluminescence kit or 
with the Lumi-Light Plus Western blotting kit (Roche Diagnostics). Protein 
concentrations were determined using the DC Biorad protein assay. In all experiments 
20-40 g protein lysates were loaded on gel. Actin expression was used as loading 
control. Western blot analyses were performed at least three times. 
 
BrdU/propidium iodide cell cycle staining 
Cells were seeded in 6-well plates, treated for the indicated times before harvest. Cells 
were then stained using the BrdU/FITC flow kit (BD Biosciences Pharmingen) 
according to the manufacturer’s instructions. Propidium iodide was substituted to 7-
AAD for total DNA staining before analysis on a FACSCalibur flow cytometer (BD 
Biosciences). Three independent assays were performed. 
 
Transfection with siRNA 
For small interfering RNA (siRNA)-mediated downregulation of the various mRNA of 
interest using the first set of duplexes, the following PAGE-purified siRNA sequences 
were purchased from Eurogentec: 5’-GAGGUAAGCUGUCUGUCGGdTdT-3’ (sense 
strand) and 5’-AUGGGCCUCCGGUUCAUGCdTdT-3’ (anti-sense strand) for FLIP, (5’-
GAAACGCGGUAAUCGGACUdTdT-3’ (sense) and 5’-AGUCCGAUUACCGCGUUUC 
dTdT-3’ (anti-sense) for Mcl-1 (19), 5’-UGAGUACUUCACCAAGAUUdTdT-3’(sense)  
and 5’-AAUCUUGGUGAAGUACUCAdTdT-3’ (anti-sense) for Bcl-2 homologous 
antagonist/killer 1 (Bak). A second set of siRNA was also used: 5’-
CATCCACAGAATAGACCTGdTdT-3’ (sense strand) and 5’-CAGGTCTATTCTGTGGA 
TGdTdT-3’ (anti-sense strand) for FLIP (20), 5’-GGTCGGGGAATCTGGTAATdTdT-3’ 
(sense) and 5’-ATTACCAGATTCCCCGACCdTdT-3’ (anti-sense) for Mcl-1 (19), 5’-
GAGUACAGAAGCUUUAGCAdTdT-3’(sense)  and 5’-UGCUAAAGCUUCUGUACU 
CdTdT-3’ (anti-sense) for Bak (home-made). A scrambled sequence without any known 
homology to the human genome was used as negative control siRNA, also from 
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Eurogentec. Cells were transfected in 96-well (5,000 cells/well) or 6-well plates (0.3 x 106 
cells/well) with 0.5 or 20 μL respectively of 20 μM siRNA duplexes with Lipofectamine 
2000 reagent, following the manufacturer’s instructions (Invitrogen). The same absolute 
amounts of siRNA were used for double siRNA transfections. To maintain the 
RNA/Lipofectamine 2000 ratio and the amounts of each individual siRNA between 
experiments, single siRNA conditions were equalized to co-siRNA transfection 
conditions by mixing single targeted siRNA with scrambled siRNA, at a 1:1 ratio. The 
next day, cells were treated with various drugs for the indicated times before apoptosis 
determination using acridine orange staining (96-well plate) and/or protein isolation for 
Western-blotting (6-well plate). All apoptosis assays were performed in triplicate and at 
least three independent assays were performed. 
 
TaqMan real-time PCR 
Total RNA was isolated with the Qiagen RNeasy mini kit using the manufacturer’s 
instructions. Trace amounts of DNA contamination were removed by DNase I digestion. 
cDNA was reverse-transcribed into cDNA from 1600 ng purified RNA using MMLV 
reverse transcriptase and oligo (dT)11  primers, as described by the manufacturer’s 
protocol (Life Technologies). The profile of the reverse transcription reaction was 10 min 
at 70 °C, 50 min at 42 °C, and 10 min at 70 °C. Taqman PCR (qRT-PCR) was performed 
on 50 ng of cDNA. Applied Biosystems Taqman Gene expression assays and Taqman 
Universal PCR master mix were used to perform qRT-PCR on FLIP (Hs01116280_m1, 
Applied Biosystems), Mcl-1 (Hs01050896_m1, Applied Biosystems) and the 
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
(Hs02758991_g1, Applied Biosystems). All reactions were performed in triplicate in 384-
well plates and measured on an ABI PRISM 7900 HT Sequence Detection System. 
Amplification of the samples was carried out in triplicate in a final reaction volume of 20 
µl containing 10 µl 2X PCR Mix, 4 µl H2O, 1 µl of each assay on demand (5 µM) and 5 µl 
cDNA (1:3). PCR reaction conditions were as follows: Step 1: AmpErase uracil-N-
glycosylase incubation for 2 min at 50 °C, step 2: 10 min AmpliTaq Gold activation at 95 
°C, step 3: 50 cycles of 15 s denaturation at 95 °C followed by annealing/extension at 60 
°C for 1 min. Presence of unique reaction products was determined from the melting 
curves obtained at the end of 50 cycles of amplification. 
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To determine RT-PCR efficiency and initial starting quantity of the samples, a 
standard curve was generated using a 1:3 serial dilution from total starting cDNA 
sample. Water control and samples without reverse transcription were included to 
check for absence of DNA contamination. Differences in the amount of starting cDNA 
between samples were corrected using GAPDH as a housekeeping reference gene. 
Experiments were performed with cDNA generated from four independent RNA 
isolation procedures. 
 
Mcl-1 immunohistochemistry staining 
Selection of patient and tissue material was described earlier (21). A small number of 
samples from the original report had to be excluded because of insufficient remaining 
material for further analysis.  Immunohistochemistry was performed on samples 
embedded in paraffin using the benchmark system (Ventana). Fresh serial 3 µm thick 
sections were cut from paraffin blocks. Following deparaffinization in xylol and 
rehydratation in alcohol, antigen retrieval was performed by immersing the slides in 10 
mM citrate buffer pH 6 for 15 min in a microwave. After blocking of endogeneous 
peroxidase with H2O2, rabbit anti-Mcl-1 (1:400) antibody (Pharmingen) was applied for 
1 h at room temperature. Binding specificity was controlled using rabbit IgG1 isotype 
control (Dakocytomation). Aspecific binding for both antibodies was prevented by 
adding 1 % standard human serum to the antibody dilution solution (PBS). After several 
washing steps, the Envision horseradish peroxidase system was used according to the 
manufacturer’s instructions (DAKO). Peroxidase activity was visualized with 
diaminobenzidine. All slides were counterstained with hematoxylin. Slides were 
evaluated by an experienced pathologist (HH) and two investigators (BP and WB), 
using an Olympus BX50 microscope. Expression was quantified semi-quantitatively 
according to the following scale: negative (less than 10 % positive cells), moderate (+), 
strong (++) and very strong (+++) based on the intensity of the perinuclear staining. In 
case of heterogeneous staining, the highest staining intensity was chosen when found in 
>50 % of the tumor. When the observers’ score differed, the smaller value was selected 
to avoid over-estimating the staining intensity. Diffuse expression was very weak and 
mostly detected in epithelial cells near the luminal surface in healthy control, as 
reported by Krajewski et al. (22). For statistical analysis, all classes were afterwards 
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dichotomized. Moderate, strong and very strong staining were considered positive and 
negative staining as negative. 
 
Statistical analysis 
Data are represented as the mean ± SD. In all cases, statistical analyses were done using 
2-tailed student’s t test. P-values < 0.05 were considered significant and are indicated 
with an asterisk. In the immunohistochemical study, differences in Mcl-1 expression 
between normal, adenoma and carcinoma were assessed using Chi-square tests. P-




The combination of aspirin and sorafenib potently inhibits colon cancer cell growth 
Sorafenib was previously shown to possess anti-proliferative activity in colon cancer cell 
lines (7,8). First, we determined in a 96-h viability assay the cell growth inhibitory effect 
of sorafenib in our panel of human colon cancer cell lines, composed of SW948, Lovo, 
Colo205, Colo320, Caco-2 and HCT116. All cell lines tested showed micromolar 
sensitivity to the compound, with an average concentration of sorafenib necessary to 
inhibit growth by 50% of less than 7.5 μM (GI50; the drug concentration causing a 50% 
reduction in cell growth compared to the untreated cells) (Fig. 1A, see also 
Supplementary Fig. S1 for exact GI50 values). This GI50 value is within reported plasma 
concentrations for sorafenib (23). The GI50 of SW948, Lovo, Colo320 and HCT116 cells 
were comparable or even below the GI50 values of the B-Raf mutant cell lines Caco-2 and 
Colo205 (V600E) (24,25)(see also http://www.sanger.ac.uk). All cell lines also showed 
sensitivity to aspirin alone (Supplementary Fig. S2). Next, we show that in 4 colon cell 
lines, namely, SW948, Lovo, Colo320, and Caco-2, the effects of sorafenib were 
potentiated by aspirin (Fig. 1B). In Colo205 and HCT116 cells, the effects of the 
combination on cell survival were mostly additive. Aspirin increased the growth 
inhibitory effects of sorafenib in B-Raf wild-type SW948, Lovo and Colo320 cells, which 





Figure 1: Aspirin and sorafenib 
effectively inhibit colon cancer cell 
survival and cell cycle progression of 
these cells. A:  Sensitivity of colon 
cancer cell lines to sorafenib. Cells 
were treated for 96 h before cell 
survival determination. Values are 
mean    SD of at least three 
independent experiments. B: 
Sensitivity of colon cancer cell lines to 
the combination of aspirin and 
sorafenib. Cells were treated for 96 h 
with the indicated drug concentrations 
before cell survival determination. C: 
Effects of an incubation with aspirin 
(A) (2 mM), sorafenib (S) (2 µM) or the 
combination (A/S) on cell cycle 
distribution in SW948 (top panel) and 
in Colo320 (lower panel). Cells were 
pre-incubated for 41 h with the various 
treatments before analysis. Values are 
mean of at least 3 independent 
experiments. D: Effects of a 41 h-
incubation with aspirin (2 mM), 
sorafenib (2 µM) and the combination 
(left page panel) or time-dependent 
effects of the combination (right page 
panel) on the expression of cell-cycle 
related proteins. One representative of 
at least three independent experiments 
is shown. 
 




Combining aspirin and sorafenib inhibits cell cycle progression in colon cancer cells 
To identify the cause of the inhibition of cell growth by aspirin plus sorafenib, we 
investigated the effects of aspirin, sorafenib and the combination on cell cycle 
distribution in SW948 and Colo320 cells (Fig. 1C). In both cell lines, simultaneous 
treatment with aspirin and sorafenib significantly decreased the percentage of cells in S 
phase compared to control, from 49.2 to 32.5% in Colo320 (P < 0.01) and from 35.3 to 
5.1% in SW948 (P < 0.005).  Colo320 cells also exhibited a significant increase in 
percentage of cells in G2/M, from 26.3 to 32.3% (P < 0.05). Similar results were found in 
Lovo cells where aspirin and sorafenib co-treatment decreased the percentage of cells in 
S phase and increased the percentage of cells in  G2/M compared to control, from 18.2 to 
7.9% (P < 0.01) and from 38.9 to 51.9% (P < 0.05), respectively (Supplementary Fig. S3). 
This suggests that the decrease in cell survival following co-treatment with aspirin and 
sorafenib is due to inhibition of cell cycle progression. Next, we assessed the expression 
of several cell cycle proteins that have been individually reported as targets of aspirin 
and sorafenib. At the concentrations used, single treatment with aspirin or sorafenib did 
not alter the expression levels of the cell cycle protein cyclin D1 and phosphorylated 
pRB (ppRB) or of the oncoprotein c-myc, as shown in three colon cancer cell lines (Fig. 
1D, left panel). 
 Combination of aspirin and sorafenib however led to important decreases in 
expression of proteins involved in regulating progression through the G1 phase of the 
cell cycle such as cyclin D1, ppRb and c-myc, as seen consistently in all three cell lines. 
The effects were time-dependent (Fig. 1D, right panel) and a striking reduction in 
expression was seen after 24 to 48 h incubation with aspirin and sorafenib, depending 
on the cell line. Altogether, our results suggest that the combination of aspirin and 
sorafenib induces cell cycle arrest.  
 
Low doses of aspirin and sorafenib synergize to increase TRAIL sensitivity 
The anti-apoptotic proteins FLIP and Mcl-1 have been individually reported as targets of 
aspirin and sorafenib. We noticed that the expression of both proteins was much more 
efficiently inhibited by the combination of aspirin and sorafenib (Fig. 2A, left panel). The 
decrease in FLIP and Mcl-1 was seen across cell lines, and was time-dependent (Figure 
2A, right panel). Both FLIP and Mcl-1 have been associated with resistance to TRAIL in 
cancer cells, at different levels of the apoptotic signalling. Notably, FLIP can inhibit 
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DISC formation and caspase 8 cleavage (26), while Mcl-1 inhibits the mitochondrial 
route of apoptosis by sequestering pro-apoptotic Bak (27). 
Previously, we reported the strong resistance of Colo320 cells and limited 
sensitivity of Lovo cells to the pro-apoptotic agent rhTRAIL (15,18). Because aspirin and 
sorafenib decreased expression of the anti-apoptotic proteins FLIP and Mcl-1, we tested 
whether rhTRAIL sensitivity was increased. In Lovo and Colo320 cells, limited 
apoptosis (≤ 30%) was induced by a 5 h-rhTRAIL treatment (100 ng/mL) if cells were 
only pretreated with aspirin and/or sorafenib for 17 h (Figure 2B, left panel). Because 
we showed that optimal FLIP and Mcl-1 downregulation required long incubation with 
aspirin and sorafenib, we extended the pre-incubation with these two drugs from 17 to 
36 h before rhTRAIL treatment. Following 36 h pre-incubation both with aspirin and 
sorafenib, rhTRAIL (100 ng/mL) sensitivity markedly increased in Lovo and Colo320 
cells, up to about 60 and 40%, respectively (Fig. 2B, right panel). In Lovo and in Colo320 
cells, aspirin, sorafenib or their combination did not induce apoptosis. In Lovo cells, 
aspirin also slightly enhanced rhTRAIL-induced apoptosis (≤ 40%) but less efficiently 
than the combination of all three therapeutics. 
We questioned whether longer treatment with rhTRAIL (17 h) could induce 
higher levels of apoptosis within the same total treatment window (41 h). When cells 
were pre-treated with aspirin and sorafenib for 24 h before treatment with rhTRAIL (10-
100 ng/mL) for an additional 17 h, apoptosis levels could be further increased up to 80% 
in Lovo and 70% in Colo320 cells (compare Fig. 2C with 2B, right panel). In both cell 
lines, apoptosis was greatly stimulated by relatively low amounts of rhTRAIL (10 
ng/mL) in combination with aspirin and sorafenib. 
Next, we analyzed the effects of aspirin, sorafenib, rhTRAIL and their combination on 
activation of proteins of the TRAIL apoptotic pathway in Lovo (Fig. 2D, left panel) and 
Colo320 cells (Fig. 2D, right panel). Treating Lovo cells with aspirin, sorafenib or a 
combination of these drugs for 41 h induced (slight) cleavage of caspase 9 only. 
Treatment with rhTRAIL alone (10 ng/mL) for the last 17 h of incubation slightly 
stimulated caspase 9 and PARP cleavage. Pre-incubation with aspirin or sorafenib did 
not further induce cleavage of these proteins upon rhTRAIL treatment. However, when 
cells were pre-treated with both aspirin and sorafenib, potent processing of caspase 8, 
Bid, caspase 9, caspase 3 and PARP was seen in response to rhTRAIL, indicating high 
levels of apoptosis. In Colo320 cells as well, only the combination of rhTRAIL, aspirin 
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and sorafenib could induce cleavage of caspase 8, Bid, caspase 9, caspase 3 and PARP. 
Similar results were seen in the SW948 cell line (Supplementary Fig. S4). These results 
confirm that the combination of rhTRAIL, aspirin and sorafenib achieve levels of 
apoptosis superior to combinations of two of these agents only. 
 
The decrease in Mcl-1 and c-FLIP expression levels is involved in the effects of aspirin 
and sorafenib on rhTRAIL-induced apoptosis 
We then investigated whether the aspirin and sorafenib-induced decrease in FLIP and 
Mcl-1 protein levels caused the increase in rhTRAIL sensitivity. The expression of these 
proteins was therefore selectively inhibited using a small interfering RNA (siRNA) 
approach in Lovo cells. For each protein, efficient expression silencing was confirmed 
with two different sets of sequences by Western-blot (Fig. 3A, top). Following 
downregulation of FLIP or Mcl-1 with the each set of siRNAs, cells were stimulated with 
rhTRAIL (Fig. 3A, bottom). Results show that rhTRAIL sensitivity increased, confirming 
the ability of FLIP and Mcl-1 to inhibit TRAIL receptor-mediated apoptosis. 
Next, we investigated using Western-blotting which steps of the rhTRAIL-
induced apoptotic pathway were affected by FLIP and Mcl-1 (Fig. 3B). FLIP 
downregulation stimulated procaspase 8 processing in presence of rhTRAIL in Lovo 
cells. As expected, Mcl-1 downregulation did not increase caspase 8 cleavage in 
response to rhTRAIL. Cleavage of procaspase 3 and PARP were enhanced by FLIP and 
Mcl-1 siRNA but not cleavage of procaspase 9. These findings indicate that both FLIP 
and Mcl-1 downregulation enhanced rhTRAIL-induced apoptosis. 
Figure 2: The combination of aspirin and sorafenib downregulates anti-apoptotic proteins and sensitize 
colon cancer cells to rhTRAIL-induced apoptosis. A: Effects of a 41 h-incubation with aspirin (2 mM), 
sorafenib (2 µM) and the combination (left panel) or time-dependent effects of the combination (right 
panel) on the expression of anti-apoptotic proteins. One representative of at least three independent 
experiments is shown. B: Apoptosis in cells pre-incubated with aspirin (2 mM), sorafenib (2 µM) or the 
combination before treatment with 10-100 ng/ml rhTRAIL (indicated as T10 and T100, respectively) in 
Lovo and Colo320 cells. Cells were pre-incubated for 17 (left) or 36 h (right) with aspirin and/or sorafenib 
before treatment with rhTRAIL (T) for 5 h. C: Apoptosis in cells pre-incubated for 24 h with aspirin (2 
mM), sorafenib (2 µM) or the combination before treatment with rhTRAIL for 17 h in Lovo and Colo320 
cells. D: Western-blot analysis showing activation of caspases, Bid and PARP in Lovo (left) and Colo320 
(right) cells pre-treated with aspirin (2 mM) and/or sorafenib (2 µM) for 24 h before 17 h-treatment with 
rhTRAIL (10 ng/ml). 
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Figure 3: FLIP and Mcl-1 downregulation sensitize colon cancer cells to rhTRAIL-induced apoptosis. A: 
Downregulation of FLIP or Mcl-1 in Lovo cells using siRNA sensitizes cells to rhTRAIL. Cells were either 
transfected with scrambled siRNA (Scr.) or with two sets of FLIP- or Mcl-1-specific siRNA for 32 h before 
treatment with 5 and 50 ng/ml rhTRAIL (T5 and T50, respectively) for 17 h. B: Activation of caspases and 
PARP in siRNA-transfected Lovo cells treated with rhTRAIL for 17 h. Cells were transfected for 32 h with 
negative control or specific siRNAs before treatment with rhTRAIL (10 ng/ml) for 17 h. C: Apoptosis in 
HCT116 cell transfected with negative control, FLIP or Mcl-1 siRNA for 24 h before treatment with 
rhTRAIL 10 and 100 ng/ml rhTRAIL (indicated as T10 and T100, respectively) for 24 h. Western blots 
demonstrating the efficacy of the two siRNA sets specific for FLIP or Mcl-1 in HCT116 are also shown. D: 
Effects of aspirin and sorafenib co-treatment on rhTRAIL-induced apoptosis in cells transfected with FLIP 
and Mcl-1 siRNAs. Apoptosis was determined in Lovo cells treated for 17 h with rhTRAIL following 
prior transfection for 24 h with scrambled siRNA, with both FLIP and Mcl-1 siRNAs, or with both FLIP 
and Mcl-1 siRNAs simultaneously to aspirin (2 mM) and sorafenib (2 μM) co-treatment. 
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Colo320 cells were refractory to transient siRNA transfection (data not shown). We 
therefore used HCT116 cells to confirm the importance of FLIP and Mcl-1 levels for 
rhTRAIL-sensitivity in colon cell lines. These cells were also sensitized to rhTRAIL with 
a combination of aspirin and sorafenib (data not shown). Downregulating FLIP, Mcl-1 
or both proteins increased rhTRAIL-induced apoptosis in HCT116 cells, thus supporting 
the importance of FLIP and Mcl-1 for rhTRAIL sensitivity in colon cancer cells (Fig. 3C). 
To further investigate the contribution of FLIP and Mcl-1 downregulation to the effects 
on rhTRAIL sensitivity of the combination of aspirin with sorafenib, we combined 
siRNA downregulation of FLIP and Mcl-1 together with aspirin and sorafenib co-
treatment before incubation with rhTRAIL (Fig. 3D). In cells transfected with scrambled 
siRNA, rhTRAIL (25 ng/mL) induced apoptosis in ~30% of Lovo cells. RhTRAIL 
treatment induced apoptosis in up to 70% of cells following co-downregulation of FLIP 
and Mcl-1. Combining aspirin and sorafenib co-treatment shortly after transfection with 
FLIP and Mcl-1 siRNA induced some minor toxicity in absence of rhTRAIL, but it only 
slightly increased rhTRAIL sensitivity compared to cells with FLIP and Mcl-1 siRNAs 
only. Although aspirin and sorafenib might modulate the expression of additional pro- 
or anti-apoptotic proteins, this indicates that downregulation of FLIP and Mcl-1 plays a 
major role in the increase in rhTRAIL sensitivity. 
We investigated whether the diminished FLIP and Mcl-1 protein levels were due 
to a decrease in mRNA levels (Supplementary Fig. S5). Quantitative real time PCR 
indicates that aspirin and sorafenib, either alone or in combination, did not decrease 
FLIP or Mcl-1 mRNA levels in Colo320 or Lovo. The decrease in FLIP and Mcl-1 protein 
levels following incubation with aspirin and sorafenib is likely caused by either 
decreased translation or lower stability of these proteins. 
 
RhTRAIL-induced apoptosis following Mcl-1/ FLIP downregulation or 
aspirin/sorafenib pre-incubation requires activation of the mitochondrial pathway 
To investigate the increase in TRAIL sensitivity following Mcl-1 downregulation in 
relation to the mitochondrial apoptotic pathway, we inhibited Bcl-2 homolog killer 1 
(Bak) expression in Lovo cells. Since Lovo cells do not express Bax (28), depleting Bak 
should impair activation of the mitochondrial apoptotic pathway (29,30). Bak was 
efficiently downregulated (Fig. 4A, left) and completely blocked rhTRAIL-induced 
apoptosis (Fig. 4A, middle), suggesting that Lovo is a type II cell line (31). The increase 
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Figure 4:  Mcl-1 downregulation, FLIP downregulation and the combination aspirin/sorafenib sensitizes 
Lovo and HCT116 cells to rhTRAIL-induced apoptosis via the mitochondria. A: Bak downregulation 
prevents rhTRAIL-induced apoptosis in Lovo cells, co-transfected or not with FLIP or Mcl-1 siRNA. Cells 
were either transfected with scrambled siRNA or with two different Bak-specific siRNAs before harvest 
and Western-blotting (left panel). Apoptosis in Lovo cells transfected with negative control, Mcl-1, Bak or 
a combination of Mcl-1 and Bak siRNAs 32 h before rhTRAIL treatment for 17 h (middle panel). 
Alternately, Lovo cells were transfected with scrambled, FLIP, Bak or a combination of FLIP and Bak 
siRNA 32 h before treatment with rhTRAIL for 17 h (right panel). Results obtained with two different sets 
of siRNAs specific for Bak, FLIP and Mcl-1 are shown. B: Apoptosis in HCT116 cells transfected with 
scrambled, Mcl-1, Bak or a combination of Mcl-1 and Bak siRNAs 32 h before rhTRAIL treatment for 17 h 
(left figure). HCT116 cells were also transfected with scrambled, FLIP, Bak or a combination of FLIP and 
Bak siRNAs 32 h before treatment with rhTRAIL for 17 h (right figure). C: The mitochondrial route plays 
an important role for rhTRAIL-induced apoptosis in Lovo cells co-treated with aspirin and sorafenib. 
Lovo cells were transfected with scrambled and/or Bak siRNA for 24 h, alone or in combination with 
simultaneous aspirin/sorafenib treatment followed by a 17 h-incubation with rhTRAIL at the indicated 
concentrations. 
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in rhTRAIL sensitivity following Mcl-1 downregulation required Bak, consistent with 
the established role of Mcl-1 as a modulator of the intrinsic pathway of apoptosis (Fig. 
4A, middle). Interestingly, the pro-apoptotic effect of FLIP downregulation on TRAIL-
induced apoptosis was also lost when Bak was also downregulated (Fig. 4A, right). 
These findings were confirmed with a second set of FLIP, Mcl-1 and Bak siRNAs (Fig. 
4A, lower panel). We obtained similar results in the Bax and Bak-expressing HCT116 
cell line (Fig. 4B). Inhibition of Bak expression alone prevented basal rhTRAIL 
sensitivity in control HCT116 cells but also rhTRAIL sensitivity in cells sensitized with 
siRNA targeting FLIP or Mcl-1. Although in some cell lines downregulating FLIP before 
rhTRAIL treatment converts type II cells into type I cells (32), this does not seem to be 
sufficient in Lovo and HCT116 cells.  
Next, we tested whether the effects of aspirin and sorafenib cotreatment on 
rhTRAIL-induced apoptosis was also mediated by the mitochondrial pathway of 
apoptosis in a Bak-dependent manner (Fig. 4C). In vehicle-treated cells, rhTRAIL 
induced apoptosis in up to 30% of Lovo cells, which was inhibited by Bak 
downregulation. Treatment with aspirin and sorafenib greatly increased rhTRAIL-
induced apoptosis in cells transfected with scrambled siRNA. The pro-apoptotic effect 
was lost in Bak-suppressed cells. These results further strengthen our finding that, by 
downregulating FLIP and Mcl-1, aspirin and sorafenib sensitizes cells to rhTRAIL in a 
mitochondria-dependent manner.  
 
FLIP and Mcl-1 expression increases during colon carcinogenesis 
Studies performed previously in our lab using patient material demonstrated a 
significant increase in FLIP protein levels in colorectal cancer compared to normal colon 
mucosa and colon adenoma (21). The therapeutic relevance of Mcl-1 protein in colon 
cancer has not been clearly established. Mcl-1 expression was therefore examined in the 
patient material that we previously used to evaluate FLIP expression (Fig. 5A). 
Altogether, Mcl-1 staining was detected in 70.5% of all adenomas (n = 57) and 59.1% of 
all carcinomas (n = 49), which was significantly higher than the 10% positivity found in 
normal mucosa (n = 20) (both P < 0. 001) (Fig. 5B). Staining of Mcl-1 was perinuclear, 
which has been associated with an anti-apoptotic function at the mitochondria (33). 
Thus, our results highlight the potential of Mcl-1 as a marker and/or therapeutic target 










Figure 5: Mcl-1 expression is increased during colorectal carcinogenesis. A: Representative examples of 
Mcl-1 expression in normal colonic mucosa with negative perinuclear staining but moderate diffuse 
staining, in colorectal adenoma and in carcinoma , both with positive perinuclear staining, shown at the 
10 and 40 times magnification. B: Expression of Mcl-1 in % positive cases in normal colonic mucosa, 
sporadic adenomas, sporadic carcinomas, Lynch syndrome adenomas and Lynch syndrome carcinomas. 




RhTRAIL, in combination with either chemotherapy or targeted drugs, is highly 
effective in inducing apoptosis in colon cancer cells (34). We now demonstrate that 
combining the drugs aspirin and sorafenib, at clinically relevant concentrations, strongly 
inhibits colon cancer cell viability. Next, we show that at the same concentrations, the 
combination of aspirin and sorafenib is much more effective at enhancing rhTRAIL-
induced apoptosis than either drug alone. The mechanism of this rhTRAIL sensitization 
by aspirin and sorafenib was identified, namely FLIP and Mcl-1 protein 
downregulation. These two proteins were found to be highly expressed in human colon 
cancer samples, confirming the relevance of our findings. The results of this study 
regarding the strong potentiating effect of low doses of aspirin and sorafenib on 
rhTRAIL sensitivity in colon cancer cells, including rhTRAIL-resistant cells, should 
therefore stimulate further clinical development of this targeted drug combination. 
TRAIL resistance is often due to high levels of anti-apoptotic proteins; this can be 
reversed with inhibition of their expression. We find that the increase in rhTRAIL 
sensitivity following aspirin and sorafenib cotreatment was caused by a time-dependent 
downregulation in levels of the. FLIP is a widely accepted inhibitor of TRAIL sensitivity 
at the DISC (26) and has also been shown to induce resistance to chemotherapy in colon 
cancer cells (35,36). FLIP expression is increased in colorectal cancer, supporting the 
potential of combining FLIP-targeting strategies with TRAIL receptor agonists (21). The 
influence of Mcl-1 expression in association with colon carcinogenesis is less evident. By 
comparing human adenomatous polyps and primary colorectal adenocarcinomas to 
their adjacent normal mucosa, Krajewska et al. found stronger Mcl-1 immunointensity in 
29% of adenomas but lower immunointensity in 67% of primary cancers (37). 
Comparing Mcl-1 expression in four colon carcinomas with their surrounding 
epithelium, Schulze-Bergkamen et al. reported that Mcl-1 expression was slightly higher 
in colon cancer (38). Using the same patient material as in our study on FLIP expression, 
we show here that Mcl-1 expression is increased during colorectal carcinogenesis. As 
suggested for Bcl-2 (39), Mcl-1 might provide a survival advantage to colon adenoma 
and carcinoma cells compared to healthy cells due to its anti-apoptotic properties. In 
contrast to previous studies, clearly higher expression of Mcl-1 was seen in adenomas 
but also in carcinomas compared to normal colonic tissue. Abnormality of the colonic 
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mucosa up to several centimeters away from the edge of a tumors has been suggested 
previously (39), and might explain the discrepancies with earlier studies on Mcl-1. 
Altogether, our results support that Mcl-1 protein expression increases early during 
colorectal carcinogenesis and is largely conserved in cancer. 
We show that the combination of aspirin and sorafenib increases rhTRAIL-
sensitivity in the Bax-deficient Lovo cell line. This is of particular importance since Bax 
is frequently lost in colon cancer (up to 50% in Lynch syndrome patients) and plays an 
important role in acquisition of rhTRAIL resistance in vitro and in vivo (40). In contrast, 
the NSAID sulindac sulfide induced TRAIL sensitization via a Bax-dependent 
mechanism by decreasing Bcl-xL expression in colorectal cancer cells (41). Since Bak is 
less frequently lost in colon cancer than Bax, it might be interesting to exploit the 
potential of Bak to activate the mitochondrial pathway. Notably, we found that the 
combination of aspirin and sorafenib reduced expression of the well-known Bak 
inhibitor Mcl-1 (27) and sensitized colon cancer cells to rhTRAIL-induced apoptosis in a 
Bak-dependent manner. No specific agent targeting Mcl-1 has been developed yet. 
Although Obatoclax targets the Bcl-2 family proteins including Mcl-1, it was found to 
induce apoptosis in cells lacking Bax and Bak expression as well, suggesting 
mitochondria-independent effects on apoptosis (42). Wei et al. previously showed that 
simultaneous knock-out of Bax and Bak was necessary for impairing Bid-mediated 
apoptosis, suggesting that these two proteins were redundant in function (43). Based 
notably on experiments performed in the Bax-proficient and Bax-deficient HCT116 cell 
model, the current paradigm has been that Bax but not Bak is critical for the TRAIL-
induced activation of the mitochondrial pathway in cancer cells (40,44). Our Bak siRNA 
experiments partially challenge this assumption since the type II cell line Lovo is 
initially moderately sensitive to rhTRAIL, whereas it only expresses Bak. Furthermore, 
Bak siRNA completely blocks rhTRAIL-induced apoptosis in HCT116 and Lovo, further 
suggesting the importance of this protein. Chemotherapeutic drugs modify the balance 
between pro and anti-apoptotic Bcl-2 family members, often with preferential activation 
of Bax or Bak (45-47). A better knowledge on the mechanisms and proteins regulating 
Bid-induced activation of Bax and Bak appears needed to improve mitochondrial 
activation following TRAIL treatment. 
It is noteworthy that little to no apoptosis was induced by aspirin and sorafenib 
cotreatment alone despite downregulation of FLIP and Mcl-1. Rather, aspirin and 
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sorafenib cotreatment had a strong potentiating effect on growth inhibition. Previous 
reports have shown that both aspirin and sorafenib inhibit expression of cell cycle-
related proteins associated with G1-S progression such as cyclin D1 and ppRb (8,48,49). 
Sorafenib prevented cell survival in all colon cancer cell lines tested in vitro. The effects 
of sorafenib alone were independent of the B-Raf status, as previously observed in 
melanoma cell lines by Plastaras et al. (8). We now show that aspirin can potentiate the 
effects of sorafenib in colon cancer cells. An increase in the proportion of cells in G1 and 
a decrease in number of cells in S phase were observed, suggesting that the combination 
delays cell cycle progression. Accordingly, a decrease in expression of cyclin D1 and 
ppRb was also seen. We cannot rule out that the combination of aspirin and sorafenib 
might also inhibit different phases of the cell cycle depending on the cell line used. 
Sorafenib has been shown to exert cell line-dependent effects on cell cycle progression 
(8). Since the anti-proliferative effects of the combination of aspirin with sorafenib were 
seen both in wild type and mutant Raf cells, response to the combination seems 
independent of the mutational status of the Raf/MEK/ERK pathway. 
In conclusion, aspirin and sorafenib potentiate each other in preventing colon 
cancer cell proliferation by inhibiting cell cycle progression. Combining these two drugs 
at low concentrations also markedly increases colon cancer cell sensitivity to rhTRAIL-
induced apoptosis. This is due to a decrease in levels of the proteins FLIP and Mcl-1, 
both of which we found to be over-expressed in human colon cancer specimens. 
Therefore, our results provide a strong rationale to explore the clinical potential of 
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S1: GI50 of various colon cancer cell lines for sorafenib.  
S2: Sensitivity of colon cancer cell lines to aspirin. Cells were treated for 96 h with the indicated drug 
concentrations before cell survival determination. 
S3: Effects of an incubation with aspirin (A) (2 mM), sorafenib (S) (2 µM) or the combination (A/S) on cell 
cycle distribution in Lovo. Cells were treated as described in Figure 1C before analysis. Values are mean 
of at least 3 independent experiments. 
S4: Western-blot analysis showing activation of caspases, Bid and PARP in SW948 cells pre-treated with 
aspirin (2 mM) and/or sorafenib (2 µM) for 24 h before 17 h-treatment with rhTRAIL (10 ng/mL). 
S5: The combination of sorafenib and aspirin does not downregulate FLIP and Mcl-1 mRNA levels. 
Effects of a 41 h-incubation with aspirin, sorafenib or both drugs in combination on FLIP and Mcl-1 
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Summary of results 
 
Colorectal cancer is the second cause of cancer-related death in western countries. 
Although therapeutic progress has been made, intrinsic and/or acquired drug resistance 
remains a problem, which is probably caused by disruption of the apoptosis pathway in 
colon cancer cells. Both anti-tumor and anti-metastatic roles have been suggested for the 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptotic 
pathway in vivo. This makes the TRAIL apoptotic pathway a therapeutic target. Novel 
agents - among them, recombinant human (rh)TRAIL and agonistic antibodies targeting 
either TRAIL receptor 1 (TRAIL-R1) or TRAIL-R2 - have been designed to stimulate the 
extrinsic pathway of apoptosis in cancer cells. Combination therapies making use of 
these agents are currently being evaluated for their ability to re-establish apoptosis in 
chemotherapy-resistant cells. This thesis investigated various aspects of the TRAIL 
apoptotic pathway, with the goal to improve the molecular targeting of this pathway in 
colon cancer. 
To delineate new strategies leading to higher sensitivity to TRAIL death receptor-
mediated apoptosis, we first reviewed current knowledge on the initiating step of the 
pathway, the so-called death-inducing signaling complex (DISC) formation (chapter 2). 
DISC assembly is triggered in cancer cells via binding of TRAIL to its two proapoptotic 
receptors, TRAIL-R1 and TRAIL-R2. Primary components of the DISC are trimerized 
TRAIL-R1/-R2, FADD, caspase 8 and caspase 10. The anti-apoptotic protein FLIP can 
also be recruited to the DISC to replace caspase 8, thereby forming an inactive complex. 
Caspase 8/10 processing at the DISC triggers the caspase cascade, which eventually 
leads to apoptotic cell death. Besides TRAIL, TRAIL-R1- and TRAIL-R2-selective 
variants of TRAIL and agonistic antibodies have been designed. These ligands are of 
interest as anti-cancer agents, since they selectively kill tumor cells. To increase tumor 
sensitivity to TRAIL death receptor-mediated apoptosis and to overcome drug 
resistance, TRAIL receptor ligands have already been combined with various therapies 
in preclinical models. In chapter 2, we discuss factors influencing the initial steps of 
TRAIL apoptosis pathway signaling, focusing on mechanisms modulating DISC 
assembly and caspase activation at the DISC. These insights can direct rational design of 
drug combinations with TRAIL receptor ligands to maximize DISC signaling. 
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One way to identify combinations that increase TRAIL-induced apoptosis has 
been the development of cancer cell line models for TRAIL resistance, often in mismatch 
repair-deficient colon cancer cells. These cells are prone to mutations in genes containing 
tandem repeats, including the gene encoding for the pro-apoptotic protein Bax, but they 
only represent a small fraction of colorectal cancers (15-20%). In chapter 3, we 
investigated the mechanism underlying TRAIL resistance acquisition in a mismatch 
repair-proficient colon carcinoma cell line. The TRAIL-resistant cell line SW948-TR was 
established from the TRAIL-sensitive cell line SW948 by continuous exposure to 
rhTRAIL, and exhibited a 140-fold lower sensitivity to rhTRAIL in a cell viability assay. 
Resistance was stable for over a year in the absence of rhTRAIL. Both cell lines had 
similar TRAIL receptor cell membrane expression levels. Treatment with the protein 
synthesis inhibitor cycloheximide sensitized SW948-TR to rhTRAIL-induced apoptosis, 
indicating that the functionality of the TRAIL receptors was maintained. In SW948-TR, 
procaspase 8 protein levels but not mRNA levels were notably lower than in SW948. 
Downregulation of c-FLIP with short interfering RNA (siRNA) sensitized SW948-TR 
cells to rhTRAIL, while caspase 8 siRNA decreased rhTRAIL sensitivity in SW948, 
highlighting the importance of the caspase 8/FLIP ratio. Proteasome inhibition with 
MG-132 did not restore basic procaspase 8 levels but stabilized cleaved caspase 8 in 
rhTRAIL-treated SW948-TR cells. Altogether, our results suggest that colon cancer cells 
may acquire rhTRAIL resistance by primarily reducing the basal procaspase 8/FLIP 
ratio and by increasing active caspase 8 degradation after rhTRAIL treatment. 
Proteasome inhibitors may effectively overcome acquired rhTRAIL resistance in 
mismatch repair-proficient colon cancer cells. 
Several agents have been designed to target the TRAIL receptors, including 
TRAIL receptor-specific ligands. Because these various ligands might have different 
properties, we investigated in chapter 4 the contribution of TRAIL-R1 and of TRAIL-R2 
to rhTRAIL-sensitivity and rhTRAIL-resistance in the SW948 and SW948-TR cell line 
model. We also assessed whether anti-TRAIL-R1 or anti-TRAIL-R2 agonistic antibodies 
could circumvent rhTRAIL resistance. SW948 cells were sensitive to all three of 
the TRAIL receptor-targeting agents tested, although the anti-TRAIL-R2 antibody 
induced only weak caspase 8 cleavage and low apoptosis levels. Nonetheless, anti-
TRAIL-R1 and anti-TRAIL-R2 antibodies induced equivalent DISC formation as well as 
equivalent caspase 8 cleavage at the level of their individual receptors. This indicates 
Chapter 7 
184 
that further caspase 8 processing is impaired upon stimulation of TRAIL-R2. SW948-TR 
cells were resistant to all TRAIL receptor-targeting agents due to their lower caspase 8 
expression levels. Caspase 8 levels could be restored by MG-132 or interferon-γ (IFN-γ) 
pretreatment, and sensitivity to rhTRAIL and the anti-TRAIL-R1 antibody was 
increased. Surprisingly, MG-132 also enhanced TRAIL-R2-mediated apoptosis. These 
results highlight a critical difference between TRAIL-R1 and TRAIL-R2 apoptotic 
signaling modulation, with possible implications for future combinatorial regimens. 
The activity of the insulin-like growth factor 1 (IGF-1) survival pathway is often 
increased in cancer, influencing both cell proliferation and apoptosis. In chapter 5, we 
hypothesized that inhibiting the IGF-1 receptor (IGF-1R) could increase TRAIL death 
receptor-mediated apoptosis in colon cancer cells. NVP-AEW541, a small molecular 
weight tyrosine kinase inhibitor of the IGF-1R, surprisingly decreased sensitivity to 
rhTRAIL and to an anti-TRAIL-R1 antibody; sensitivity to an anti-TRAIL-R2 antibody 
was increased. NVP-AEW541 did inhibit IGF-1-induced activation of the 
phosphatidylinositol 3-kinase (PI3K) pathway. The effects of the PI3K inhibitor 
LY294002 on TRAIL-induced apoptosis were similar to those of NVP-AEW541, further 
supporting a role for IGF-1R-mediated activation of PI3K. We show that PI3K inhibition 
enhances TRAIL-R2-mediated caspase 8 processing but at the same time lowers TRAIL-
R1 membrane expression and TRAIL-R1-mediated caspase 8 processing. Inhibition of 
PI3K reduced rhTRAIL sensitivity, an effect which was independent of the cell line’s 
initial preference for either TRAIL-R1- or TRAIL-R2-mediated apoptosis signaling. 
These results suggest that individual effects on TRAIL-R1 and TRAIL-R2 apoptosis 
signaling should be taken into consideration when combining TRAIL receptor ligands 
with PI3K inhibition. 
The multikinase inhibitor sorafenib is highly effective against certain types of 
cancer in the clinic and prevents colon cancer cell proliferation in vitro. Non-steroidal 
anti-inflammatory drugs such as acetylsalicylic acid (aspirin) have shown activity 
against colon cancer cells. The aims of chapter 6 were to determine whether the 
combination of aspirin with sorafenib has enhanced anti-proliferative effects and 
increases rhTRAIL-induced apoptosis in the human SW948, Lovo, Colo205, Colo320, 
Caco-2, and HCT116 colon cancer cell lines. In four cell lines, aspirin strongly stimulated 
the anti-proliferative effects of sorafenib (~ four-fold enhancement) by inducing cell 
cycle arrest. Furthermore, combining low doses of aspirin (≤ 2.5 mM) and sorafenib (≤ 
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2.5 μM) greatly sensitized TRAIL-sensitive and TRAIL-resistant colon cancer cells to 
rhTRAIL. The increase in rhTRAIL sensitivity was caused by a reduction in basal levels 
of the anti-apoptotic proteins FLIP and Mcl-1 following aspirin and sorafenib 
cotreatment, as confirmed with small interfering RNA. Next, the clinical relevance of 
targeting FLIP and Mcl-1 in colon cancer was examined. Using immunohistochemistry, 
we found that Mcl-1 expression was significantly increased in colon adenoma and 
carcinoma patient material compared to healthy colonic epithelium, similar to the 
enhanced FLIP expression we recently observed in colon cancer. These results 
underscore the potential of combining low doses of aspirin with sorafenib to inhibit 
proliferation and target the anti-apoptotic proteins FLIP and Mcl-1. Our findings also 
support further pre(clinical) investigation of  this combination  with TRAIL receptor-
targeting agents in colon cancer. 
 
Discussion and future perspectives 
 
Resistance of colorectal cancer cells to standard 5-fluorouracil (FU)-based chemotherapy 
can be attributed in part to a failure of cancer cells to go into apoptosis. So far, most 
chemotherapeutic agents used to treat colorectal cancer have targeted the intrinsic 
apoptosis pathway (1). Agents activating the TRAIL apoptotic pathway offer a novel 
strategy to complement current chemotherapeutic regimens by stimulating the extrinsic 
apoptosis pathway, without toxicity toward normal cells. Since the discovery of TRAIL 
receptors in 1997, much emphasis has been put on defining the optimal drug 
combination(s) to increase cancer cell sensitivity to TRAIL, and on identifying the key 
proteins regulating the TRAIL apoptotic pathway. 
 
Properties of TRAIL-R1 and TRAIL-R2 
Although the two pro-apoptotic TRAIL death receptors were initially described as 
functionally homologous, a significant body of work suggests that they also possess 
some distinct properties. This neglected aspect might be particularly important in view 
of the wide range of TRAIL receptor agonists currently in development (2). To 
summarize, TRAIL-R1 expression is principally regulated by stress-activated pathways 
such as c-Jun, while the tumor suppressor p53 plays a crucial role in regulating TRAIL-
R2 expression (3). In some cancer cell types, such as chronic lymphoid leukaemia, 
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TRAIL mostly signals apoptosis via TRAIL-R1. Not surprisingly, loss of TRAIL-R1 
expression is more frequent than loss of TRAIL-R2 expression in this type of tumor (2). 
Moreover, the two pro-apoptotic receptors also have distinct prognostic value in various 
cancer types (4). Upon ligand stimulation, specific proteins can be recruited to either 
TRAIL-R1- or TRAIL-R2-associated DISC complexes where they modulate caspase 8 
activation and/or stimulate various downstream survival pathways (2,5). These 
properties might contribute to the various efficacies of the different TRAIL receptor 
ligands, alone or in combination with cytotoxic drugs. 
 
TRAIL receptor ligand-specific properties 
In chapters 4 and 5, we showed that antibodies specific for TRAIL-R1 or TRAIL-R2 
might not always achieve the levels of cell death reached by the dual TRAIL-R1/-R2-
agonist rhTRAIL. As we highlight in chapter 4, in the isogenic SW948/SW948-TR colon 
cancer cell line model, the anti-TRAIL-R2 antibody was less potent than rhTRAIL or the 
anti-TRAIL-R1 antibody. Our results further show that these inequalities between 
ligands were conserved when sensitivity to apoptosis was increased with the 
therapeutic agent IFN-γ. The proteasome inhibitor MG-132 could, however, improve 
TRAIL-R2-mediated apoptosis to the levels of TRAIL-R1-mediated apoptosis. Based on 
these results, rhTRAIL or simultaneous treatment with TRAIL-R1 and TRAIL-R2 
agonists might seem to be the best workaround options since potential TRAIL-R1- and 
TRAIL-R2-specific drug effects could be bypassed. However, our data in chapter 5 
partially challenge this assumption. 
 In chapter 5, we showed that agents targeting the IGF-1R/PI3K survival 
pathway, in this case NVP-AEW541 or LY294002, decreased colon cancer cell sensitivity 
to rhTRAIL and to anti-TRAIL-R1 antibodies, while sensitivity to anti-TRAIL-R2 
antibodies was increased. This was seen both in the SW948/SW948-TR cell line model 
and in the Colo205 cell line. This implies that for a given treatment option, a particular 
TRAIL receptor agonist may have to be used to avoid a possible lack of potentiating 
effects or, even more dramatically, potential antagonistic effects. Unlike TRAIL-R1 or 
TRAIL-R2-specific agonists, rhTRAIL can recruit TRAIL receptor heterotrimers; their 
ability to transduce apoptosis, compared to homotrimers, remains to be further 
investigated. In addition to their effects on the apoptotic cascade, the propensity of the 
various TRAIL receptor ligands and/or TRAIL death receptor to co-activate pro-
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survival pathways largely remains to be investigated (5). Altogether, in vitro results on 
the efficacy of the various ligands should be expanded to larger cell line panels and 
substantiated by human tumor xenograft animal model data. This would allow 
evaluating the translation of these TRAIL receptor agonist-specific properties into in vivo 
models. 
Very few studies have compared the efficiency of TRAIL-R1- and TRAIL-R2-
agonists in vitro to their efficiency in vivo in preclinical models. The results obtained so 
far suggest that, to some extent, the response to anti-TRAIL-R1 and anti-TRAIL-R2 
antibodies alone observed in vitro hold some predictive value on response in xenograft 
models (6). However, in vitro data on the combinations of the anti-TRAIL-R1 and anti-
TRAIL-R2 antibodies with ionizing radiation did not concur with the gain in response 
seen in vivo in xenograft models. Clinical data comparing the efficacy of two (or more) 
TRAIL receptor ligands in combination with the same anti-cancer therapeutic regimen 
are also sparse. Our in vitro data support the idea that standard anti-cancer treatments 
might have TRAIL receptor ligand-specific properties, which should be taken into 
consideration when combining these treatments with a particular ligand. 
Determining the functionality of the TRAIL-R1- and TRAIL-R2-apoptotic 
signaling pathways in a given tumor could help to define the optimal TRAIL receptor 
agonist to be used. If possible, functionality should be based on ex vivo response to the 
TRAIL receptor agonist(s), alone or upon combination with the standard treatment 
option(s). Cultures of precision-cut human tumor tissue slices or human xenotransplants 
in mice could be used to determine optimal drug-response. Preclinical data, including 
results obtained in isogenic colon cancer cell lines, suggest that primary tumors are 
more sensitive to TRAIL than their metastases (7,8). Therefore, it will be important to 
determine whether the response of primary tumor material to the TRAIL receptor 
ligands, either alone or in combination with cytotoxic drugs, can also predict response of 
the metastases to these combinations. Tumor specific- and, by extension, patient 
tailored-TRAIL receptor agonist combination therapies may be very effective, but 
necessitate a major leap in screening modalities. Until advanced screening strategies are 
implemented, it may also be useful to characterize the most effective TRAIL receptor 




Critical role of the DISC and importance of (a high) caspase 8/FLIP ratio for TRAIL 
sensitivity 
A large amount of data has been accumulated on how to further sensitize cells to TRAIL 
death receptor-mediated apoptosis by stimulating the intrinsic apoptosis pathway. The 
review presented in chapter 2 argues that TRAIL sensitivity should already be improved 
at the DISC. Optimal caspase 8 activation at the DISC signifies better activation of Bid 
upstream of the mitochondria and better ability to directly activate executioner caspases 
such as caspase 3. Further knowledge on the mechanisms that determine the efficiency 
of caspase 8 cleavage is therefore needed. The ability of the various TRAIL receptor 
ligands to initiate efficient DISC formation, the influence of TRAIL-R1 or TRAIL-R2 
mutations on caspase 8 cleavage and the intracellular mechanisms modulating DISC 
activity should be carefully examined (2).  
Resistance to TRAIL can be intrinsic, but it can also develop in a subset of cells 
after repeated exposure to TRAIL. We show that procaspase 8 downregulation and 
active caspase 8 degradation play a role in MMR-proficient cells with long-term 
acquired rhTRAIL resistance. One of the mechanisms by which anti-cancer drugs 
increase TRAIL sensitivity is by enhancing the expression of pro-apoptotic proteins at 
the DISC. We show in chapter 3 and 4 that both proteasome inhibitors and IFN-γ 
increase caspase 8 levels, thereby reversing rhTRAIL-resistance in SW948-TR cells. 
Future studies should therefore aim at defining optimal TRAIL-based therapies for 
increasing caspase 8 activation. In a broader perspective, our results demonstrate the 
importance of the caspase 8/FLIP ratio for TRAIL sensitivity. Drugs that decrease FLIP 
protein levels can enhance response to chemotherapy and TRAIL-induced apoptosis in 
colorectal cancer cells (9,10). FLIP-specific targeted therapeutic agents are currently 
awaited. 
The parental TRAIL-sensitive cell line used in chapter 3 is classified as a type I 
cell line, characterized by potent caspase 8 cleavage at the DISC and independence from 
the mitochondria for TRAIL-induced apoptosis, as determined in vitro. Alteration in the 
TRAIL apoptotic pathway at the level of the DISC itself, for instance through caspase 8 
downregulation, seems expected in a type I cell line that has acquired resistance to 
TRAIL. However, many cancer cells are classified type II and the mitochondrial 
amplification loop is critical for apoptosis in these cells. It would be of interest to test 
whether the acquisition of TRAIL-resistance in type II cells also correlates with changes 
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in DISC component levels, or promotes alterations in proteins involved in regulation of 
the mitochondrial apoptotic pathway. 
In view of the broad range of mechanisms leading to acquired TRAIL resistance, studies 
on the selective pressure induced by prolonged TRAIL treatment should preferably be 
performed in a broad range of colon cancer cell lines. This would allow assessing the 
relevance of the resistance mechanisms described and permit characterizing agents that 
re-sensitize the widest panel of cell lines.  
 
Additional targets of interest downstream of the DISC 
Although we show in chapter 3 and 6 that FLIP inhibition enhances apoptosis induction 
in colon cancer cell lines, it may not be sufficient in these type II cell lines that  strongly 
depend on the mitochondrial amplification loop for caspase 3 activation (11). Our results 
in chapter 6 suggest that combining drug-induced inhibition of FLIP with drug-induced 
inhibition of the anti-apoptotic mitochondrial protein Mcl-1 strongly enhances TRAIL 
sensitivity in colon cancer cells. Others have shown that a double-hit strategy, including 
inhibition of both FLIP and XIAP expression, can stimulate TRAIL-induced apoptosis 
both in vitro and in vivo in a xenograft model (11). This might open the way for 
combinations that include standard chemotherapy and TRAIL receptor-targeting agents, 
supplemented by (specific) agents inactivating key inhibitors of the TRAIL apoptotic 
pathway. Targeting key blockers could be either tumor (sub) type-specific or patient-
tailored. Three critical inhibition levels, namely the DISC (via FLIP), the mitochondria 
(via Bcl-2, Bcl-XL, Mcl-1) or the inhibitor of apoptosis proteins (via XIAP, cIAP1, cIAP2, 
survivin) offer interesting pools of potential therapeutic targets in colorectal cancer. 
Data show that some anti-apoptotic proteins such as the Bcl-2 family member Mcl-1 (12) 
are further upregulated in cancer cells after stimulation of the TRAIL apoptotic 
pathway, via a negative feedback loop preventing TRAIL-induced apoptosis. Similarly, 
tumor necrosis factor-α (TNF-α) induces activation of the NFκB pathway. The 
subsequent FLIP upregulation acts as a potent switch that determines whether a pro-
apoptotic or pro-survival effects will be induced by TNF-α. (13,14). Future research 
should determine which of the key proteins discovered in vitro are most relevant for 
TRAIL sensitivity in vivo, either in a broad context or in a tumor-specific perspective, for 
instance based on immunohistochemical studies. Basal protein levels, in absence of 
stimulation of the TRAIL receptor(s), may not be sufficient to predict sensitivity to 
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TRAIL receptor ligands. These studies should therefore consider the importance of the 
anti-apoptotic proteins that play a critical role in TRAIL sensitivity but are only 
detectable after stimulation of the TRAIL receptors.  
 
MiRNA and TRAIL receptor-mediated apoptosis 
First discovered in 1993, microRNAs (miRNAs) are small non-coding RNAs (19-25 
nucleotides-long) that can block mRNA transcription and/or negatively regulate mRNA 
stability. MiRNAs possess oncogenic and tumor suppressing activities. As a 
consequence, the expression of these miRNAs is often deregulated in cancer. The 
oncogene MET upregulates miR-221&222 in aggressive non-small cell lung cancers and 
hepatocellular carcinomas. By inhibiting PTEN and TIMP3 expression, miR-221&222 
induced TRAIL resistance (15). MiR29b, a negative regulator of Mcl-1 expression, was 
found to be downregulated in malignant cholangiocarcinomas, thereby preventing 
TRAIL-induced apoptosis (16). Interestingly, miR29b is also downregulated in colorectal 
cancer cells compared to normal (17). It is also worth noting that some DISC proteins are 
putative miRNA targets (18,19). Future research should determine whether one or 
several of these miRNA constitute good marker(s) for TRAIL sensitivity, which may also 
be improved by therapeutic targeting of the anti-apoptotic miRNAs. 
 
Dual-drug combinations as a strategy to increase sensitivity to TRAIL death receptor-
mediated apoptosis 
Various drugs can inhibit the expression of anti-apoptotic proteins and/or upregulate 
pro-apoptotic proteins. So far, most studies have focused on combining single agents 
with TRAIL receptor-targeted therapies. In chapter 6, we show that combinations of two 
different drugs may achieve TRAIL-sensitizing effects far superior to the effects 
obtained from combining TRAIL with two drugs separately. Sorafenib and aspirin 
effectively increased TRAIL sensitivity in a panel of colon cancer cell lines, via combined 
inhibition of FLIP and Mcl-1. In medulloblastoma and neuroblastoma cells, combining a 
demethylating agent or histone deacetylase inhibitors with IFN-γ induced potent 
caspase 8 upregulation. Consequently, treatment with a combination of these drugs 
increased TRAIL sensitivity both in vitro and in vivo in a chorioallantoic membrane 
model (20,21). These data further support the rationale for similar dual-drug 
combinations in colorectal cancer. Since 5-FU constitutes an important part of adjuvant 
Summary of the results, future perspectives and conclusions 
191 
and palliative treatments for colorectal cancer, integrating the interactions of 5-FU with 
other treatment options might be critical for improving TRAIL sensitivity in colon 
cancer cells. 5-FU increase TRAIL-sensitivity in colon cancer cells (22). However, 5-FU 
also stimulates the NF-κB pathway, therefore hampering TRAIL-induced apoptosis (23). 
Similarly, 5-FU stimulates Mcl-1 mRNA levels and protein expression in pancreatic 
cancer cells with acquired resistance to this chemotherapeutic agent (24). Thus, 
inhibitors of the NF-κB pathway or of Mcl-1 might increase the pro-apoptotic effects of 
5-FU on TRAIL-induced apoptosis in cancer cells. Altogether, TRAIL receptor-targeting 
therapies should benefit from a better knowledge on drug-drug interactions. 
 
TRAIL and colorectal cancer chemoprevention 
Because of the slow progression of the adenoma-carcinoma sequence, colorectal cancer 
is particularly suitable for chemoprevention, notably on patients genetically 
predisposed to this disease. Although NSAIDs have shown some activity, truly effective 
chemopreventive drugs for colorectal cancer are lacking (25). Here, we have 
demonstrated that the expression of Mcl-1 is significantly increased in adenomas, 
including those of patients with Lynch syndrome. It remains to be determined whether 
the high Mcl-1 expression contributes to adenoma formation and development, for 
instance by blocking apoptosis. Early changes in expression of proteins belonging to the 
Bcl-2 family have been found during colorectal carcinogenesis (26). ABT-263, Genasense, 
TW-37, HA14-1 and Obatoclax are novel inhibitors specific for some or several proteins 
of the Bcl-2 family (27). These agents, currently in clinical trials, might help shifting the 
balance toward apoptosis. TRAIL receptor-agonists are generally well-tolerated in 
cancer patients and rhTRAIL induce apoptosis in colorectal adenoma cells (28). 
Combining NSAIDs with TRAIL receptor agonists or Bcl-2 family inhibitors might 




Finally, early clinical studies performed in extensively pre-treated patients did not allow 
to determine whether TRAIL is the natural born killer of cancer cells that many had 
hoped it would be based on preclinical work. The study of the TRAIL apoptotic 
pathway has, however, already increased our mechanistic understanding of apoptosis 
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and its regulation in cancer cells. Novel key proteins have been defined, targeting of 
which could be beneficial to both TRAIL receptor-mediated apoptosis and 
chemotherapy-induced apoptosis. As demonstrated in this thesis, efficient DISC activity, 
and more particularly a favorable (high) caspase 8/FLIP ratio, is critical for efficient 
stimulation of the TRAIL apoptotic pathway in vitro. Enhancing caspase 8 cleavage at 
the DISC might also hold the key to TRAIL death receptor-mediated apoptosis in vivo. 
Rational application in the clinic of the knowledge obtained in preclinical models will 
increase the potential to translate TRAIL death receptor-mediated apoptosis into 
therapies that improve the prognosis of patients.  
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Samenvatting van de resultaten 
 
Darmkanker is de op één na grootste veroorzaker van kanker-gerelateerde 
doodsoorzaken in westerse landen. Hoewel er therapeutisch gezien vooruitgang 
geboekt is, blijft intrinsieke en/of verkregen resistentie tegen cytostatica een probleem. 
Hoogstwaarschijnlijk wordt deze resistentie veroorzaakt door verstoring van de route 
van geprogrammeerde celdood, oftewel apoptose, in darmkankercellen.  
In de literatuur worden anti-tumor en anti-metastasering eigenschappen 
toegedicht aan de tumor necrosis factor-gerelateerde apoptose-inducerende ligand 
(TRAIL) apoptoseroute. Dit maakt deze route een aantrekkelijk therapeutisch doel voor 
antikankerbehandeling. Er zijn nieuwe medicijnen ontwikkeld – waaronder 
recombinant humane TRAIL en agonistische antilichamen, die ofwel TRAIL receptor 1 
of TRAIL receptor 2 (TRAIL-R1 of -R2) kunnen aanzetten om de extrinsieke 
apoptoseroute in kankercellen te stimuleren. Combinatietherapieën die deze middelen 
gebruiken worden momenteel geëvalueerd op hun vermogen om apoptose in 
cytostatica-resistente cellen te herstellen. In het onderzoek, zoals beschreven in dit 
proefschrift, worden verschillende aspecten van de TRAIL apoptoseroute bekeken, met 
als doel het aanpakken van moleculaire doelwitten van deze route  in darmkanker te 
verbeteren.  
Ten eerste wordt in hoofdstuk 2 de huidige kennis betreffende de eerste stap in 
deze route, het zogenaamde death inducing signaling complex (DISC) oftewel het 
celdoodinducerende signaleringscomplex beschreven, om zo nieuwe strategieën te 
definiëren, die tot een hogere gevoeligheid voor TRAIL death receptor-gemedieerde 
apoptose  zouden kunnen leiden.  
De samenstelling van de DISC wordt in kankercellen geïnitieerd via het binden 
van TRAIL aan een van zijn proapoptotische death receptoren, TRAIL-R1 of TRAIL-R2. 
Componenten van de DISC zijn trimeren TRAIL-R1/R2 in complex met FADD, caspase 
8 en caspase 10. Wanneer het anti-apoptotische eiwit FLIP naast caspase 8 deel uitmaakt 
van de DISC, wordt een inactief complex gevormd. De activering van caspase 8/10 in 
een DISC initieert de caspasecascade, die uiteindelijk leidt tot geprogrammeerde 
celdood. Er zijn naast TRAIL en TRAIL-R1- en TRAIL-R2-selectieve varianten van 
TRAIL ook agonistische antilichamen ontwikkeld, die specifiek gericht zijn tegen 
TRAIL-R1 of TRAIL-R2. Deze liganden zijn interessant als antikanker medicijnen, 
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aangezien ze selectief tumorcellen doden. Om de gevoeligheid voor TRAIL death 
receptor-gemedieerde apoptose in de tumor te verhogen en om cytostaticaresistentie te 
omzeilen, zijn in preklinische modellen al TRAIL receptorliganden gecombineerd met 
verschillende andere medicamenten. In hoofdstuk 2 worden factoren die de eerste 
stappen in de TRAIL apoptosesignaalroute beïnvloeden besproken, waarbij de focus 
gelegd wordt op mechanismen die de DISC vorming kunnen moduleren, en op het 
activeren van caspases in de DISC. Deze inzichten kunnen zo het ontwerpen van 
verdere studies sturen, waarin medicijnen worden gecombineerd met TRAIL 
receptorliganden om zo een maximale DISC signalering te krijgen. 
Een manier, om combinaties die TRAIL-geïnduceerde apoptose verhogen te 
identificeren, is het ontwikkelen van kankercellijnen die resistent gemaakt zijn voor 
TRAIL. Hierbij zijn in het verleden vaak darmkankercellen, die al een verminderde 
capaciteit voor reparatie van DNA mismatches hebben, gebruikt. Deze kankercellen 
hebben vaak mutaties in genen die tandem repeats in het DNA bevatten, waaronder het 
gen voor het pro-apoptotische eiwit Bax. Tumoren met deze eigenschappen 
vertegenwoordigen echter slechts een klein gedeelte van de darmkankers (15-20%). In 
hoofdstuk 3 onderzochten we het onderliggende mechanisme voor het verkrijgen van 
resistentie tegen TRAIL in een darmkankercellijn, die nog wel een intact mismatch-
herstel-mechanisme bevatte. De TRAIL-resistente cellijn SW948-TR werd verkregen uit 
de TRAIL-gevoelige cellijn SW948 door constante blootstelling van de cellen aan 
rhTRAIL. De SW948-TR cellen vertonen een 140 keer verlaagde gevoeligheid voor 
TRAIL in een overlevingsassay. In afwezigheid van TRAIL bleven de cellen resistent 
gedurende meer dan één jaar. Beide cellijnen vertoonden een vergelijkbaar TRAIL death 
receptor-expressieniveau op de celmembraan. Behandeling van de cellen met de 
eiwitsyntheseremmer cycloheximide maakte de SW948-TR cellen gevoelig voor TRAIL-
geinduceerde apoptose, wat een aanwijzing was dat de TRAIL death receptoren niet 
gemuteerd waren, maar dat de resistentie op een ander niveau in de cel zit. 
De caspase 8 eiwitspiegels in SW948-TR cellen waren duidelijk lager dan in 
SW948 cellen. Caspase 8 mRNA niveaus in de twee cellijnen waren niet verschillend. 
Downregulatie van c-FLIP met short interfering RNA (siRNA) verhoogde de 
gevoeligheid van SW948-TR cellen voor TRAIL, terwijl caspase 8 siRNA de TRAIL 
gevoeligheid in SW948 cellen verlaagde. Dit onderstreept het belang van de caspase 
8/FLIP ratio. Proteasoomremming met MG-132 zorgde niet voor een herstel van het 
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caspase 8 basisniveau in SW948-TR cellen, maar stabiliseerde het door TRAIL 
geactiveerde caspase 8 in deze cellen. Onze resultaten suggereren dat darmkankercellen 
TRAIL resistent worden door een verlaging van de caspase 8/FLIP ratio en door een 
verhoogde afbraak van actief caspase 8 na TRAIL behandeling. Proteasoomremmers 
zouden deze verkregen TRAIL resistentie kunnen terugdraaien in met name 
darmkankercellen die een intact mismatch-repair-systeem bevatten.  
Er zijn verschillende medicijnen ontwikkeld die op de TRAIL death receptoren 
aangrijpen, zoals TRAIL en TRAIL-R1/R2-specifieke antilichamen. Omdat verschillende 
liganden ook verschillende eigenschappen kunnen hebben, onderzochten we in 
hoofdstuk 4 de bijdrage van TRAIL-R1 en TRAIL-R2 aan de TRAIL-gevoeligheid en -
resistentie in SW948 en SW948-TR cellen. Ook bepaalden we of TRAIL-R1 of TRAIL-R2 
agonistische antilichamen de TRAIL resistentie zouden kunnen opheffen. SW948 cellen 
waren gevoelig voor alle drie de TRAIL death receptor-liganden, hoewel het TRAIL-R2 
antilichaam slechts zwakke caspase 8 activering en lage apoptose liet zien. Toch 
induceerden de anti-TRAIL-R1 en anti-TRAIL-R2 antilichamen gelijkwaardige DISC 
vorming en was er ongeveer evenveel geactiveerd caspase 8 in de DISC aanwezig in 
SW948. Dit is een aanwijzing dat verdere caspase 8 activering geremd wordt na 
stimulering van TRAIL-R2. SW948-TR cellen waren resistent voor alle TRAIL death 
receptor-liganden door de lagere caspase 8 eiwitniveaus en dus minder caspase 8 
activering. Caspase 8 niveaus konden worden hersteld in SW948-TR door 
voorbehandeling met MG-132 of interferon-gamma (IFN-γ), waarna eveneens de 
gevoeligheid voor rhTRAIL en TRAIL-R1 antilichaam verhoogd werd. Verrassend 
genoeg vergrootte MG-132 ook TRAIL-R2 gemedieerde apoptose. Deze resultaten 
benadrukken dat er een kritiek verschil bestaat tussen TRAIL-R1 en TRAIL-R2 
apoptotische signalering, hetgeen mogelijk gevolgen heeft voor toekomstige 
combinaties met TRAIL death receptor-liganden.  
De activiteit van de insulin-like growth factor 1 (IGF-1) “pro-survival” route is 
vaak verhoogd in kankercellen, hetgeen invloed heeft op celdelingsactiviteit en 
apoptose. In hoofdstuk 5 stellen we dat remming van de IGF-1 receptor (IGF-1R) de 
TRAIL death receptor-gemedieerde apoptose zal verhogen in darmkankercellen. NVP-
AEW541, een IGF-1R tyrosinekinaseremmer met laag moleculair gewicht, verlaagde de 
gevoeligheid voor TRAIL en voor een TRAIL-R1 antilichaam, maar verrassend genoeg 
werd de gevoeligheid voor een TRAIL-R2 antilichaam verhoogd. NVP-AEW541 remde 
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de IGF-1 geïnduceerde activering van phosphatidylinositol 3-kinase (PI3K) route. De 
effecten van de PI3K remmer LY294002 op TRAIL-geinduceerde apoptose waren 
vergelijkbaar met die van NVP-AEW541, wat de rol voor IGF-1R gemedieerde 
activering van PI3K onderbouwt. We hebben laten zien dat PI3K remming de TRAIL-R2 
gemedieerde caspase 8 activering verhoogde, maar tegelijkertijd de TRAIL-R1 
membraanexpressie en TRAIL-R1-gemedieerde caspase 8 activering verlaagde. 
Daarnaast toonden we aan dat remming van PI3K de TRAIL gevoeligheid verlaagde. 
Dit effect is onafhankelijk is van de initiële voorkeur van de cellijn voor TRAIL-R1 of 
TRAIL-R2 gemedieerde apoptosesignalering. Deze resultaten suggereren dat rekening 
gehouden moet worden met individuele effecten op TRAIL-R1 of TRAIL-R2 
gemedieerde apoptosesignalering, wanneer TRAIL receptorliganden gecombineerd 
worden met PI3K remmers.  
De multikinaseremmer sorafenib is in de kliniek effectief bij bepaalde 
kankertypes, en voorkomt celdeling van darmkankercellen in vitro. Niet-steroide anti-
inflammatoire medicijnen zoals acetylsalicylzuur (aspirine) remmen darmkankercellen 
in vitro. Het doel in hoofdstuk 6 was om te bepalen of de combinatie van aspirine met 
sorafenib de celdelingremmende effecten van beide medicijnen versterkt, en of de 
combinatie tevens de TRAIL-geïnduceerde apoptose in menselijke darmkankercellijnen 
(SW948, Lovo, Colo205, Colo320, Caco-2 en HCT116) vergroot. Aspirine versterkte de 
celdelingremmende werking van sorafenib in vier cellijnen zeer sterk (ongeveer 4 keer 
verhoogd) door het remmen van de celcyclus. 
De combinatie van lage doseringen van aspirine (≤ 2,5 mM) en sorafenib (≤ 2,5 
μM) verhoogde de gevoeligheid van TRAIL-gevoelige en -resistente darmkankercellen 
voor TRAIL sterk. De oorzaak voor de toegenomen TRAIL gevoeligheid was een 
verlaging van de cellulaire spiegels van de anti-apoptotische eiwitten FLIP en Mcl-1 na 
combinatiebehandeling met aspirine en sorafenib, wat werd bevestigd met specifieke 
verlaging van deze eiwitten met behulp van small interfering RNA.  
Vervolgens werd de klinische relevantie van het aangrijpen op FLIP en Mcl-1 in 
darmkanker onderzocht. Immunohistochemie op weefsel verkregen van patiënten wees 
uit dat Mcl-1 expressie significant verhoogd was in darm-adenomen en -carcinomen 
vergeleken met gezond darmepitheel, wat vergelijkbaar was met de verhoogde FLIP 
expressiewaarden die recentelijk gezien werden in darmkankerweefsel met behulp van 
immunohistochemie. Deze resultaten benadrukken het belang van het combineren van 
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lage doseringen aspirine en sorafenib om de celdeling te remmen en de expressie van de 
anti-apoptotische eiwitten FLIP en Mcl-1 te verlagen. Verder pre(klinisch) onderzoek zal 
moeten uitwijzen wat de effecten van deze medicijncombinatie met TRAIL 




De veelbelovende resultaten met TRAIL receptorliganden in preklinisch onderzoek 
hebben geleid tot klinische studies. De eerste klinische studies uitgevoerd in patiënten 
die al vele voorafgaande behandelingen hadden ondergaan, maken het echter nog niet 
mogelijk om iets te zeggen over de bijdrage van TRAIL receptorliganden in de 
behandeling van darmkankerpatienten. Het  onderzoek aan de TRAIL apoptoseroute 
heeft ons al wel veel geleerd heeft over apoptose en de regulatie van apoptose in 
kankercellen. Nieuwe eiwitten, die een centrale rol spelen in apoptose, zijn 
geïdentificeerd. Het richten van medicijnen op deze eiwitten kan een voordeel zijn om 
zo samen met TRAIL receptor liganden of in combinatie met cytostatica meer apoptose 
te krijgen in darmkankercellen. Zoals aangetoond in in vitro modellen in dit proefschrift, 
is een effectieve DISC formatie en activering van caspase 8 die vooral afhangt van een 
hoge caspase 8/FLIP ratio essentieel om apoptose via de TRAIL receptorenroute te 
induceren. Efficiëntere activering van caspase 8 in de DISC door specifiek op TRAIL-R1 
of TRAIL-R2 gerichte liganden te gebruiken in combinatie met caspase 8 expressie 
verhogende medicijnen zou een mogelijke oplossing zijn om ook in vivo TRAIL death 
receptor gemedieerde apoptose te krijgen. Rationele toepassing in de kliniek van de 
kennis verkregen uit preklinische modellen zou dan mogelijk kunnen leiden tot op 
TRAIL receptor gerichte therapieën, die daadwerkelijk de prognose van darmkanker 
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